{"text_format":"1","workbook":"xlsx","n_sheets":31,"sheets":["CoverSheet","Data","Impact Outcome Indicators_1A","Coverage Indicators_1B","ImpactOutcomeDisaggData","Impactoutcome","Coverage Indicators","CoverageDisaggregationData","WPTM_1C","Intervention By Modules old","Intervention By Modules","PR Cash Reconciliation_2A,B,C","SR_Cash Reconciliation_2D","Budget Variance_2E","Procurement_3","Grant Management_4","PR-LFA Evaluation_5","LFA_Findings&Recommendations_6","PR EFR_7A","LFA EFR_7B","Annual Cash Forecast_8A"," Request and Recommendation_8B","PR Authorization_9A","LFA Authorization_9B","PR_Disbursement Request_7","Modules","EFR Data","Checklist","Memo HIV","Memo TB","Memo Malaria"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":8,"defined_names":554,"comments":2,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CoverSheet","index":0,"n_rows":13,"n_cols":12,"rows_kept":13,"cut":false,"hidden":false,"merged":[[12,3,12,5],[9,0,9,2],[10,0,10,2],[0,0,0,11],[4,0,4,2],[5,0,5,2],[6,0,6,2],[7,0,7,2],[8,0,8,2],[1,0,2,14],[0,12,0,14]]}
["Ongoing Progress Update and Disbursement Request"]
["Cover Sheet: Instructions\n\n• This template is compatible with MS Excel 2000 and later versions. Some drop-downs and formulae may not work with earlier versions. Therefore, Principal Recipients with earlier versions of MS Excel are requested to upgrade to MS 2000 or more recent versions.\n\n• Principal Recipients are first required to complete the Cover Sheet with the General Grant Information listed in the boxes below. They can refer to their Grant Face Sheet/Grant Confirmation to fill part of this information.\n\n• Principal Recipients are required to fill in the information related to the periods covered by the progress update and disbursement request.\n\n• Principal Recipients are required to select the type of submission, i.e. whether they are submitting a Mid-Year (or Quarterly) Progress Update or a Year-End Progress Update/Disbursement Request. This is important as the forms will change depending on the type of submission selected."]
[]
["GENERAL GRANT INFORMATION"]
["Country:",null,null,null,null,"PROGRESS UPDATE "]
["(Disease) Component",null,null,"HIV/AIDS",null,"Progress Update - Reporting Period:",null,null,"Cycle:","Semester","Number:",4]
["Grant Name/Number:",null,null,"GEO-H-NCDc",null,"Progress Update - Period Covered:",null,null,"Beginning Date:","2015-07-01","End Date:","2015-12-31"]
["Principal Recipient:",null,null,"National Center for Disease Control and Public Health"]
["LFA Name",null,null,"UNOPS",null,"DISBURSEMENT REQUEST "]
["Program Start Date:",null,null,"2014-04-01",null,"Disbursement Request  - Disbursement Period:",null,null,"Cycle:","Semester","Number:",3]
["Currency:",null,null,"EUR",null,"Disbursement Request  - Period Covered:",null,null,"Beginning Date:","2016-01-01","End Date:","2016-06-30"]
[]
[null,null,null,"Are you submitting:\n•    A Progress Update (PU); or \n•    A Progress Update/Disbursement Request (PU/DR)."]

{"sheet":"Data","index":1,"n_rows":307,"n_cols":19,"rows_kept":307,"cut":false,"hidden":true,"merged":[]}
["Component","Catalog Module Name","Intervention Name","Old Component","Module - Intervention",null,null,null,"Component",null,null,"Component","Catalog Module Name",null,"Component","Impact/Outcome",null,null,"Data Sources "]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In pregnancy","Malaria",{"$f":"CONCATENATE(B2,\"  -  \",C2)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In pregnancy"},null,null,null,"Malaria",null,null,"Malaria","Specific prevention interventions (SPI)","Module1","Malaria","Impact",{"$f":"CONCATENATE(O2,P2)","v":"MalariaImpact"},"Type1","HMIS"]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In infancy","Malaria",{"$f":"CONCATENATE(B3,\"  -  \",C3)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In infancy"},null,null,null,"Tuberculosis",null,null,"Malaria","Vector control","Module2","Tuberculosis","Impact",{"$f":"CONCATENATE(O3,P3)","v":"TuberculosisImpact"},"Type2","Patient records"]
["Malaria","Specific prevention interventions (SPI)","Seasonal malaria chemoprevention","Malaria","Specific prevention interventions (SPI)  -  Seasonal malaria chemoprevention",null,null,null,"HIV/TB",null,null,"Malaria","Case management","Module3","HIV/TB","Impact","HIV/TBImpact","Type3","Training records"]
["Malaria","Specific prevention interventions (SPI)","IEC/BCC","Malaria","Specific prevention interventions (SPI)  -  IEC/BCC",null,null,null,"HIV/AIDS",null,null,"Tuberculosis","TB care and prevention","Module4","HIV/AIDS","Impact","HIV/AIDSImpact","Type4","MICS (Multiple Indicator Cluster Survey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Mass campaign","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Mass campaign",null,null,null,"Health Systems Strengthening",null,null,"Tuberculosis","MDR-TB","Module5","Health Systems Strengthening","Impact","Health Systems StrengtheningImpact","Type5","DHS/DHS+ (Demographic and Health\nSurvey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Continuous distribution",null,null,null,null,null,null,"HIV/TB","TB care and prevention","Module6","Malaria","Outcome","MalariaOutcome","Type6","AIS (AIDS Indicator Survey)"]
["Malaria","Vector control","Indoor residual spraying (IRS)","Malaria","Vector control  -  Indoor residual spraying (IRS)",null,null,null,null,null,null,"HIV/TB","MDR-TB","Module7","Tuberculosis","Outcome","TuberculosisOutcome","Type7","BSS (Behavioral Surveillance Survey)"]
["Malaria","Vector control","Other vector vontrol measures","Malaria","Vector control  -  Other vector vontrol measures",null,null,null,null,null,null,"HIV/TB","Prevention programs for general population","Module8","HIV/TB","Outcome","HIV/TBOutcome","Type8","Health Facility survey"]
["Malaria","Vector control","Entomological monitoring","Malaria","Vector control  -  Entomological monitoring",null,null,null,null,null,null,"HIV/TB","Prevention programs for MSM and TGs","Module9","HIV/AIDS","Outcome","HIV/AIDSOutcome","Type9","SAMS (Service Availability Mapping\nSurvey)"]
["Malaria","Case management","Facility-based treatment","Malaria","Case management  -  Facility-based treatment",null,null,null,null,null,null,"HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Module10","Health Systems Strengthening","Outcome","Health Systems StrengtheningOutcome","Type10","Households survey"]
["Malaria","Case management","Epidemic preparedness and response","Malaria","Case management  -  Epidemic preparedness and response",null,null,null,null,null,null,"HIV/TB","Prevention programs for other vulnerable populations (please specify)","Module11",null,null,null,null,"Specific surveys and research (specify)"]
["Malaria","Case management","Integrated community case management (ICCM)","Malaria","Case management  -  Integrated community case management (ICCM)",null,null,null,null,null,null,"HIV/TB","Prevention programs for adolescents and youth, in and out of school","Module12",null,null,null,null,"Reports (specify)"]
["Malaria","Case management","Active case detection and investigation (elimination phase)","Malaria","Case management  -  Active case detection and investigation (elimination phase)",null,null,null,null,null,null,"HIV/TB","Prevention programs for sex workers and their clients","Module13",null,null,null,null,"Vital and disease-specific registry"]
["Malaria","Case management","Therapeutic efficacy surveillance","Malaria","Case management  -  Therapeutic efficacy surveillance",null,null,null,null,null,null,"HIV/TB","PMTCT","Module14",null,null,null,null,"Operational Research"]
["Malaria","Case management","Severe malaria","Malaria","Case management  -  Severe malaria",null,null,null,null,null,null,"HIV/TB","Treatment, care and support","Module15",null,null,null,null,"Health Provider survey"]
["Malaria","Case management","Private sector co-payment mechanism","Malaria","Case management  -  Private sector co-payment mechanism",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for general population","Module16",null,null,null,null,"National Health Account"]
["Malaria","Case management","Private sector case management (other)","Malaria","Case management  -  Private sector case management (other)",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for MSM and TGs","Module17",null,null,null,null,"Administrative records"]
["Malaria","Case management","Ensuring drug quality","Malaria","Case management  -  Ensuring drug quality",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Module18",null,null,null,null,"R&R TB system, quarterly reports"]
["Tuberculosis","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Module19",null,null,null,null,"R&R TB system, yearly management report "]
["Tuberculosis","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Module20",null,null,null,null,"TB prevalence survey"]
["Tuberculosis","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for sex workers and their clients","Module21",null,null,null,null,"TB patient register"]
["Tuberculosis","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","PMTCT","Module22",null,null,null,null,"TB laboratory register"]
["Tuberculosis","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","Treatment, care and support","Module23",null,null,null,null,"TB treatment card"]
["Tuberculosis","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","TB/HIV","Module24",null,null,null,null,"Specify- Reports, Surveys, Questionnaires etc."]
["HIV/TB","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"Tuberculosis","TB/HIV","Module25",null,null,null,null,"MIS (Malaria Indicator Survey)"]
["HIV/TB","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/TB","TB/HIV","Module26",null,null,null,null,"Situation Analysis"]
["HIV/TB","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Removing legal barriers to access","Module27",null,null,null,null,"Key informant survey"]
["HIV/TB","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Service delivery","Module28",null,null,null,null,"Surveillance systems"]
["HIV/TB","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health and community workforce","Module29",null,null,null,null,"Modelled"]
["HIV/TB","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health information systems and M&E","Module30",null,null,null,null,"Other survey, specify"]
["HIV/TB","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)",null,null,null,null,null,null,"HIV/AIDS","Program management","Module31",null,null,null,null,"IBBS"]
["HIV/TB","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify",null,null,null,null,null,null,"HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Module32"]
["HIV/TB","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Policy and governance","Module33"]
["HIV/TB","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Healthcare financing","Module34"]
["HIV/TB","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Financial management","Module35"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs",null,null,null,null,null,null,"Tuberculosis","Removing legal barriers to access","Module36"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners",null,null,null,null,null,null,"Tuberculosis","HSS - Service delivery","Module37"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)",null,null,null,null,null,null,"Tuberculosis","HSS - Health and community workforce","Module38"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","HSS - Health information systems and M&E","Module39"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","Program management","Module40"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,null,null,null,"Tuberculosis","HSS - Procurement supply chain management (PSCM)","Module41"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify",null,null,null,null,null,null,"Tuberculosis","HSS - Policy and governance","Module42"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Healthcare financing","Module43"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Financial management","Module44"]
["HIV/TB","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population",null,null,null,null,null,null,"Malaria","Removing legal barriers to access","Module45"]
["HIV/TB","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population",null,null,null,null,null,null,"Malaria","HSS - Service delivery","Module46"]
["HIV/TB","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision",null,null,null,null,null,null,"Malaria","HSS - Health and community workforce","Module47"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs",null,null,null,null,null,null,"Malaria","HSS - Health information systems and M&E","Module48"]
["HIV/TB","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify",null,null,null,null,null,null,"Malaria","Program management","Module49"]
["HIV/TB","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients",null,null,null,null,null,null,"Malaria","HSS - Procurement supply chain management (PSCM)","Module50"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)",null,null,null,null,null,null,"Malaria","HSS - Policy and governance","Module51"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify",null,null,null,null,null,null,"Malaria","HSS - Healthcare financing","Module52"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Malaria","HSS - Financial management","Module53"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","Removing legal barriers to access","Module54"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Service delivery","Module55"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health and community workforce","Module56"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health information systems and M&E","Module57"]
["HIV/TB","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population",null,null,null,null,null,null,"Health Systems Strengthening","Program management","Module58"]
["HIV/TB","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Module59"]
["HIV/TB","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Policy and governance","Module60"]
["HIV/TB","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Healthcare financing","Module61"]
["HIV/TB","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Financial management","Module62"]
["HIV/TB","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age",null,null,null,null,null,null,"HIV/TB","Removing legal barriers to access","Module63"]
["HIV/TB","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV",null,null,null,null,null,null,"HIV/TB","HSS - Service delivery","Module64"]
["HIV/TB","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission",null,null,null,null,null,null,"HIV/TB","HSS - Health and community workforce","Module65"]
["HIV/TB","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B67,\"  -  \",C67)","v":"PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"},null,null,null,null,null,null,"HIV/TB","HSS - Health information systems and M&E","Module66"]
["HIV/TB","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify",null,null,null,null,null,null,"HIV/TB","Program management","Module67"]
["HIV/TB","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify",null,null,null,null,null,null,"HIV/TB","HSS - Procurement supply chain management (PSCM)","Module68"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Policy and governance","Module69"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Healthcare financing","Module70"]
["HIV/TB","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care",null,null,null,null,null,null,"HIV/TB","HSS - Financial management","Module71"]
["HIV/TB","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)",null,null,null,null,null,null,"HIV/AIDS","Community systems strengthening","Module72"]
["HIV/TB","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring",null,null,null,null,null,null,"HIV/AIDS","Results based Financing","Module73"]
["HIV/TB","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence",null,null,null,null,null,null,"Tuberculosis","Community systems strengthening","Module74"]
["HIV/TB","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections",null,null,null,null,null,null,"Tuberculosis","Results based Financing","Module75"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,"Malaria","Community systems strengthening","Module76"]
["HIV/TB","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB","Treatment, care and support  -  Counseling and psycho-social support",null,null,null,null,null,null,"Malaria","Results based Financing","Module77"]
["HIV/TB","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care",null,null,null,null,null,null,"HIV/TB","Community systems strengthening","Module78"]
["HIV/TB","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care",null,null,null,null,null,null,"HIV/TB","Results based Financing","Module79"]
["HIV/TB","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/TB","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/TB","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)"]
["HIV/AIDS","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify"]
["HIV/AIDS","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients"]
["HIV/AIDS","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age"]
["HIV/AIDS","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV"]
["HIV/AIDS","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission"]
["HIV/AIDS","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB","PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"]
["HIV/AIDS","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care"]
["HIV/AIDS","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)"]
["HIV/AIDS","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring"]
["HIV/AIDS","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence"]
["HIV/AIDS","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B131,\"  -  \",C131)","v":"Treatment, care and support  -  Counseling and psycho-social support"}]
["HIV/AIDS","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care"]
["HIV/AIDS","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care"]
["HIV/AIDS","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/AIDS","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/AIDS","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/AIDS","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/AIDS","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/AIDS","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["Tuberculosis","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["Tuberculosis","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["Tuberculosis","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["Tuberculosis","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["Tuberculosis","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/TB","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/TB","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/TB","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/TB","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/TB","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/AIDS","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/AIDS","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/AIDS","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/AIDS","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/AIDS","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/AIDS","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/AIDS","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/AIDS","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/AIDS","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/AIDS","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/AIDS","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/AIDS","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/AIDS","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/AIDS","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/AIDS","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/AIDS","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/AIDS","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/AIDS","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/AIDS","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/AIDS","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/AIDS","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/AIDS","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/AIDS","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/AIDS","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/AIDS","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Tuberculosis","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Tuberculosis","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Tuberculosis","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Tuberculosis","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Tuberculosis","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Tuberculosis","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Tuberculosis","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Tuberculosis","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Tuberculosis","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Tuberculosis","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Tuberculosis","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Tuberculosis","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Tuberculosis","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Tuberculosis","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Tuberculosis","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B195,\"  -  \",C195)","v":"HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"}]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Tuberculosis","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Tuberculosis","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Tuberculosis","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Tuberculosis","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Tuberculosis","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Tuberculosis","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Tuberculosis","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Tuberculosis","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Tuberculosis","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Tuberculosis","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Malaria","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Malaria","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Malaria","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Malaria","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Malaria","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Malaria","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Malaria","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Malaria","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Malaria","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Malaria","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Malaria","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Malaria","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Malaria","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Malaria","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Malaria","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Malaria","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Malaria","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Malaria","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Malaria","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Malaria","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Malaria","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Malaria","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Malaria","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Malaria","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Malaria","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Malaria","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Malaria","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Health Systems Strengthening","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Health Systems Strengthening","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Health Systems Strengthening","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Health Systems Strengthening","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Health Systems Strengthening","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Health Systems Strengthening","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Health Systems Strengthening","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Health Systems Strengthening","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Health Systems Strengthening","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Health Systems Strengthening","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Health Systems Strengthening","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Health Systems Strengthening","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Health Systems Strengthening","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Health Systems Strengthening","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Health Systems Strengthening","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Health Systems Strengthening","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Health Systems Strengthening","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Health Systems Strengthening","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Health Systems Strengthening","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B259,\"  -  \",C259)","v":"Removing legal barriers to access  -  Community-based monitoring of legal rights"}]
["Health Systems Strengthening","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/TB","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/TB","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/TB","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/TB","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/TB","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/TB","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/TB","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/TB","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/TB","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/TB","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/TB","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/TB","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/TB","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/TB","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/TB","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/TB","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/TB","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/TB","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/TB","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/TB","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/TB","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/TB","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/TB","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/TB","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/TB","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/AIDS","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/AIDS","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/AIDS","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/AIDS","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/AIDS","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Tuberculosis","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Tuberculosis","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Tuberculosis","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Tuberculosis","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Tuberculosis","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Malaria","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Malaria","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Malaria","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Malaria","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Malaria","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["HIV/TB","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/TB","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/TB","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/TB","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/TB","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]

{"sheet":"Impact Outcome Indicators_1A","index":2,"n_rows":51,"n_cols":32,"rows_kept":51,"cut":false,"hidden":false,"merged":[[0,0,0,5],[23,28,23,33],[42,29,42,33],[43,29,43,33],[44,29,44,33],[45,29,45,33],[46,29,46,33],[47,29,47,33],[48,29,48,33],[24,16,24,17],[24,18,25,18],[24,19,25,19],[24,20,25,20],[23,16,23,27],[47,23,47,27],[48,23,48,27],[24,21,25,21],[24,22,25,22],[24,23,25,27],[6,0,6,1],[6,2,6,5],[4,0,4,1],[4,2,4,5],[5,0,5,1],[24,28,25,28],[24,29,25,33],[26,29,26,33],[27,29,27,33],[28,29,28,33],[29,29,29,33],[30,29,30,33],[31,29,31,33],[32,29,32,33],[50,29,50,33],[33,29,33,33],[34,29,34,33],[35,29,35,33],[36,29,36,33],[37,29,37,33],[38,29,38,33],[39,29,39,33],[40,29,40,33],[41,29,41,33],[49,29,49,33],[49,23,49,27],[50,23,50,27],[26,23,26,27],[42,23,42,27],[43,23,43,27],[44,23,44,27],[45,23,45,27],[46,23,46,27],[37,23,37,27],[38,23,38,27],[39,23,39,27],[40,23,40,27],[41,23,41,27],[32,23,32,27],[33,23,33,27],[34,23,34,27],[35,23,35,27],[36,23,36,27],[27,23,27,27],[28,23,28,27],[29,23,29,27],[30,23,30,27],[31,23,31,27],[5,2,5,5],[7,0,7,1],[7,2,7,5],[8,0,8,1],[8,2,8,5],[9,0,9,1],[9,2,9,5],[13,2,13,5],[17,2,17,5],[19,0,19,15],[23,14,23,15],[24,0,25,0],[24,1,25,5],[24,6,24,7],[24,8,25,8],[24,9,25,9],[24,10,25,10],[24,11,25,11],[24,12,25,12],[24,13,25,15],[26,13,26,15],[28,1,28,5],[28,13,28,15],[29,1,29,5],[29,13,29,15],[27,1,27,5],[27,13,27,15],[26,1,26,5],[30,1,30,5],[30,13,30,15],[31,1,31,5],[31,13,31,15],[32,1,32,5],[32,13,32,15],[33,1,33,5],[33,13,33,15],[34,1,34,5],[34,13,34,15],[35,1,35,5],[35,13,35,15],[36,1,36,5],[36,13,36,15],[37,1,37,5],[37,13,37,15],[38,1,38,5],[38,13,38,15],[39,1,39,5],[39,13,39,15],[40,1,40,5],[40,13,40,15],[41,1,41,5],[41,13,41,15],[50,1,50,5],[50,13,50,15],[46,1,46,5],[46,13,46,15],[47,1,47,5],[47,13,47,15],[48,1,48,5],[48,13,48,15],[42,1,42,5],[42,13,42,15],[43,1,43,5],[43,13,43,15],[44,1,44,5],[44,13,44,15],[45,1,45,5],[45,13,45,15],[49,1,49,5],[49,13,49,15]]}
["On-going Progress Update and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"AIS (AIDS Indicator Survey)",null,null,null,null,null,"AIS (AIDS Indicator Survey)"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)",null,null,null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["GENERAL GRANT INFORMATION",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Census",null,null,null,null,null,"Census"]
["Country:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Clinical cohort follow-up studies",null,null,null,null,null,"Clinical cohort follow-up studies"]
["Disease:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)",null,null,null,null,null,"DHS/DHS+ (Demographic and Health Survey)"]
["Grant Number:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)",null,null,null,null,null,"MICS (Multiple Indicator Cluster Survey)"]
["Principal Recipient:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"MIS (Malaria Indicator Survey)",null,null,null,null,null,"MIS (Malaria Indicator Survey)"]
["Program Start Date:",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"WHO Global report/estimates",null,null,null,null,null,"WHO Global report/estimates"]
["Currency:",null,"Select",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Other (type as appropriate)",null,null,null,null,null,"Other (type as appropriate)"]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:","Select","Number:"]
["Progress Update - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:","Select","Number:"]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",null,"End Date:"]
["Disbursement Request  - Number:"]
[]
[]
[]
["Section 1:  Programmatic Progress"]
["Note: The table below should contain those Impact/Outcome indicators that are (1) due for reporting during the current year of a grant and (2) those reporting on which is overdue from the previous periods."]
["A.  Impact / Outcome Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Impact / Outcome ","Indicator Description",null,null,null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Actual Result","Data Source of Results","Comments on results on Impact/Outcome indicators and data sources, and any other comments",null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Verification Method","Verified Result","LFA comments on (a) verified result, (b) source of information used by the PR to report results, including the status of completion of surveys and other methods to measure Impact/Outcome, as applicable,  ",null,null,null,null,"Validated Result","Country Team comments on validated results"]
[null,null,null,null,null,null,"Value","Year",null,null,null,null,null,null,null,null,"Value","Year"]
["Impact","Percentage of men who have sex with men who are living with HIV ",null,null,null,null,0.13,2012,"2015",0.15,"2016-02-15",0.25,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W27","v":0}]
["Impact","Percentage of people who inject drugs who are living with HIV",null,null,null,null,0.03,2012,"2014",0.03,"2015-02-15",2.0199999999999999E-2,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W28","v":0}]
["Impact","Percentage of sex workers who are living with HIV ",null,null,null,null,1.0999999999999999E-2,2012,"2014",2.3E-2,"2015-02-15",7.0000000000000001E-3,"BSS (Behavioral and Surveillance Survey)","The prevalcne of HIV in Tbilisi was 0.6% and 0.8% in Batumi, total number of study participants tested on HIV was 277",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Impact","AIDS related mortality per 100,000 population ",null,null,null,null,2.4,2012,"2014",2.2999999999999998,"2015-02-15",1.9,"HMIS","Preliminary data of the last census is 3.7 million population, the adjustment will be made when the census data will be officially validated by the State. ",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy. ",null,null,null,null,0.85,2013,"HMIS",0.86,"2016-02-15",0.84199999999999997,"HMIS","Nominator+507; denominator+602",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of men reporting the use of a condom the last time they had anal sex with a male partner",null,null,null,null,0.67300000000000004,2012,"BSS (Behavioral Surveillance Survey)",0.75,"2016-02-15",0.63200000000000001,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of sex workers reporting the use of a condom with their most recent client",null,null,null,null,0.91100000000000003,2012,"BSS (Behavioral Surveillance Survey)",0.92,"2015-02-15",0.9,"BSS (Behavioral and Surveillance Survey)","The value of the indicator was 94.4% in Tbilisi, but it was only 82.7% in Batumi (total number of respondents was 224",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected ",null,null,null,null,0.83499999999999996,2012,"BSS (Behavioral Surveillance Survey)",0.84,"2015-02-15",0.74299999999999999,"BSS (Behavioral and Surveillance Survey)",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]

{"sheet":"Coverage Indicators_1B","index":3,"n_rows":42,"n_cols":38,"rows_kept":42,"cut":false,"hidden":false,"merged":[[22,29,22,33],[13,29,13,33],[14,29,14,33],[15,29,15,33],[16,29,16,33],[17,29,17,33],[18,29,18,33],[19,29,19,33],[20,29,20,33],[21,29,21,33],[29,2,29,5],[29,15,29,16],[30,2,30,5],[28,2,28,5],[23,29,23,33],[24,29,24,33],[25,29,25,33],[26,29,26,33],[32,29,32,33],[27,29,27,33],[28,29,28,33],[29,29,29,33],[30,29,30,33],[0,0,0,8],[10,26,10,28],[10,29,11,33],[12,29,12,33],[10,15,11,16],[2,0,2,2],[2,3,2,6],[5,3,5,6],[9,0,9,16],[10,0,11,0],[10,1,11,1],[10,2,11,5],[10,6,11,6],[10,7,11,7],[10,8,11,8],[12,2,12,5],[9,17,9,33],[10,12,10,14],[10,17,11,17],[10,18,11,18],[10,19,10,22],[10,23,10,25],[14,2,14,5],[14,15,14,16],[15,2,15,5],[16,2,16,5],[10,9,10,11],[12,15,12,16],[13,2,13,5],[13,15,13,16],[15,15,17,16],[21,2,21,5],[21,15,21,16],[22,2,22,5],[22,15,22,16],[17,2,17,5],[18,2,18,5],[18,15,18,16],[19,2,19,5],[19,15,19,16],[20,15,20,16],[37,2,37,5],[30,15,30,16],[34,2,34,5],[34,15,34,16],[35,2,35,5],[35,15,35,16],[23,2,23,5],[23,15,23,16],[28,15,28,16],[37,15,37,16],[31,2,31,5],[31,15,31,16],[32,2,32,5],[32,15,32,16],[33,2,33,5],[33,15,33,16],[25,2,25,5],[25,15,25,16],[26,2,26,5],[26,15,26,16],[27,2,27,5],[27,15,27,16],[24,2,24,5],[24,15,24,16],[10,34,10,36],[9,34,9,41],[22,37,22,41],[23,37,23,41],[24,37,24,41],[25,37,25,41],[36,0,36,41],[10,37,11,41],[12,37,12,41],[13,37,13,41],[14,37,14,41],[15,37,15,41],[16,37,16,41],[17,37,17,41],[18,37,18,41],[19,37,19,41],[20,37,20,41],[21,37,21,41],[28,37,28,41],[29,37,29,41],[30,37,30,41],[26,37,26,41],[27,37,27,41],[20,2,20,5]]}
["On-going Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant number:",null,null,{"$f":"IF('[6]PR_Programmatic Progress_1A'!C7=\"\",\"\",'[6]PR_Programmatic Progress_1A'!C7)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!D12=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!D12)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!F12=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!F12)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!D13=\"\",\"\",'[6]PR_Programmatic Progress_1A'!D13)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF('[6]PR_Programmatic Progress_1A'!F13=\"\",\"\",'[6]PR_Programmatic Progress_1A'!F13)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,null,{"$f":"IF('[6]PR_Programmatic Progress_1A'!C14=\"Select\",\"\",'[6]PR_Programmatic Progress_1A'!C14)","v":{"$error":"#REF!"}}]
[]
["Section 1:  Programmatic Progress"]
["Note: All programmatic indicators contained in the current Performance Framework should be listed, regardless of whether there are targets/results for the period covered by the Progress Update or whether the targets have been met in previous periods.  "]
["B.  Coverage Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Objective\nNo.","* Indicator No.","Indicator Description",null,null,null,"Tied To","Targets cumulative?\n","Top 10 indicator?","Target",null,null,"Results",null,null,"Reasons for programmatic deviation from intended target and deviations from the related workplan activities",null,"Targets cumulative?\n","Top 10 indicator?","Baseline \n(if applicable)",null,null,null,"Target",null,null,"Verified Results",null,null,"LFA analysis on progress to date and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)",null,null,null,null,"Validated Results",null,null,"Country Team comments on validated results"]
[null,null,null,null,null,null,null,null,null,"N#","D#","%","N#","D#","%",null,null,null,null,"N#","D#","%","Year","N#","D#","%","N#","D#","%",null,null,null,null,null,"N#","D#","%"]
[2,1,"Number of MARPs (IDUs, MSM and FSWs) covered with HIV testing and counselling (including provision of results) ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",12691,{"$f":"45000+6500+17000","v":68500},{"$f":"IFERROR(J13/K13,\"\")","v":0.18527007299270074},11842,{"$f":"K13","v":68500},{"$f":"IFERROR(M13/N13,\"\")","v":0.17287591240875913},"Number of PWIDs reached with VCT services during P3 is 9994; Number of 956 MSM   and number of FSWs 892.    Total number 11,842                                                                  (source for the data is electronic dabatase of SRs - GHRN and Tanadgoma).",null,"Select","Select",null,null,{"$f":"IFERROR(T13/U13,\"\")","v":""},null,null,null,{"$f":"IFERROR(X13/Y13,\"\")","v":""},null,null,{"$f":"IFERROR(AA13/AB13,\"\")","v":""},null,null,null,null,null,{"$f":"AA13","v":0},{"$f":"AB13","v":0},{"$f":"IFERROR(AI13/AJ13,\"\")","v":""}]
[2,"1.1.","Number of prisoners covered with VCT (HIV testing and counselling, including provision of results) ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",3500,10000,{"$f":"IFERROR(J14/K14,\"\")","v":0.35},3265,10000,{"$f":"IFERROR(M14/N14,\"\")","v":0.32650000000000001},null,null,"Select","Select",null,null,{"$f":"IFERROR(T14/U14,\"\")","v":""},null,null,null,{"$f":"IFERROR(X14/Y14,\"\")","v":""},null,null,{"$f":"IFERROR(AA14/AB14,\"\")","v":""},null,null,null,null,null,{"$f":"AA14","v":0},{"$f":"AB14","v":0},{"$f":"IFERROR(AI14/AJ14,\"\")","v":""}]
[2,1.2,"Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",{"$f":"K15*0.9","v":645.30000000000007},{"$f":"N15","v":717},0.90000000000000013,653,717,0.9107391910739191,null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.1,"Number and percentage of MSM reached with HIV prevention programmes - defined package of services",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",2515,17000,0.14794117647058824,2316,17000,0.13623529411764707,"Although, there is underachievement in coverage of FSWs, MSM and PWIDs, the SRs has demonstrated improved performance. PR has ongoing communication with SRs how to further improve the coverage data. PDI methodology proved to be effective among MSM in general. The same strategy was successfully tested among FSWs in Telavi. Procurement of Mobile Ambulatories should further increase coverage of PWIDs. The coverage data for PWIDs doesn't include the secondary clients any more as it was suggested by the GF Management Letter (Clients that were reached by the program beneficiaries and not by outreach workers).",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.2000000000000002,"Number and percentage of IDUs reached with HIV prevention programmes - defined package of services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",18638,45000,0.41417777777777776,15272,45000,0.33937777777777778,null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.2999999999999998,"Number and percentage of FSWs reached with HIV prevention programmes - defined package of services ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",1828,6500,0.28123076923076923,1692,6500,0.2603076923076923,null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.4,"Percentage of individuals receiving OST who received treatment for at least 6 months",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",600,21000,2.8571428571428571E-2,717,21000,3.4142857142857141E-2,"717 people were receiving OST through GF funding continuously over the period of 6 months . Opening of a new OST center and imrpoved linkadge between the GF and the State OST programs has contributed to increased results. The tracking of a patient for 6 month in both programs became possible through the OST module.  ",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[2,2.5,"Percentage of key affected population screened for TB",null,null,null,"Current grant","N-not cumulative","No",7615,12691,0.60003151839886537,7409,{"$f":"K20","v":12691},0.58379954298321646,"Source is electronic database of GNRH and Tanadgoma.",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3,"Number and percentage of eligible adults and children currently receiving antiretroviral therapy  ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",3270,4689,0.69737683941138839,3044,4689,0.6491789294092557,"3044 patients were receiving ART as of December 31, 2015.(Source is electronic database of National AIDS Center). The denominator was updated by the NCDC through Sepctrum in June, 2015, as it was requested in the GF Management letter of May, 2015. New Denominator is 4689 (the previous one was 5080). The new figure was provided by survaillance department of NCDC and is agreed with UNAIDS. ",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3.1,"Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)",null,null,null,"Current grant","Y-cumulative annually","No",284,334,0.85029940119760483,295,334,0.88323353293413176,"Source: HIS of the National AIDS Center; Overachivement is due high quality of ART implementation and monitoring",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[3,3.2,"Number of patients with HIV Hep C co-infection receiving Hep C treatment ",null,null,null,"Current grant","Y-cumulative annually","No",150,150,1,220,150,1.4666666666666666,"Overachivement has resulted from the initiation of the State Hep C Elimination Program that provides free access to highly effective anti-HCV medicine (sofosbovir).  Within the GF program patients have free laboratory monitoring of treatment. From July, 2016 the state will take full responsibility for the Lab monitoring also. ",null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select",null,null,"",null,null,"",null,null,"Select","Select",null,null,"",null,null,null,"",null,null,"",null,null,null,null,null,0,0,""]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-",null,null,null,null,null,null,null,null,null,null,0]
[]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select","-","-",null,null,null,null,null,null,"Select","Select",null,null,null,null,"-","-"]

{"sheet":"ImpactOutcomeDisaggData","index":4,"n_rows":33,"n_cols":9,"rows_kept":33,"cut":false,"hidden":true,"merged":[[0,1,0,8]]}
[null,"Impact/outcome disaggregation Data "]
[]
[null,"HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIVI1","Sex",{"$f":"CONCATENATE(C3,D3)","v":"HIVI1Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Sex",{"$f":"CONCATENATE(C4,D4)","v":"HIVI2Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Age",{"$f":"CONCATENATE(C5,D5)","v":"HIVI2Age"},"15-24"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Sex","HIVI4Sex","Male","Female",null,"Impact"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Age","HIVI4Age","<15","15+","15-24","Impact"]
[null,"HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIVI9a","Age","HIVI9aAge","<25","25+",null,"Impact"]
[null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIVI9b","Age","HIVI9bAge","<25","25+",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Sex","MalariaI1Sex","Male","Female",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Age","MalariaI1Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Sex","MalariaI2Sex","Male","Female",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Age","MalariaI2Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Species","MalariaI2Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Sex","MalariaI3Sex","Male","Female",null,"Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Age","MalariaI3Age","<5","5+",null,"Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Species","MalariaI4Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Type of testing",{"$f":"SUBSTITUTE(CONCATENATE(C18,D18),\" \",\"\")","v":"MalariaI4Typeoftesting"},"Microscopy","RDT",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Sex","MalariaI5Sex","Male","Female",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Species","MalariaI5Species","P. Vivax","P. Falciparum","Other - specify"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","MalariaI6","Sex","MalariaI6Sex","Male","Female",null,"Impact"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Sex","HIVO1Sex","Male","Female",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Age","HIVO1Age","<15","15+",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Duration of treatment",{"$f":"SUBSTITUTE(CONCATENATE(C24,D24),\" \",\"\")","v":"HIVO1Durationoftreatment"},"24 months","36 months",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Sex","HIVO2Sex","Male","Female",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Age","HIVO2Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Sex","HIVO3Sex","Male","Female",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Age","HIVO3Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIVO5","Sex","HIVO5Sex","Male","Female",null,"Outcome"]
[null,"HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIVO6","Sex","HIVO6Sex","Male","Female",null,"Outcome"]
[null,"HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIVO8","Sex","HIVO8Sex","Male","Female",null,"Outcome"]
[null,"Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","MalariaO1a","Sex","MalariaO1aSex","Male","Female",null,"Outcome"]
[null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","MalariaO3","Sex","MalariaO3Sex","Male","Female",null,"Outcome"]

{"sheet":"Impactoutcome","index":5,"n_rows":28,"n_cols":11,"rows_kept":28,"cut":false,"hidden":true,"merged":[]}
[]
[null,"Type1","Type2","Type3","Type4","Type5","Type6","Type7","Type8","Type9","Type10"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","TB I-1: TB prevalence rate (per 100,000 population)","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HSS I-1: Under 5 mortality rate per 1000 live births","Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HSS O-1: Percentage of women attending antenatal care"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","TB I-2: TB incidence rate (per 100,000 population)","HIV I-2: HIV incidence among 15-49 age group","HIV I-2: HIV incidence among 15-49 age group","HSS I-2: Neonatal mortality rate, per 100,000 population","Malaria O-1b: Proportion of children under five years old who slept under an insecticide-treated net* the previous night","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HSS O-2: Percentage of births attended by skilled health professional"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","TB I-3: TB mortality rate (per 100,000 population)","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HSS I-3: Maternal mortality ratio, per 100,000 population","Malaria O-1c: Proportion of pregnant women who slept under an insecticide-treated net* the previous night","TB O-2a: Treatment success rate - all forms of TB","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,"Malaria I-4: Malaria test positivity rate","TB I-4: MDR-TB prevalence among new TB patients","HIV I-3b: Percentage of men who have sex with men with active syphilis","HIV I-3b: Percentage of men who have sex with men with active syphilis","Custom","Malaria O-2: Proportion of population with access to an ITN within their household","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HSS O-4: General service readiness score for health facilities"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","TB I-5: Modelled lives saved based on latest epidemiological data","HIV I-3c: Percentage of sex workers with active syphilis","HIV I-3c: Percentage of sex workers with active syphilis",null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","Custom"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","TB I-6: Modelled infections averted based on latest epidemiological data","HIV I-4: AIDS related mortality per 100,000 population","HIV I-4: AIDS related mortality per 100,000 population",null,"Malaria O-4: Proportion of households with at least one insecticide-treated net for every two people and/or sprayed by IRS within the last 12 months","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client"]
[null,"Malaria I-7: Modelled lives saved (based on latest epidemiological data)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population","HIV I-5: New HIV infections among children","HIV I-5: New HIV infections among children",null,"Malaria O-6: Proportion of households with at least one insecticide-treated net* for every two people","HSS O-1: Percentage of women attending antenatal care","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected"]
[null,"Malaria I-8: Modelled infections averted (based on latest epidemiological data)","HSS I-1: Under 5 mortality rate per 1000 live births","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months",null,"HSS O-1: Percentage of women attending antenatal care","HSS O-2: Percentage of births attended by skilled health professional","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse"]
[null,"HSS I-1: Under 5 mortality rate per 1000 live births","HSS I-2: Neonatal mortality rate, per 100,000 population","HIV I-7: Modelled lives saved based on latest epidemiological data","HIV I-7: Modelled lives saved based on latest epidemiological data",null,"Malaria O-5: Proportion of households with at least one insecticide-treated net","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIV O-8: Current school attendance rate among orphans compared to non-orphans"]
[null,"HSS I-2: Neonatal mortality rate, per 100,000 population","HSS I-3: Maternal mortality ratio, per 100,000 population","HIV I-8: Modelled infections averted based on latest epidemiological data","HIV I-8: Modelled infections averted based on latest epidemiological data",null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-5: Specific services readiness score for health facilities","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases"]
[null,"HSS I-3: Maternal mortality ratio, per 100,000 population","Custom","HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIV I-9a: Percentage of men who have sex with men who are living with HIV",null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","Custom","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse"]
[null,"Custom",null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIV I-9b: Percentage of transgender people who are living with HIV",null,"HSS O-5: Specific services readiness score for health facilities",null,"TB O-2a: Treatment success rate - all forms of TB","TB O-2a: Treatment success rate - all forms of TB"]
[null,null,null,"HIV I-10: Percentage of sex workers who are living with HIV","HIV I-10: Percentage of sex workers who are living with HIV",null,"Custom",null,"TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases"]
[null,null,null,"HIV I-11: Percentage of people who inject drugs who are living with HIV","HIV I-11: Percentage of people who inject drugs who are living with HIV",null,null,null,"TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases"]
[null,null,null,"HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV","HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV",null,null,null,"TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated"]
[null,null,null,"TB I-1: TB prevalence rate (per 100,000 population)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population",null,null,null,"HSS O-1: Percentage of women attending antenatal care","HSS O-1: Percentage of women attending antenatal care"]
[null,null,null,"TB I-2: TB incidence rate (per 100,000 population)","HSS I-1: Under 5 mortality rate per 1000 live births",null,null,null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-2: Percentage of births attended by skilled health professional"]
[null,null,null,"TB I-3: TB mortality rate (per 100,000 population)","HSS I-2: Neonatal mortality rate, per 100,000 population",null,null,null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,null,null,"TB I-4: MDR-TB prevalence among new TB patients","HSS I-3: Maternal mortality ratio, per 100,000 population",null,null,null,"HSS O-5: Specific services readiness score for health facilities","HSS O-5: Specific services readiness score for health facilities"]
[null,null,null,"TB I-5: Modelled lives saved based on latest epidemiological data","Custom",null,null,null,"Custom","Custom"]
[null,null,null,"TB I-6: Modelled infections averted based on latest epidemiological data"]
[null,null,null,"TB/HIV I-1: TB/HIV mortality rate, per 100,000 population"]
[null,null,null,"HSS I-1: Under 5 mortality rate per 1000 live births"]
[null,null,null,"HSS I-2: Neonatal mortality rate, per 100,000 population"]
[null,null,null,"HSS I-3: Maternal mortality ratio, per 100,000 population"]
[null,null,null,"Custom"]

{"sheet":"Coverage Indicators","index":6,"n_rows":20,"n_cols":26,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS"]
[null,null," ",null,null,null,null,null,null,null,null,null,null,null,null,"Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","HIV/AIDS"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","HIV/AIDS","Tuberculosis"]
[null,null,null,null,null,"Tuberculosis","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Tuberculosis","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","HIV/TB","Malaria"]
[null,"Malaria","Malaria","Malaria","Tuberculosis","HIV/TB","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Malaria","HIV/TB"]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","HIV/AIDS","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results based Financing"]
[null,"Module1","Module2","Module3","Module4","Module5","Module8","Module9","Module10","Module11","Module12","Module13","Module14","Module15","Module24","Module27","Module28","Module29","Module30","Module31","Module32","Module33","Module34","Module35","Module72","Module73"]
[null,"SPI-1: Proportion of pregnant women attending antenatal clinics who received three or more doses of intermittent preventive treatment (IPTp) for malaria","VC-1: Number of long-lasting insecticidal nets distributed to at-risk populations through mass campaigns","CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)","GP-1: Number of women and men aged 15+ who received an HIV test and know their results","KP-1a: Percentage of MSM reached with HIV prevention programs - defined package of services","KP-1d: Percentage of PWID reached with HIV prevention programs - defined package of services","KP-1e: Percentage of other vulnerable populations reached with HIV prevention programs - defined package of services","YP-1: Percentage of young people aged 10?24 years reached by life skills?based HIV education in schools","KP-1c: Percentage of sex workers reached with HIV prevention programs - defined package of services","PMTCT-1: Percentage of pregnant women who know their HIV status","TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register","Custom ","SD-1: Number of health facilities per 10,000 population","HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines","Custom","PSM-1: Percentage of health facilities reporting no stock-outs of essential drugs","Custom","HF-1: Government expenditure on health as percentage of general government expenditure","Custom","Custom","Custom"]
[null,"Custom","VC-2: Proportion of population at risk potentially covered by long lasting insecticidal nets distributed","CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses","MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","GP-2: Percentage of individuals from targeted population reached through community outreach with standardized HIV prevention interventions","KP-1b: Percentage of TG reached with HIV prevention programs - defined package of services","KP-2d: Percentage of PWID reached with HIV prevention programs - individual and/or smaller group level interventions","KP-2e: Percentage of other vulnerable populations reached with HIV prevention programs - individual and/or smaller group level interventions","Custom","KP-2c: Percentage of sex workers reached with HIV prevention programs - individual and/or smaller group level interventions","PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission","TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TB/HIV-4: Percentage of new HIV-positive patients starting IPT during the reporting period",null,"SD-2: Number of outpatients visits per 10,000 population","HW-2: Distribution of health workers","M&E-2: Proportion of facility reports received over the reports expected during the reporting period",null,"Custom",null,"Custom"]
[null,null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","GP-3: Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services","KP-2a: Percentage of MSM reached with HIV prevention programs - individual and/or smaller group level interventions","KP-3d: Percentage of PWID that have received an HIV test during the reporting period and know their results","KP-3e: Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results",null,"KP-3c: Percentage of sex workers that have received an HIV test during the reporting period and know their results","PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth","TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TB/HIV-3: Percentage of HIV-positive patients who were screened for TB in HIV care or treatment settings",null,"Custom","HW-3: Number of health workers newly recruited at primary health care facilities in the past 12 months, expressed as a percentage of planned recruitment targets","M&E-3: Percentage of deaths registered (as reported by civil or sample registration systems, hospitals, community-based reporting systems) among the total deaths for the same period and geographical region"]
[null,null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period","MDR TB-4: Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up at six months","GP-4: Percentage of antenatal care attendees tested for syphilis","KP-2b: Percentage of TG reached with HIV prevention programs - individual and/or smaller group level interventions","KP-4: Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs","Custom",null,"Custom","Custom","TCS-4: Percentage of health facilities dispensing antiretroviral therapy that experienced a stock-out of at least one required antiretroviral drug in the last 12 month","TB/HIV-2: Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment",null,null,"HW-4: Annual rate of retention of service providers at primary health care facilities","Custom"]
[null,null,"VC-5: Proportion of households in targeted areas that received Indoor Residual Spraying during the reporting period","CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period","MDR TB-5: Percentage of DST laboratories showing adequate performance on External Quality Assurance","GP-5: Number of male circumcisions performed according to national standards","KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results","KP-5: Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months",null,null,null,null,"TCS-5: Proportion of undernourished PLHIV that received therapeutic or supplementary food at any point during the reporting period","Custom",null,null,"Custom"]
[null,null,"VC-6: Proportion of population protected by Indoor Residual Spraying within the last 12 months","CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","DOTS-4: Percentage of reporting units reporting no stock-out of first-line anti-TB drugs on the last day of the quarter","Custom","GP-6: Percentage of orphaned and vulnerable children aged 0?17 years whose households received free basic external support in caring for the child according to national guidelines","KP-3b: Percentage of TG that have received an HIV test during the reporting period and know their results","Custom",null,null,null,null,"Custom"]
[null,null,"Custom","CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","DOTS-5: Number of children <5 in contact with TB patients who began IPT",null,"Custom","Custom"]
[null,null,null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups"]
[null,null,null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","DOTS-7a: Percentage of notified TB cases, all forms, contributed by non-NTP providers - private/non-governmental facilities"]
[null,null,null,"CM-4: Proportion of health facilities without stock-outs of key commodities during the reporting period","DOTS-7b: Percentage of notified TB cases, all forms, contributed by non-NTP providers - public sector"]
[null,null,null,"CM-5: Percentage of confirmed cases fully investigated (malaria elimination phase)","DOTS-7c: Percentage of notified TB cases, all forms, contributed by non-NTP providers - community referrals"]
[null,null,null,"CM-6: Percentage of foci fully investigated (malaria elimination phase)","Custom"]
[null,null,null,"Custom"]

{"sheet":"CoverageDisaggregationData","index":7,"n_rows":37,"n_cols":10,"rows_kept":37,"cut":false,"hidden":true,"merged":[]}
[null,"Coverage disaggregation Data "]
[null,"Name of Indicator","ShortName","Disaggregation ","Concatenatedcode","Module","Categories"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Sex",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C3,D3),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DSex"},"Prevention programs for general population","Male","Female"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","HIV status","GP1DHIVstatus","Prevention programs for general population","Positive","Negative"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Age",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C5,D5),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DAge"},"Prevention programs for general population","15-24"]
[null,"PMTCT-1: Percentage of pregnant women who know their HIV status","PMTCT1","HIV status-pregnant women","PMTCT1HIVstatuspregnantwomen","PMTCT","Known positive HIV infection at ANC","Newly identified as HIV positive","Testing HIV negative"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Sex","TCS1aSex","Treatment, care and support","Male","Female"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Age","TCS1aAge","Treatment, care and support","<15","15+","15-24"]
[null,"TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TCS2a","Sex","TCS2aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Sex","TCS3aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Age","TCS3aAge","Treatment, care and support","15-24"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Sex","DOTS1aSex","TB care and prevention","Male","Female"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","HIV test result","DOTS1aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Age","DOTS1aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Sex","DOTS2aSex","TB care and prevention","Male","Female"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Age","DOTS2aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","HIV test result","DOTS2aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups","DOTS6","KAPs/high risk groups","DOTS6KAPshighriskgroups","TB care and prevention","Prisoners","Migrants/ Refugees/ IDPs","Others - specify"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Sex","MDRTB2Sex","MDR-TB","Male","Female"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Age","MDRTB2Age","MDR-TB","<15","15+"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Sex","MDRTB3Sex","MDR-TB","Male","Female"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Age","MDRTB3Age","MDR-TB","<15","15+"]
[null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","VC3a","Targeted risk group","VC3aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","VC4a","Targeted risk group","VC4aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Age","CM1aAge","Case management","<5","5+"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Type of testing","CM1aTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Age","CM1bAge","Case management","<5","5+"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Type of testing","CM1bTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Age","CM1cAge","Case management","<5","5+"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Type of testing","CM1cTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","CM2a","Age","CM2aAge","Case management","<5","5+"]
[null,"CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","CM2b","Age","CM2bAge","Case management","<5","5+"]
[null,"CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","CM2c","Age","CM2cAge","Case management","<5","5+"]
[null,"CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","CM3a","Age","CM3aAge","Case management","<5","5+"]
[null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","CM3b","Age","CM3bAge","Case management","<5","5+"]
[null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","CM3c","Age","CM3cAge","Case management","<5","5+"]
[null,"HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","HW1a","Specialization","HW1aSpecialization","HSS - Health and community workforce","Doctors","Nurses","Lab technicians","Other - specify"]

{"sheet":"WPTM_1C","index":8,"n_rows":41,"n_cols":28,"rows_kept":41,"cut":false,"hidden":false,"merged":[[14,12,14,18],[14,20,14,21],[6,2,6,5],[10,2,10,5],[0,0,0,11],[14,0,14,11]]}
["Ongoing Progress Update and Disbursement Request"]
["Grant number:",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Component",null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,"Cycle:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"Number:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}},null,null,null,null,null,null,"End Date:",{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Section 1:  Programmatic Progress"]
["Note: Enter only the Workplan Tracking Measures that are due for the reporting period "]
["C- Workplan Tracking Measures",null,null,null,null,null,null,null,null,null,null,null,"LFA Use Only",null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Module",null,"Intervention","Activity","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Target","Progress Status","Score","Reasons for deviation from workplan activities and milestones","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Progress Status","Verified Score","LFA analysis of progress and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)","Progress Status","Validated Score","Country Team Comments on Validated Score"]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A17,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,null,null,{"$f":"_1__xlfn.IFNA(VLOOKUP(J17,$AA$19:$AB$22,2,FALSE),\"\")","v":{"$error":"#NAME?"}},null," "," ",null," ",null,{"$f":"_1__xlfn.IFNA(VLOOKUP(Q17,$AA$19:$AB$22,2,FALSE),\"\")","v":{"$error":"#NAME?"}},null,null,{"$f":"R17","v":{"$error":"#NAME?"}}]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A18,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"_1__xlfn.IFNA(VLOOKUP(J18,$AA$19:$AB$22,2,FALSE),\"\")","v":{"$error":"#NAME?"}},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$f":"R18","v":{"$error":"#NAME?"}}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"},null,null,null,null,null,"Not Started",0]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"},null,null,null,null,null,"Started",1]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"},null,null,null,null,null,"Advancing",2]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"},null,null,null,null,null,"Completed",3]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]
[null,"",null,null,null,null,null,null,"-",null,{"$error":"#NAME?"},null,null,null,null,null,null,{"$error":"#NAME?"},null,null,{"$error":"#NAME?"}]

{"sheet":"Intervention By Modules old","index":9,"n_rows":20,"n_cols":80,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[]
[null,null," "]
[]
[]
[]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TBcareandprevention","MDR-TB","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","TB/HIV","TB/HIV","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing"]
[null,"MalariaModule1","MalariaModule2","MalariaModule3","TuberculosisModule4","TuberculosisModule5","HIV/TBModule6","HIV/TBModule7","HIV/TBModule8","HIV/TBModule9","HIV/TBModule10","HIV/TBModule11","HIV/TBModule12","HIV/TBModule13","HIV/TBModule14","HIV/TBModule15","HIV/AIDSModule16","HIV/AIDSModule17","HIV/AIDSModule18","\nHIV/AIDSModule19","HIV/AIDSModule20","HIV/AIDSModule21","HIV/AIDSModule22","\nHIV/AIDSModule23","HIV/AIDSModule24","\nTuberculosisModule25","\nHIV/TBModule26","\nHIV/AIDSModule27","HIV/AIDSModule28","HIV/AIDSModule29","HIV/AIDSModule30","HIV/AIDSModule31","HIV/AIDSModule32","HIV/AIDSModule33","HIV/AIDSModule34","HIV/AIDSModule35","TuberculosisModule36","TuberculosisModule37","TuberculosisModule38","TuberculosisModule39","TuberculosisModule40","TuberculosisModule41","TuberculosisModule42","TuberculosisModule43","TuberculosisModule44","Module45","MalariaModule46","MalariaModule47","MalariaModule48","MalariaModule49","MalariaModule50","MalariaModule51","MalariaModule52","MalariaModule53","Health Systems StrengtheningModule54","Health Systems StrengtheningModule55","Health Systems StrengtheningModule56","Health Systems StrengtheningModule57","Health Systems StrengtheningModule58","Health Systems StrengtheningModule59","Health Systems StrengtheningModule60","Health Systems StrengtheningModule61","Health Systems StrengtheningModule62","HIV/TBModule63","HIV/TBModule64","HIV/TBModule65","HIV/TBModule66","HIV/TBModule67","HIV/TBModule68","HIV/TBModule69","HIV/TBModule70","HIV/TBModule71","HIV/AIDSModule72","HIV/AIDSModule73","TuberculosisModule74","TuberculosisModule75","MalariaModule76","MalariaModule77","HIV/TBModule78","HIV/TBModule79"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","TB/HIV collaborative interventions","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Engaging all care providers","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community TB care delivery","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Key Affected Populations","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support","HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care","Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care","Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify",null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"Intervention By Modules","index":10,"n_rows":17,"n_cols":26,"rows_kept":17,"cut":false,"hidden":true,"merged":[]}
[]
[]
[null,"SpecificpreventioninterventionsSPI","Vectorcontrol","Casemanagement","TBcareandprevention","MDR-TB","Preventionprogramsforgeneralpopulation","PreventionprogramsforMSMandTGs","PreventionprogramsforpeoplewhoinjectdrugsPWIDandtheirpartners","Preventionprogramsforothervulnerablepopulationspleasespecify","Preventionprogramsforadolescentsandyouthinandoutofschool","Preventionprogramsforsexworkersandtheirclients","PMTCT","Treatmentcareandsupport","TBHIV","Removinglegalbarrierstoaccess","HSSServicedelivery","HSSHealthandcommunityworkforce","HSSHealthinformationsystemsandME","Programmanagement","HSSProcurementsupplychainmanagementPSCM","HSSPolicyandgovernance","HSS-Healthcarefinancing","HSSFinancialmanagement","Communitysystemsstrengthening","Results basedFinancing"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,"Other interventions for IDUs and their partners - Please specify"]
[null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"PR Cash Reconciliation_2A,B,C","index":11,"n_rows":73,"n_cols":12,"rows_kept":73,"cut":false,"hidden":false,"merged":[[3,0,3,11],[48,1,48,11],[24,1,24,11],[59,5,59,8],[66,5,66,8],[65,1,65,11],[66,2,66,4],[66,9,66,11],[19,0,20,11],[21,0,21,11],[25,2,25,4],[25,5,25,8],[25,9,25,11],[58,1,58,11],[59,1,60,1],[59,2,59,4],[59,9,59,11],[12,6,12,9],[17,6,17,9],[17,1,17,3],[10,1,10,3],[11,1,11,3],[12,1,12,3],[15,1,15,3],[16,1,16,3]]}
[]
[]
[]
["Ongoing Progress Update and Disbursement Request "]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"GA Number",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Number:"]
[]
["Section 2: Financial Information"]
[]
[]
[]
[]
[null,"A. Principal Recipient Cash Reconciliation Statement in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
["Item No.","Description","Cumulative for Previous Periods","Current Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[1.1000000000000001,"Cash Balance: Beginning of the Period",0,2878484.3549595419,null,null,null,{"$f":"D28+G28","v":2878484.3549595419},null,null,{"$f":"H28+J28","v":2878484.3549595419}]
[null,"2. Grant Income"]
[null,"Add: "]
[2.1,"Disbursement made to the Principal Recipient ",{"$f":"4418100+438789+3576040.99","v":8432929.9900000002},{"$f":"550879+1768890.77","v":2319769.77},null,0,0,{"$f":"D31+G31","v":2319769.77},null,0,{"$f":"H31+J31","v":2319769.77}]
[2.2000000000000002,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",193752.19,{"$f":"1021728.79-200-193752.19","v":827776.60000000009},null,0,0,{"$f":"D32+G32","v":827776.60000000009},null,0,{"$f":"H32+J32","v":827776.60000000009}]
[2.2999999999999998,"Interest received on bank accounts",0,0,null,0,0,{"$f":"D33+G33","v":0},null,0,0]
[2.4,"Revenue from income-generating activities (if applicable)",0,0,null,0,0,{"$f":"D34+G34","v":0},null,0,0]
[2.5,"Other income, if applicable (e.g. VAT/Other Tax returns, income from disposal of assets etc.)",0,{"$f":"15970.48+34589.41+64813/2.6872","v":74679.04748734743},"VAT refund",0,0,{"$f":"D35+G35","v":74679.04748734743},null,0,74679.04748734743]
[2.6,"Total Grant Income",{"$f":"SUM(C31:C35)","v":8626682.1799999997},{"$f":"SUM(D31:D35)","v":3222225.4174873475},null,{"$f":"SUM(F31:F35)","v":0},{"$f":"SUM(G31:G35)","v":0},{"$f":"SUM(H31:H35)","v":3222225.4174873475},null,{"$f":"SUM(J31:J35)","v":0},{"$f":"SUM(K31:K35)","v":3222225.4174873475}]
[null,"3. Grant Cash Outflows"]
[null,"Less:"]
[3.1,"Principal Recipient Expenditure (including payments and other advance payments)",{"$f":"1965716.01474278-193752.19","v":1771963.8247427801},{"$f":"1199187.22008376+193752.19","v":1392939.41008376},null,{"$f":"F32","v":0},0,{"$f":"D39+G39","v":1392939.41008376},null,{"$f":"J32","v":0},{"$f":"H39+J39","v":1392939.41008376}]
[3.2,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"C32","v":193752.19},{"$f":"D32","v":827776.60000000009},null,0,0,{"$f":"D40+G40","v":827776.60000000009},null,0,{"$f":"H40+J40","v":827776.60000000009}]
[3.3,"Principal Recipient disbursement to sub-recipients",3790603.5305948136,1499461.2431307815,null,0,0,{"$f":"D41+G41","v":1499461.2431307815},null,0,{"$f":"H41+J41","v":1499461.2431307815}]
[3.4,"Bank charges on disbursements and payments",100,200,null,0,0,{"$f":"D42+G42","v":200},null,0,200]
[3.5,"Total Grant Cash Outflows",{"$f":"SUM(C39:C42)","v":5756419.5453375932},{"$f":"SUM(D39:D42)","v":3720377.2532145418},null,{"$f":"SUM(F39:F42)","v":0},{"$f":"SUM(G39:G42)","v":0},{"$f":"SUM(H39:H42)","v":3720377.2532145418},null,{"$f":"SUM(J39:J42)","v":0},{"$f":"SUM(K39:K42)","v":3720377.2532145418}]
[null,"4. Reconciling Adjustments"]
[4.0999999999999996,"Other reconciliation adjustments (including for prior periods)",0,0,null,0,0,{"$f":"D45+G45","v":0},null,0,{"$f":"H45+J45","v":0}]
[4.2,"Net exchange gains/losses on translation of balances",-8221.7199999999993,-28454.880000000001,null,0,0,{"$f":"D46+G46","v":-28454.880000000001},null,0,{"$f":"H46+J46","v":-28454.880000000001}]
[4.3,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",0,0,null,0,0,{"$f":"D47+G47","v":0},null,0,0]
[4.4000000000000004,"Reimbursement of ineligible transaction from previous periods",0,0,null,0,0,{"$f":"D48+G48","v":0},null,0,0]
[null,"5. Total Cash Balances: End of the reporting period"]
[5.0999999999999996,"Principal Recipient Cash Balance",0,{"$f":"(D28+D36-D43)+D45+D46+D48","v":2351877.6392323477},null,null,{"$f":"(G36-G43)+G46+G48+G45","v":0},{"$f":"(H28+H36-H43)+H45+H46-H47","v":2351877.6392323477},null,{"$f":"J28+J36-J43+J46+J45","v":0},{"$f":"K28+K36-K43+K46+K45-K47","v":2351877.6392323477}]
[5.2,"Sub-Recipient Cash Balance",0,{"$f":"'SR_Cash Reconciliation_2D'!H54","v":0},null,null,{"$f":"'SR_Cash Reconciliation_2D'!K54","v":0},{"$f":"'SR_Cash Reconciliation_2D'!L54","v":0},null,0,{"$f":"+H51+J51","v":0}]
[5.3,"Total Cash Balance",{"$f":"C50+C51","v":0},{"$f":"D50+D51","v":2351877.6392323477},null,{"$f":"F50+F51","v":0},{"$f":"G50+G51","v":0},{"$f":"H50+H51","v":2351877.6392323477},null,{"$f":"J50+J51","v":0},{"$f":"K50+K51","v":2351877.6392323477}]
[null,"6. Commitments & Other Obligations"]
[6.1,"Unpaid invoices, accrued expenditure for severance pay, leave and other liabilities ",0,{"$f":"(14964.4+1100+678620.93)/2.6169+(330561.66)/2.6169","v":391779.20058084},null,0,0,{"$f":"D54+G54","v":391779.20058084},null,0,{"$f":"H54+J54","v":391779.20058084}]
[6.2,"Open legal obligations (including signed contracts not yet invoiced) ",0,{"$f":"(23980/2+248430*2/3+24554/2)/2.6169","v":72561.809774924535},null,0,0,{"$f":"D55+G55","v":72561.809774924535},null,0,{"$f":"H55+J55","v":72561.809774924535}]
[6.3,"Tenders and/or procurement contracts initiated but not yet signed as contracts",0,0,null,0,0,{"$f":"D56+G56","v":0},null,0,{"$f":"H56+J56","v":0}]
[6.4,"Total Commitments & Other Obligations",{"$f":"SUM(C54:C56)","v":0},{"$f":"SUM(D54:D56)","v":464341.01035576453},null,{"$f":"SUM(F54:F56)","v":0},{"$f":"SUM(G54:G56)","v":0},{"$f":"SUM(H54:H56)","v":464341.01035576453},null,{"$f":"SUM(J54:J56)","v":0},{"$f":"SUM(K54:K56)","v":464341.01035576453}]
[]
[null,"B. Principal Recipient Bank Statement Balance & Cash In Transit in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,null,"End of Period","Comments",null,"LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[7.1,"Principal Recipient Cash Balance as per bank statements (For Information Only):",null,2351877.6419095113,"The amount consists of GEL 1,000,199.78 and EUR 1,969,669.77 )",null,0,{"$f":"D62+G62","v":2351877.6419095113},null,0,{"$f":"H62+J62","v":2351877.6419095113}]
[7.2,"Cash in Transit for the reporting period",null,0,null,null,0,{"$f":"D63+G63","v":0},null,0,{"$f":"H63+J63","v":0}]
[7.3,"Cash in Transit after the current reporting period",null,0,null,null,0,{"$f":"D64+G64","v":0},null,0,0]
[]
[null,"C. Principal Recipient Ineligible Transactions in Grant Currency "]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,"Cumulative for Previous Periods","End of Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on current Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[8.1,"Ineligible transactions validated for the reporting period",0,0,null,null,{"$f":"G52","v":0},{"$f":"D69+G69","v":0},null,{"$f":"J41","v":0},{"$f":"H69+J69","v":0}]
[8.1999999999999993,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",{"$f":"C47","v":0},{"$f":"D47","v":0},null,{"$f":"F47","v":0},{"$f":"G47","v":0},{"$f":"D70+G70","v":0},null,0,{"$f":"H70+J70","v":0}]
[8.3000000000000007,"Reimbursement of ineligible transactions from previous periods",{"$f":"C48","v":0},{"$f":"D48","v":0},null,{"$f":"F48","v":0},{"$f":"G48","v":0},{"$f":"D71+G71","v":0},null,{"$f":"J48","v":0},0]
[8.4,"Cumulative ineligible transactions for the implementation period",0,{"$f":"D69+C72","v":0},null,null,0,{"$f":"D72+G72","v":0},null,0,{"$f":"K69+C72","v":0}]
[8.5,"Open ineligible transactions to be justified and/or reimbursed",{"$f":"C69-C70-C71","v":0},{"$f":"C73+D69-D70-D71","v":0},null,null,0,{"$f":"D73+H69-H70-H71","v":0},null,0,{"$f":"H73+J69-J70-J71","v":0}]

{"sheet":"SR_Cash Reconciliation_2D","index":12,"n_rows":56,"n_cols":16,"rows_kept":56,"cut":false,"hidden":false,"merged":[[21,13,21,15],[16,0,17,11],[19,0,19,15],[6,0,6,2],[7,0,7,2],[8,0,8,2],[11,0,11,2],[12,0,12,2],[8,3,8,6],[13,3,13,6],[13,0,13,2],[21,0,21,9],[21,10,21,12]]}
["Ongoing Progress Update and Disbursement Request "]
[]
["Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
["PROGRESS UPDATE "]
["Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Number:"]
[]
["DISBURSEMENT REQUEST "]
["Disbursement Request  - Disbursement Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:"]
[]
[]
["Section 2: Financial Information"]
[]
[]
["D. Principal Recipient Reconciliation of funds provided to Sub-Recipients for the Current Implementation Period"]
[]
["Principal Recipient",null,null,null,null,null,null,null,null,null,"For Local Fund Agent Use Only ",null,null,"For the Global Fund Use Only"]
["(1) \nSub-Recipient Name","(2) \n Cumulative Sub-Recipient expenses for prior periods at Principal Recipient level","(3) \nSub-Recipient Open Advances at Principal Recipient Level","(4) \nDisbursements made by Principal Recipient during the Reporting Period","(5) \nOther Income* during the Reporting Period ","(6) \nExpenditure validated by Principal Recipient during the Reporting Period","(7) \nSub-Recipient Closing Balance at Principal Recipient Level","(8) \nActual Sub-Recipient Cash Balance (if applicable)"," (9)\nVariances on Sub-Recipient Balances","Comments","LFA Adjustments","As verified by LFA","Comments","Country Team Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[null,0,0,0,0,0,{"$f":"+C24+D24+E24-F24","v":0},0,{"$f":"+H24-G24","v":0},null,null,{"$f":"H24+K24","v":0},null,null,{"$f":"L24+N24","v":0}]
[null,0,0,0,0,0,{"$f":"+C25+D25+E25-F25","v":0},0,0,null,null,{"$f":"H25+K25","v":0},null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H38-G38","v":0},null,null,{"$f":"H38+K38","v":0},null,null,{"$f":"L38+N38","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H51-G51","v":0},null,null,{"$f":"H51+K51","v":0},null,null,{"$f":"L51+N51","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
["Total for the Reporting Period",{"$f":"SUM(B24:B53)","v":0},0,0,0,0,0,0,0,null,null,0,null,null,0]
[]
["* Includes interest income, income generating activites etc."]

{"sheet":"Budget Variance_2E","index":13,"n_rows":43,"n_cols":14,"rows_kept":43,"cut":false,"hidden":false,"merged":[[36,1,36,2],[35,1,35,2],[39,1,39,2],[40,1,40,2],[42,1,42,2],[41,1,41,2],[37,1,37,2],[6,1,6,3],[7,1,7,3],[8,1,8,3],[8,5,8,8],[11,1,11,3],[12,1,12,3],[19,1,19,2],[20,1,20,2],[19,7,19,8],[20,7,20,8],[14,0,14,13],[16,0,16,13],[21,1,21,2],[34,1,34,2],[22,1,22,2],[26,1,26,2],[27,1,27,2],[24,1,24,2],[31,0,31,11],[25,1,25,2],[39,7,39,8],[41,7,41,8],[42,7,42,8],[18,3,18,13],[33,3,33,13],[27,7,27,8],[34,7,34,8],[35,7,35,8],[36,7,36,8],[37,7,37,8],[21,7,21,8],[22,7,22,8],[24,7,24,8],[25,7,25,8],[26,7,26,8]]}
["Ongoing Progress Update and Disbursement Request"]
[]
[null,"Grant Name:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"(Disease) Component",{"$f":"#REF!","v":{"$error":"#REF!"}}]
[]
[null,"PROGRESS UPDATE "]
[null,"Progress Update - Reporting Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"DISBURSEMENT REQUEST "]
[null,"Disbursement Request  - Disbursement Period:",null,null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Disbursement Request  - Period Covered:",null,null,null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"End Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Section 2: Financial Information"]
[]
["E. Total Principal Recipient Budget Variance and Funding Absorption Analysis"]
[]
[null,null,null,"Principal Recipient"]
[null,null,null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D22:D23)","v":5976105.9371561045},{"$f":"SUM(E22:E23)","v":3720377.2532145418},{"$f":"IF(D21=\"\",IF(E21=\"\",\"\",D21-E21),D21-E21)","v":2255728.6839415627},{"$f":"E21/D21","v":0.62254205202141821},null,null,{"$f":"SUM(J22:J23)","v":17581514.506065555},{"$f":"SUM(K22:K23)","v":9476796.798552135},{"$f":"IF(J21=\"\",IF(K21=\"\",\"\",J21-K21),J21-K21)","v":8104717.7075134199},{"$f":"K21/J21","v":0.53902050334074902}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,4125414.2349604941,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42","v":2220916.0100837601},{"$f":"IF(D22=\"\",IF(E22=\"\",0,D22-E22),D22-E22)","v":1904498.224876734},{"$f":"E22/D22","v":0.53834981982240337},"Net variance of EUR 1,904,498 consists of Positive variance of EUR 3,362,400 and negative variance of EUR 1,457,902\nPositive variance is derived from activities that were budgeted in current reporting period and represent either saving , commitment or  postponed activity.\nSaving EUR 2,407,164  include:  \nEUR 2,343,397 -  Actual cost for MPP and PSM was less than budgeted (ARVs , vaccines, quality control) mainly due to lower price offer from MPP and low cost local procurement of HP and ARV QC service. \nEUR 63,295 - Saving in Project management costs including International PSM consultant fee, Fuel cost for PR ; Audit cost, HR costs due to vacant positions (Logistics, Finance specialist)  FX rate change had also impact on current savings.\nEUR 472 – Actual cost for fuel provided to Srs was less than budgeted\nPostponed Activities: EUR 797,837 – remaining amount for PFSCM order placed in 2014 and new order placed in 2015 pushed to NFM budget. Also IDA remainig amount for Syringes Order moved to NFM. \nCommitment EUR 6,054 include: \nEUR 5,511 – Part of Fuel cost provided to SRs in December, paid in January 2016.  \nEUR 543 - Project Management costs (fuel cost, ERP consultant fee ) for December that was actually paid in January 2016\nNegative Variance EUR 1,306,557– The driver of negative variance is Actual cost of all procurements that were delayed from the previuos budgeting periods (Mobile laboratories, payment for ARVs, Office equipment and furniture for SRs and etc.)\nEUR 17,071– SRs fuel cost budgeted in the previous reporting period for the entire year. \nEUR 1,117,410 – Procurement of all HPHE budgeted in the previous reporting periods. \nEUR 135,176  – Cost of MPP (interferon, vaccines, STI drugs)  procured in current period and budgeted in previous period. \nEUR 8,925 – Cost of office equipment/Furniture and printing of the info materials procured for SRs in the current period and budgeted in the previous period\nEUR 27,975 – Project managment cost (training and media campaign) budgeted in the previuos period and carried forward to the current period. \n",null,10813852.056482488,{"$f":"'PR Cash Reconciliation_2A,B,C'!D39+'PR Cash Reconciliation_2A,B,C'!D40+'PR Cash Reconciliation_2A,B,C'!D42+'PR Cash Reconciliation_2A,B,C'!C39+'PR Cash Reconciliation_2A,B,C'!C40+'PR Cash Reconciliation_2A,B,C'!C42","v":4186732.0248265401},{"$f":"IF(J22=\"\",IF(K22=\"\",0,J22-K22),J22-K22)","v":6627120.0316559486},{"$f":"K22/J22","v":0.38716379722586969},"Net variance of EUR 6,627,120 consists of Positive variance of Euro 6,764,555 and negative variance of EUR 137,435\nTotal Saving  EUR 5,809,320 include: \nEUR 98,290 – Actual cost and quantities for Srs fuel was less than budgeted\nEUR 3,868,657  –Savings from  MPP &PSM (ARVs, interferon, methadone, STI medicines, quality control of ARVs) is derived from cancelled activities, actual consumtion rates, lower unit prices, including lower unit prices of ARVs offerd by PPM and also regimens were simplified. considerably lower price procurement of interferon through the local tender. Also Procurement of pagylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.  Procurement of methadone was conducted at much lower price than budgeted also (4 EUR vs. 9 EUR). \nEUR  1,389,360 - HPHE procurement (lab supplies, desinfectants, tests systems, Flowcytometer;syringes,condoms) is derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities. Instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resuted in substeintial seving. \nEUR 130,132 - Procurement of office equipment/furniture and printing of materials through tenders resulted in saving . Database development cost budgeted in GHRN is moved to NFM period, the amount is included in the savings.\nEUR 77,978  - Procurement of Vehicles for SRs was cancelled in agreement with GF.\nEUR 244,903 - Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist ) ; saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee.The FX rate had also impact on savings.\nPostponed Activities: EUR 822,778 – remaining amount for PFSCM order placed in 2014 and new order placed in 2015 pushed to NFM budget. Also IDA remainig amount for Syringes Order moved to NFM. \nCommitment EUR 132,457 include: \nEUR 5,511 –Fuel cost provided to SRs in December, paid in January 2016.  \nEUR 126,403- Cost of additional 4 Mobile Ambulatories, which were delivered in March, 2016.\nEUR 543 - Project Management costs (fuel cost, ERP consultant fee ) for December and paid in January 2016\nNegative Variance EUR 137,435 include:\nEUR 121,766 – Cost of addittional 4 mobile ambulatories approved by GF.\nEUR 5,411 – Additional request from TG on procurement of micropipetes approved by GF\nEUR 1,396 – Actual cost of office equipment/furniture was slightly greater than budgeted.\nEUR 2,857 – Actual cost of desinfectants and minor lab supplies was slightly greater than budgeted \nEUR 5,309 – Actual need of STI medicines was greater based on the cuurent consumption \nEUR 696– actual Cost of Printing info materials for TG was greater than budgeted.\n"]
[null,"    1b. Disbursements to sub-recipients",null,1850691.7021956102,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41","v":1499461.2431307815},{"$f":"IF(D23=\"\",IF(E23=\"\",0,D23-E23),D23-E23)","v":351230.4590648287},0.81021665648139096,"The reporting period relates to activities performed by the SRs for July-December period. Within the current reporting period SRs received payment for June –November 2015 . Advance payments were subtracted from October-Novemeber services  as their contract service period was until December 31, 2015. Total reimbursement for services equals to EUR 1,499,461 ( TG- EUR 190,838; HAPS –EUR 58,249 ; MHDAC –EUR 286,875; Aids Center EUR 288,272; CIF –EUR 60,790, GHRN- EUR 528,685, Objective 1 - EUR 77,659; BCG Research– EUR 8,093- Stigma Survey among healthcare workers was budgeted under SR HAPS , but through tender another organization was idetified as winner)\nThe variance consists of a) differences between periods for which SRs were reimbursed and the budget periods (June –Novemeber 2015 vs. July – December 2015); b) savings in program implementation (less amounts were spent per activities by SRs), some of the trainings included in the budget were not approved by the GF and were canceled; C) Mobile Laboratory related activities by GHRN that were started later (from November, 2015) when the network receive the procured vehicles; \n",null,6767662.4495830666,{"$f":"'PR Cash Reconciliation_2A,B,C'!D41+'PR Cash Reconciliation_2A,B,C'!C41","v":5290064.7737255953},{"$f":"IF(J23=\"\",IF(K23=\"\",0,J23-K23),J23-K23)","v":1477597.6758574713},0.78166794120346517,"The cumulative period relates to activities performed by the SRs for April 2014-December 2015 period. Within this period SRs received payment for April 2014-May 2015. Advance payments were subtracted from October-Novemeber services  as their contract service period was until December 31, 2015. Total reimbursement for  services equal EUR 5,290,065 ( TG- EUR 759,616; HAPS –EUR 210,989 ; MHDAC –EUR 956,833; Aids Center EUR 1,003,670; CIF –EUR 324,430, GHRN- EUR 1,899,895 Objective 1 - EUR 126,536; BCG Research– EUR 8096- Stigma Survey among healthcare workers was budgeted under SR HAPS, but through tender another organization was identified as winner). \nThe variance consists of a) differences between periods for which SRs were reimbursed and the budget periods (April 2014–Novemeber 2015 vs. April 2014 – December 2015) b) savings in program implementation (less amounts were spent per activities by SRs for trainings, meetings, M&E visits, for technical service of cars and equipment; less amounts were spent for PDI incentives and for case management and other activities; AIDS Center also procured the international laboratory QC service at a low price). C) differences in the budgeted amounts and the contractual amounts resulted from the the service procurement through the tenders; d) late opening of a new OST Center as well as procurement of mobile ambulatories and savings in related expenditures by the GHRN and Narcology Center for HR, T, ME, PA and OVE categories; National AIDS Center had postponed hiring of a new personnel for its administrative and PSM staff; e) canceled activities - Opening of a new ART Treatment Center was canceled; Drug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category, while it was initially budgeted in the OVE in approved GF budget; HAPS had canceled AIDS Victims Day Commemoration Event organization. \n"]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs.    budget",null,{"$f":"D27+D28","v":3133344.0149527816},{"$f":"E27+E28","v":1959441.3500432866},{"$f":"IF(D26=\"\",IF(E26=\"\",\"\",D26-E26),D26-E26)","v":1173902.664909495},{"$f":"E26/D26","v":0.62535149051382244},null,null,{"$f":"J27+J28","v":8705408.0641755983},{"$f":"K27+K28","v":3588459.0892438972},{"$f":"IF(J26=\"\",IF(K26=\"\",\"\",J26-K26),J26-K26)","v":5116948.9749317011},{"$f":"K26/J26","v":0.41221032521279338}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,3133344.0149527816,830863.97382803075,{"$f":"IF(D27=\"\",IF(E27=\"\",0,D27-E27),D27-E27)","v":2302480.0411247509},{"$f":"E27/D27","v":0.26516844938283979},"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance consists of Positive Variance EUR 2,437,763 and  Negative variance EUR 135,282\nSaving EUR 1,729,267– EUR 7,878– Actual unit prices for the vaccines were lower than budgeted; EUR 1,721,389–Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens  \nCommitment EUR 522 – Cost of December service of AIDS center (including the procurement of essential drugs) – reimbursed in January 2016\nPostponed EUR 707,974 -  ARVs order placed in 2015 and payment moved to NFM budget \nOverspending EUR 135,282  - EUR 100,951 procurement of Interferon was budgeted in the previous reporting period. EUR 6345 - procurement of STI essential drugs budgeted in the previous reporting period; EUR 27,880 - procurement of methadone budgeted in the previous reporting period; EUR 106 – the cost of procurement of the essential drugs by AIDS Center was slightly greater than budgeted.\n",null,5140297.1056705983,1403620.6564089607,{"$f":"IF(J27=\"\",IF(K27=\"\",0,J27-K27),J27-K27)","v":3736676.4492616374},{"$f":"K27/J27","v":0.2730621649983101},"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance consists of Positive Variance EUR 3,741,985 and  Negative variance EUR 5,309.\nDriver of saving is available stock at SR: Cheaper unit prices were gained both from the local procurement and through PPM (ARVs). Saving was made due to simplification of ART regimens based on WHO recommendations. \nSaving  EUR 3,033,489 - EUR 210,650 - Volume of Methadone was reduced according to the quota approved for the country and more precise need estimation conducted jointly by Narcology Center and MoH. The actual cost of methadone was less also (4 EUR vs. 9 EUR). \nEUR 15,529 – Actual unit price for vaccines was lower than budgeted.\nEuro 2,431,143–Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens  \nEuro 4,170 – saving in procurement of essential drugs made by AIDS  Center and lower unit price procurement of STI drugs.\nEuro 371,996 -  considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pagylated interferon and ribavirin budgeted at 342,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nCommitment EUR 522 – Cost of December service of Aids center (essential drugs) – reimbursed in January 2016\nPostponed EUR 707,974 -  ARVs order placed in 2015 and payment moved to NFM budget \nOverspending EUR 5,309 – procurement of STI essential drugs - actual cost is greater than budgeted due to updated quantification of the needs by the SR\n"]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,0,1128577.3762152558,{"$f":"IF(D28=\"\",IF(E28=\"\",0,D28-E28),D28-E28)","v":-1128577.3762152558},{"$error":"#DIV/0!"},"The Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe Negative variance EUR 1,128,577 is related to Procurement of all HPHE budgeted in the previous reporting periods. \nSaving EUR 163,148 – Actual cost of procurement syringes and needles budgeted in the previous period.\nEUR 834,223 – Actual cost of procurement tests and lab supplies for Aids Center budgeted in the previous period.\nEUR 35,573 – Actual cost of procurement Condoms and lubricants budgeted in the previous reporting period\nEUR 11,082 – Actual cost of procurement disinfectants and lab supplies budgeted in the previous period.\nEUR 65,496 - Actual cost of procurement tests (rapid tests, tests for STI) budgeted in the previous period.\nEUR 7,888 – Actual cost of procurement Centrifuges for Mobile ambulatories.\nEUR 11,167 procurement of tests by CIF budgeted in the previous reporting period.\n",null,3565110.958505,2184838.4328349368,{"$f":"IF(J28=\"\",IF(K28=\"\",0,J28-K28),J28-K28)","v":1380272.5256700632},0.61283883117936133,"The category relates to the Health product/equipment procured locally and with IDA (syringes and condoms). \nThe Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe variance consists of Positive Variance EUR 1,510,306 and Negative variance EUR 130,034 \nThe amounts spent on the procurement (lab supplies, desinfectants, tests systems, Flowcytometer; syringes, condoms) is a result of the low unit prices offered during the tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nSaving EUR 1,356,181:  EUR 316,349 - Procurement of syringes through IDA and local tenders for syringes, needles and vain sets resulted in low unit costs. Also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 88,619 – Procurement through IDA and local tenders resulted in lower than budgeted cost for condoms, also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 183,858 – Actual costs for procurement of disinfectant and lab supplies/equipment through tenders were less than budgeted also.  \nEUR 24,920 – Based on stocks of Naloxon available at SR level, the less q-ties were procured and  cost was lower also. \nEUR 90,203 – Actual cost of Procurement of tests (rapid tests, tests for STI, including cost of tests budgeted in PR and transferred to CIF) was lower than budgeted\nEUR 652,232 – Actual cost for tests and lab supplies for AIDS Center were less than budgeted through local tenders\nPostponed EUR 24,941 - Order placed for syringes with IDA in 2014 and remaining payment moved to NFM budget.\nCommitments EUR 129,184   - EUR 126,403- Cost of additional 4 Mobile Ambulatories, which were delivered in March, 2016; EUR 2,781 December service cost for CIF reimbursed in January 2016;\nOverspending EUR 130,034 -  EUR 5,411 – Additional request from TG on procurement of micropipetes approved by GF; EUR 2,857 – Actual cost of disinfectants and minor lab supplies was slightly greater than budgeted ; EUR 121,766 – Cost of procurement of additional 4 mobile ambulatories approved by GF.\n"]
[]
[]
["For LFA Use Only"]
["E. Total Principal Recipient Budget Variance and Absorption Analysis"]
[]
[null,null,null,"Local Fund Agent (LFA)"]
[null,null,null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on thePrincipal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D37:D38)","v":0},{"$f":"SUM(E37:E38)","v":3720377.2532145414},{"$f":"IF(D36=\"\",IF(E36=\"\",\"\",D36-E36),D36-E36)","v":-3720377.2532145414},{"$f":"E36/D36","v":{"$error":"#DIV/0!"}},null,null,{"$f":"SUM(J37:J38)","v":0},3720377.2532145414,{"$f":"IF(J36=\"\",IF(K36=\"\",\"\",J36-K36),J36-K36)","v":-3720377.2532145414},{"$f":"K36/J36","v":{"$error":"#DIV/0!"}}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H39+'PR Cash Reconciliation_2A,B,C'!H41+'PR Cash Reconciliation_2A,B,C'!H42","v":2892600.6532145413},{"$f":"IF(D37=\"\",IF(E37=\"\",0,D37-E37),D37-E37)","v":-2892600.6532145413},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F39+'PR Cash Reconciliation_2A,B,C'!F41+'PR Cash Reconciliation_2A,B,C'!F42+E37","v":2892600.6532145413},{"$f":"IF(J37=\"\",IF(K37=\"\",0,J37-K37),J37-K37)","v":-2892600.6532145413},{"$f":"K37/J37","v":{"$error":"#DIV/0!"}}]
[null,"    1b. Disbursements to sub-recipients",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H40","v":827776.60000000009},{"$f":"IF(D38=\"\",IF(E38=\"\",0,D38-E38),D38-E38)","v":-827776.60000000009},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F40+E38","v":827776.60000000009},{"$f":"IF(J38=\"\",IF(K38=\"\",0,J38-K38),J38-K38)","v":-827776.60000000009},{"$error":"#DIV/0!"}]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs. budget",null,{"$f":"D42+D43","v":0},{"$f":"E42+E43","v":0},{"$f":"IF(D41=\"\",IF(E41=\"\",\"\",D41-E41),D41-E41)","v":0},{"$f":"E41/D41","v":{"$error":"#DIV/0!"}},null,null,{"$f":"J42+J43","v":0},{"$f":"K42+K43","v":0},{"$f":"IF(J41=\"\",IF(K41=\"\",\"\",J41-K41),J41-K41)","v":0},{"$f":"K41/J41","v":{"$error":"#DIV/0!"}}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,0,0,{"$f":"IF(D42=\"\",IF(E42=\"\",0,D42-E42),D42-E42)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J42=\"\",IF(K42=\"\",0,J42-K42),J42-K42)","v":0},{"$f":"K42/J42","v":{"$error":"#DIV/0!"}}]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,0,0,{"$f":"IF(D43=\"\",IF(E43=\"\",0,D43-E43),D43-E43)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J43=\"\",IF(K43=\"\",0,J43-K43),J43-K43)","v":0},{"$error":"#DIV/0!"}]

{"sheet":"Procurement_3","index":14,"n_rows":63,"n_cols":23,"rows_kept":63,"cut":false,"hidden":false,"merged":[[62,12,62,22],[63,12,63,22],[56,12,56,13],[56,16,56,22],[57,12,57,13],[58,12,58,13],[59,12,59,13],[59,16,59,22],[57,16,57,22],[58,16,58,22],[53,12,53,13],[53,16,53,22],[54,12,54,13],[54,16,54,22],[55,12,55,13],[55,16,55,22],[50,12,50,22],[51,12,51,13],[51,16,51,22],[52,12,52,13],[52,16,52,22],[45,12,45,13],[45,17,45,18],[47,12,47,13],[47,17,47,18],[48,12,48,13],[48,17,48,18],[46,12,46,13],[46,17,46,18],[42,12,42,13],[42,17,42,18],[43,12,43,13],[43,17,43,18],[44,12,44,13],[44,17,44,18],[38,12,38,22],[39,12,39,13],[40,12,40,13],[40,17,40,18],[41,12,41,13],[41,17,41,18],[25,12,25,22],[26,12,26,22],[31,12,31,22],[34,16,34,22],[35,16,35,22],[35,12,35,13],[22,12,22,13],[23,12,23,13],[23,16,23,22],[24,12,24,13],[24,16,24,17],[22,16,22,22],[19,12,19,13],[19,16,19,22],[20,12,20,13],[20,16,20,22],[21,12,21,13],[21,16,21,22],[16,12,16,13],[16,16,16,22],[17,12,17,13],[17,16,17,22],[18,12,18,13],[18,16,18,22],[8,12,8,21],[11,18,11,22],[12,18,12,22],[14,12,14,22],[15,12,15,13],[15,16,15,22],[12,12,12,16],[5,14,5,20],[3,17,3,19],[4,17,4,19],[0,12,0,22],[2,12,2,13],[2,14,2,20],[3,15,3,16],[4,15,4,16]]}
[null,null,null,null,null,null,null,null,null,null,null,null,"Ongoing Progress Review and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PROGRESS UPDATE PERIOD"]
[null,null,null,null,null,null,null,null,null,null,null,null,"Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Reporting Period:",null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"Number:",null,null,{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"+#REF!","v":{"$error":"#REF!"}},null,"End Date:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,null,null,null,null,null,null,null,null,null,null,null,"Progress Update - Number:"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3A:  PR - Procurement and Supply Management"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Comments"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1.  Have you updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  If health products procurement information has not been entered into the PQR, please explain why.\n\n!  For further guidance on PQR data entry, please refer to the guidelines.",null,null,null,null,"Yes","Prices  and  other  required details  for following  items procured  in   the covered period  was  uploaded to the PQR system:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n 1.HIV RDT & EIA-  SD Bioline HIV -1/2  3.0 [03FK10]  Tests;   - GF-H/ET/G/223                                                    2.HIV virological testing equipment:\na) Roche  Molecular Systems, Inc. USA - COBAS  Taq Man HIV-1 Test[05923468190];  PO- #  GF-H/ET/G/203     \nb) Abbot Molecular  inc. USA   -    PO- # GF-H/Et/G-204\nI. m Sample Preparation System RNA ( 4x24 Preps)  [04J70-24]\nII. Abbott RealTime HIV-1 qualititative Amplification Reagent Kit 96 tests [2G31-90];                                                   \n3. HIV CD4 testing consumables /test kits- \n a)Partec CD4 easy count kits 100s[05-8401]; PO- #  GF-H/Et/G/165                                                                                                         b) BD FACS, Multi Test CD3/CD8/CD45/CD4 with trucount tubes 50 tests [342447]; BD Callibrite 3 Beads 25 test[340486];BDCalibrite APC Beads for 25tests [340487]PO- PO# GF-H/ET/G/170\n4.Male latex condoms procured both through local procurement:                                                                                             a)R&S Consumber Goods ( Germany) contr # GF -H/ET/G-230 and                                                                                                                                                                                                                         IDA  foundation  - b)HLL Lifecare Ltd - Male latex Condoms - PO S142829-A(Ref SQ 141113   )                                                                                                          \n    5. ARVs procured  through  VPP  mechanism covered by PQ 15129  & PQ15130  - uploaded  by PFSCM team .                                                              "]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on the most up-to-date stock situation, are there any risks of stock-outs or expiries for the key pharmaceuticals & health products, listed below, at the central level in the next period of implementation?  If yes, please comment."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. Rapid Diagnostic Tests",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Yes","The file for expired ARVs with justification and comments is included in the PUDR package. The ARVs procured during the NCDC PR-ship is included only"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Yes","The lab tests information is provided in separate file included in the PUDR package. "]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3.  Comment on additional issues related to the procurement and supply management of pharmaceuticals and health products."]
[null,null,null,null,null,null,null,null,null,null,null,null,"After organising e- tender  , priavte lab \" Global test \"  was cintracted  for quality  check of    5  ARVdrugs  . Sampling was made in Tbilisi , Batumi  and Zugdidi AIDS centres.   No batches were tested while receiveing - all the drugs received were the WHO prequilified and according guidance no testing is needed on receiveing .Testing same batches the storage and transportation conditions were tested also. Quality control testing was  undertaken in 2015 q3-q4; samples were selected from3 different   points ( Tbilisi, Batumi and Zugdidi).Following   ARV  pharmaceuticals were tested by independet  Lab \"Global  test:       Emtricitabin/Tenofovir disproxil Fumarate tabs,Efavirenze  tablets , 600 mg , #30 , Avocomb,  tabs 60  ( Lamivudine/ Zidovudine-150 mg/300 mg,Nevimun ( Nevirapine) , oral suspension  10 mg/ml  240 ml;Aviro  Z  9 Zidovudine ) Tabs 300 mg x 60 0.      No  quality issues  were  - found out.  "]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3B: LFA-Verified Procurement and Supply Management Information"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR's response","LFA's response","LFA Comments/Analysis "]
[null,null,null,null,null,null,null,null,null,null,null,null,"1a.  Has the PR updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  (If health products procurement information has not been entered into the PQR, please explain why in comments box)    ",null,{"$f":"_1__xlfn.IFNA(R13,\"\")","v":{"$error":"#NAME?"}},"Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"1b.  Value of Pharmaceuticals and Health Products in the PQR (6 categories only)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"(!) This table is included in the PU/DR form with the aim to improve completeness of information in the PQR system and not for comparing PQR amounts vis-à-vis expenditure per se. NB: PQR and expenditure amounts on health products may not be equal due to a timelag between payments and delivery of pharmaceuticals/health products.\n(!)  For further guidance on PQR data entry, please refer to the guidelines."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Reporting Currency"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PQR Product Categories",null,"Value of  products received during reporting period","Value of products entered by the PR and verified as correct by the LFA in the PQR during reporting period","Variance","Reason for Variance",null,"Cumulative value of  products received since the start of the grant","Cumulative value of products verified as correct by the LFA in the PQR since the start of the grant","Variance","Reason for Variance"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,null,null,{"$f":"IF(O42=\"\",IF(P42=\"\",\"\",O42-P42),O42-P42)","v":""},null,null,null,null,{"$f":"IF(T42=\"\",IF(U42=\"\",\"\",T42-U42),T42-U42)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. Rapid Diagnostic Tests",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Internal Residual Spraying (IRS)",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"Total",null,{"$f":"SUM(O42:O48)","v":0},{"$f":"SUM(P42:P48)","v":0},{"$f":"SUM(Q42:Q48)","v":0},null,null,{"$f":"SUM(T42:T48)","v":0},{"$f":"SUM(U42:U48)","v":0},{"$f":"SUM(V42:V48)","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on best information available to the LFA, are there any risks of drug stock-out or expiries at the central level in the next period of implementation?  (If yes, please explain in comments box)\n! This section should be completed by the LFA based on best information on stock at the central level available to the LFA and should not require dedicated visits for on-site checks of stocks."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. Rapid Diagnostic Tests",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. LFA analysis of issues related to the procurement and supply management of pharmaceuticals and health products"]

{"sheet":"Grant Management_4","index":15,"n_rows":72,"n_cols":29,"rows_kept":72,"cut":false,"hidden":false,"merged":[[70,24,70,27],[71,24,71,27],[68,23,68,32],[69,28,69,32],[70,28,70,32],[71,28,71,32],[71,15,71,18],[50,24,50,32],[51,24,51,32],[52,24,52,32],[53,24,53,32],[54,24,54,32],[55,24,55,32],[56,24,56,32],[69,24,69,27],[56,14,56,22],[58,14,58,22],[59,14,59,22],[60,14,60,22],[61,14,61,22],[62,14,62,22],[70,15,70,18],[68,13,68,22],[69,13,69,14],[41,24,41,32],[42,24,42,32],[43,24,43,32],[44,24,44,32],[45,24,45,32],[46,24,46,32],[47,24,47,32],[48,24,48,32],[49,24,49,32],[11,23,11,32],[12,24,12,32],[13,24,13,32],[14,24,14,32],[15,24,15,32],[16,24,16,32],[17,24,17,32],[18,24,18,32],[19,24,19,32],[20,24,20,32],[21,24,21,32],[22,24,22,32],[23,24,23,32],[24,24,24,32],[25,24,25,32],[26,24,26,32],[27,24,27,32],[40,23,40,32],[70,13,70,14],[71,13,71,14],[71,1,71,4],[70,1,70,4],[69,1,69,4],[63,5,63,13],[69,7,69,12],[70,7,70,12],[71,7,71,12],[69,19,69,22],[70,19,70,22],[59,1,59,4],[59,5,59,13],[52,14,52,22],[58,1,58,4],[58,5,58,13],[34,7,34,13],[35,1,35,5],[66,1,66,13],[36,1,36,5],[38,1,38,13],[43,1,43,5],[63,1,63,4],[36,7,36,13],[62,1,62,4],[62,5,62,13],[61,1,61,4],[61,5,61,13],[57,1,57,4],[57,5,57,13],[63,14,63,22],[57,14,57,22],[69,15,69,18],[52,1,52,5],[53,1,53,5],[54,1,54,5],[55,1,55,5],[41,1,41,5],[42,1,42,5],[40,13,40,22],[44,14,44,22],[49,14,49,22],[50,14,50,22],[51,14,51,22],[46,14,46,22],[47,14,47,22],[48,1,48,5],[48,7,48,12],[47,7,47,12],[53,14,53,22],[54,14,54,22],[55,14,55,22],[10,1,10,13],[26,1,26,5],[27,1,27,5],[12,7,12,12],[13,7,13,12],[15,7,15,12],[24,7,24,12],[25,7,25,12],[26,7,26,12],[27,7,27,12],[11,1,11,12],[11,13,11,22],[16,1,16,5],[16,7,16,12],[16,14,16,22],[20,1,20,5],[23,14,23,22],[21,14,21,22],[14,14,14,22],[17,1,17,5],[17,7,17,12],[17,14,17,22],[18,14,18,22],[19,1,19,5],[0,1,0,19],[9,1,9,13],[71,19,71,22],[39,1,39,22],[12,14,12,22],[13,14,13,22],[15,14,15,22],[24,14,24,22],[26,14,26,22],[25,14,25,22],[27,14,27,22],[33,1,33,22],[13,1,13,5],[24,1,24,5],[25,1,25,5],[15,1,15,5],[28,1,28,5],[29,1,29,5],[2,1,2,3],[2,4,2,7],[5,4,5,7],[12,1,12,5],[14,1,14,5],[14,7,14,12],[19,7,19,12],[19,14,19,22],[18,1,18,5],[21,1,21,5],[18,7,18,12],[21,7,21,12],[20,7,20,12],[20,14,20,22],[22,1,22,5],[22,7,22,12],[22,14,22,22],[32,1,32,5],[35,7,35,13],[32,7,32,13],[34,1,34,5],[28,14,28,20],[48,14,48,22],[46,7,46,12],[47,1,47,5],[45,1,45,5],[29,14,29,20],[34,14,34,20],[35,14,35,20],[36,14,36,20],[41,14,41,22],[42,14,42,22],[43,14,43,22],[45,14,45,22],[29,7,29,13],[30,1,30,5],[30,14,30,20],[31,14,31,20],[32,14,32,20],[42,7,42,11],[23,1,23,5],[23,7,23,12],[56,1,56,5],[41,7,41,12],[43,7,43,12],[45,7,45,12],[52,7,52,12],[53,7,53,12],[54,7,54,12],[55,7,55,12],[56,7,56,12],[44,1,44,5],[44,7,44,12],[49,1,49,5],[49,7,49,12],[50,1,50,5],[50,7,50,12],[51,1,51,5],[51,7,51,12],[46,1,46,5],[28,7,28,13],[30,7,30,13],[31,1,31,5],[31,7,31,13]]}
[null,"On-going Progress Update and Disbursement Request"]
[null,"PROGRESS UPDATE PERIOD"]
[null,"Grant Name:",null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Reporting Period:",null,null,"Cycle:",{"$f":"+#REF!","v":{"$error":"#REF!"}},"Number:",{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[null,"Progress Update - Period Covered:",null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[null,"Progress Update - Number:"]
[]
[null,"Section 4:  Grant Management"]
[]
[null,"A.  PR and LFA Comments on the Fulfilment of Conditions Precedent and/or Special Conditions Under the Grant Agreement"]
[]
[null,"! Please include in this table the Condition Precedent number as per Grant Agreement and full text of Conditions Precedent and/or other special conditions due for fulfilment during this period or outstanding from previous periods. \n! Some Special Conditions may apply to more than one period of grant implementation.  Their fulfilment during one period does not automatically imply fulfilment in subsequent periods.  The LFA should verify that the status of such conditions is reported by the PR during each period concerned.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Conditions Precedent and/or other special conditions\n",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Analysis\n(this should not be a \"Copy and Paste\" of the comments provided by the PR)",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments"]
[null,"\nNo later than 30 June 2014, the CCM shall, or the Principal Recipient shall cause the CCM to, submit a Budgeted Sustainability Plan for the gradual governmental take-over of financing, starting in 2015, for activities supported by this Grant. GF agreed to postpone the terminal date of the condition to 31 December, 2015 ",null,null,"Select",null,"Unmet - In Progress","As agreed with the GF the sustainability and transition plan development for HIV and TB grants will be covered from the current TB grant - GEO-T-NCDC. ToR for the plan development is elaborated is shared with the CCM and the GF. The electronic tender is anouanced for procurement of this service. According to the ToR, the final STP document should be available for the CCM approval by the end of 2016.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N14","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N15","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,"B.  PR & LFA Review of Progress on Implementation of Outstanding Management Actions from Previous Disbursements"]
[null,"! Please list all issues raised in the last Performance Letter from the Global Fund or outstanding from previous Performance Letters, and comment on the progress. Please include the date of the Performance Letter and the item number."]
[null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Global Fund Management Actions",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Review of PR Progress on Global Fund Management Actions",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments of PR Progress on Global Fund Management Actions"]
[null,"During the review of the Progress Update as well as of the Audit for the fiscal year 2014, it was noted that the PR is using different accounrding methods to report on the financial positions, namely:  the Progress Updates submitted to the Secretariat semi-annually, are prepared on cash basis, while the statements of financial positions submitted to the MOLHSA quarterly, are prepared according to the local regulations using modified cash basis. Although the PR has sought approval for using modified cash basis for prepareation of the financial statements for fiscal year 2014 during the Audit review process, this was not disclosed to the Secretariat in advance. Due to delay in informing the Secretariat and as a result, delayed approval, the PR was required to prepare the financial statements during the audit review.  Required Actions: During the preparation for the Audit reivew of the financial statements for fiscal year 2015 we recommend the PR:                                                                                                                                                                              a) to bring to the secretarit attendion any specific regulations applied to the PR reorting and preparation of the financial statements, well in advance, The PR is required to disclose these requirements already at the stage of review and approval of the TORs for the Audit of Financial Statements for fiscal year 2015.    b) tofurther develop and refine the process of preparing the financial statements;                                                      c) to ensure that the procedures and related deadlines for all staff involved in preparation of the financial statements are developed in advance and formally documented.                                                                                                Timeline: the PR should submit to the Secretariat the TORs for Audit reeview of the financial statements for fiscal year 2015 addressing the actions outlined by no Later than 31 July 2015. ",null,null,null,null,"Met","\n\nThe required actions were taken/recommendations are considered and followed precisely. ToR was submitted to the TGF for review per indicated deadline. The actual service is provucred and the Audit process is underway by BDO.\n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N43","v":"Select"}]
[null,"a) During the review it was noted that the PR's and SR's bookkeeping systems (mostly ORIS) do not contain specific fileds of expenditure categories or individual budget lines, Consequently, the risk or error in classification process exists.                                                                                                                                                      b) Additionally, the PR expenses the Pharmaceuticals, Health Products and Health Equipment as soon as it is transferred to SRs and monitor the use of such assets off balance sheet and perform the record in MS Excel Spreadsheets. There is no other special tool set in place for monitoring the usage neither at PR nor at SR level.  Required Actions: a) The PR is expected to follow up on the integration of the new financial software in existing accounting systems. While this activity should have been implemented during the last reporting period and was postpond, the PR is requested to ensure that the transition is completed before the end of fiscal year 2015. Additionally, the Secretariat requests the PR and SRs to produce semi-annual and monthly reports while reconciling between the financial reports and other accounting data, using MS excel.                                                                                                                                                                b) The PR is requested to ensure that further automation process is taking place, to better facilitate the process of gathering information for preparation of the grant program financail statements. Additionally, the PR should explore options to incorporate the accounting of PP and HPHE in the new financial software during its integration with the existing accounting systems by the end of fiscal year 2015.                                                           Timeline: the PR is requested to report on the progress made concerning the management actions outlined above by no later than 30 June 2015",null,null,null,null,"Unmet - In Progress","\nPR and SR’s have  integrated budget categories and lines in their existing accounting software and reports are reconciled with the accounting data on regular basis.   \nSeries of  meetings were conducted with almost all representatives of the ERP  market in Georgia, particularly Exact Georgia, Microsoft Georgia, UGT, Direct Solutions, Railway IT and IBS. Development of ERP has already been initiated. From October, 2015 for the phase 1 of ERP development the local  consultant was hired to develop a detailed system requirements. The tender documents will be finalized and announcement will be made during the Q1 of 2016 within the GEO-T-NCDC grant. The development process will be completed and the system will be piloted be the end of 2016. The necessary adjustments will be made during the first semester of 2017. \n\nNCDC started using of the Software for logistic PP and HPHE from 2015. Information regarding GF PIU assets was provided to the LIMS software managers two times during the last year - as of January 1st positions and of Jane 1st positions. However, during the roll out period some technical issues raised by NCDC logistic staff regarding the system, which is now under review (DITRA GH2 project in collaboration with  USAD HSSP proved support to NCDC). PR made a decision to develop independent system from NCDC LIMS as a part of the ERP which will be piloted by the end of 2016. Meantime the exell based system is implied.\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N44","v":"Select"}]
[null,"During the review of the Enhanced Financial Report (EFR) submitted with the Progress Update 2, inconsistances in reporting were noted:                                                                                                                                    a) The PR has reporting the period from 1 July 2014 to 31 December 2014 for the current period of the EFR, instead of reporting for the annual period 01 April 2014- 31 December 2014;                                                                                                                                                                                                        b) It was noted that the PR has reported in the EFR Table E-Disburcement Breakdown by Implementing Entity the expenditures of the SRs (six HIV SRs) and not PR's disburcements to the SRs.                                                                                                                                                      c) The PR has inserted the expenditure figure of SR HAPS (line #5) of SR CIF (Line #6) in Table E.                                                                                                                                                                                       Required Action and Timelines: The PR is requested to reserve the EFR and to resubmit the document based on the findings outlined above and to submit the revised version to the Secretariat by no later than 31 May 2015. ",null,null,null,null,"Met","The revised EFR document was submitted by the PR by the requested deadline.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue 1: During the review of the progress update, it was noted that the SRs are requested to submit monthly reports, however, the cumulative reports with results covering the 6-months period are not always available. Additionally, it was noted that the disaggregated values for some of the indicators are not produced by the SRs as part of the formally submitted reports. Consequently, the PR is verifying the results for the 6-months periods and performs the final calculation of the results against the targets.                                                                                                                                                              Required Action: While the PR's role is critical in ensuring that the correct data is reported with the Progress Update, it would be beneficial for the SRs to be further involved in reporting and commenting on the progress achieved during the 6-months period. The PR is invited to request for the submission of the semi-annual reports by the SRs with data for all indicators, in addition to the monthly reports submitted.                                                                                                                                                                                   Timeline: The PR is reqeusted to report on the progress made concerning the management action outlines above with the submission of the progress updated, by no later than 14 August 2015. ",null,null,null,null,"Met","All SRs were requested to provide cummulative reports for 6 months (July-December, 2015) and the reports were provided by SRs. PR M&E personnel has validated the reported q-ties which are reported ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #2: While the Secretariat acknowledged the efforts made by the PR and SR to increase the \"number and percentage of IDUs reached with HIV prevention programs\", the PR is expected to provide more details on the results achieved. Furthermore, considering the latest overachivement, the PR should revise and set more ambitious targets for the indicator.                                                                            Required Action: The PR is rquested to submit request for revision of the targets for the indicator 2.2 (for implementation period 1 July 2015 - 31 December 2015).                                                                                                                                                                      Timeline: The PR is requested to send revised Performance Framework to the Secretariat for review by no later than 31 May 2015. ",null,null,null,null,"Met","\nWe discussed the issue with the GHRN to understand the real reasons for the reported overachievement. One of the main reasons indicated was the reporting of so called secondary distribution of syringes (giving the syringes to the PWIDs for their friends and reporting this secondary clients also). Since April of 2015  we agreed with the SR to not include these secondary clients in the database, as there is no evidence that the 7 digit codes provided by the direct clients for their friend PWIDs is accurate.  The coverage data doesn't include also PDI clients and people who used only hepatitis C testing service. The final results for the last 6 months of the program implementation showed that the coverage percent went down. Although, PR is planning to continue the observation and the monitoring of the reporting the coverage of IDUs during the next implementation period and propose the relevant changes to the GF Secretariat if necessary. PR makes projection that procurement of mobile ambulatories will farther increase the PWID coverage countrywide and improve the geograpfic access to the NSP. \n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #3: During the varification of the indicator 3.1: \"Number and percentage of eligible adults and children currently receiving ART\", it was noted that the results of SPECTRUM analysis were provided by the National AIDS Center to the PR, however the denominator for this indicator wasnot updated to reflect the data.  Required Action: The PR should ensure that the latest verified results of SPECTRUM analysis are used for reporting. Consequently, the demoninator of the idnicator 3.1 shuld be updated to reflect the latest data available. The PR should submit request to the secretariat to for revision of the denimonator for the indiactor 3.1 (implementation periods 1 January 2015 through 31 December 2015). Timeline: The PR is requested to send revised PF to the Secretariat for review by no later than 31 May, 2015",null,null,null,null,"Met","The NCDC has finalized the Spectrum results for the denominator of this indicator and the newly generated figure for the eligible adults and children for 2015 was 4,689. The figure is agreed with the UNAIDS also and it was applied to the relevant indicator calculation for the P4. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #4: During the review, it was noted that the number of beneficiares served at the SSR Telavi Health Cabinet (program run by the SR Tanadgoma) remains very low with only 17 beneficiries (FSWs and MSM) served during the last reqporting period.                                                                                                                Required action: While the PR has already initiated discussions on ways to improve the performance in Telavi, the PR should ensure that the coverage of the health cabinet is increased.                                                                                                              Timeline: The PR should demonstrate meassures taken with the next progress update, by no later than 14August, 2015. ",null,null,null,null,"Met","To address the issue, the PDI methodology was succesfully piloted in Telavi and suraunding reions and new FSWs were enrolled in the program. The new clients were given the refferals to healthy cabinet on a regular basis, but the evaluation of the last 6 months performance showed that although the number of FSWs served was increased,  little improvements were observed in using the healthy cabinet services by the FSWs reffered by Tanadgoma to the healthy cabinet. PR, SR and SSR met again to discuss the issue in July, 2015. The new strategy that was agreed to be tested was to give the rides to FSWs to the Healthy Cabinets for STI diagnostics and treatment visits by social workers of Tanadgoma's with its car. During the last 6 months 27 FSWs were given this kind of referals. Thus the P4 data are little bit increased, but the results aren't satisfactory, and PR desided to develop/test another strategy. During P5, before initiation of the NFM grant the PR and the SR plan to work out more effective mechanisms for referal of FSWs to the healthy cabinets.  One of the options that PR plans to consider is the vaucher system for STI treatment that would increase the geographic access for treatment for FSWs and MSM in the regions. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, issue #5: In the absense of the unified module for the OST program integrated in the health management information system, risk or error and inaccurate calculation of the results achieved under the OST program is high. Required Action: The PR should ensure that the unified OST module is introduced by the ned of the next implementatuin period and is fully functional by the end of the year 2015. Timelien: The PR is expected to report on the results with submission of the next progress update, by no later than 14 August 2015. ",null,null,null,null,"Met","The OST Module has been incorporated in the e-health system since March, 2015 and the GF OST sites were given the individual accesses to the system. Since April, 2015 they started entering the data on OST patients in the system. PR is closely monitoring the data entrance and chacks them against the paper reports during this piloting phase. The Module is available as a final tool for OST patients reporting for the current reporting period.  ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"M&E, Issue #6: While we acknowledge the efforts made by the PR to catch up on the implementation of the program, the PR is expected to continue to follow up on the progress and implementation of the activities under Objective 1. Required Action and Timeline: The PR is requested to report on the progress made with respect to implementation of the activities planned under Objective 1 by no later than 30 June 2015. ",null,null,null,null,"Met","The contracts for implementation of Objective 1 were signed during March and Appril of 2015 and SRs are working on the implementation of the following components since April and May.\n\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV COmmunity - SR: NGO Real People, Real Vision,\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\n\n\nIn July 2015 two additional contracts were signed for implementation of the following interventions:\n\n\n- Media Campaign for Stigma Reduction - SR: McCann Erickson company\n- Survey of health care workers on HIV related stigma and discrimination - SR: BCG Research                                                                                                    All activities outlined in the contracts for the Objaective 1 were completed by the end of 2015.                The contracts were completed successfully. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"Other Management Issues: Issue #1                                                                                                                                      During the review of the peer education trainings conducted in October 2014 at the SR Tanadgoma for FSWs and at SSR Kamara for PWIDs, weaknesses in training content and manegement were identified. Required Actions: Following the approval of the training plan for HIV grant for year 2015, the PR should ensure that following recoemndations are addressed while conducting trainings:                                                                                                      a) Establishment of trainings database per SR, which will cintain detailed information on the trainings conducted, including agenda, list of participants at the training and key populations group they are representing, which will allow to count unique participants benefiting from these trainings rather than cumulative number of people trained.                                                                                                                                            b) Training materials should be revised and aligned amongst SRs, per key population group. Clear objectives, content, as well as suitable duration of the training per each key  population group should be established.                                                                                                                                                                                          c c) Pre and post training knwoledge questionnaires should be developed and shared with participants, in order to enhance the learning experience from the trainings, the outcomes from the training shuld be recorded in the electronic database developed by the PR/SR;                                                                                         d) The SRs should report to the PR on the trainings conducted on a quarterly basis.                                            Timeline: The PR is expected to report on the progress with submission of the next progress update, by no later than 14 August 2015. ",null,null,null,null,"Met","The training plan was approved by GF and of April, 2015. The plan was disseminated among SRs and SSRs as a guidance for  planning of respective trainings. The training database tamplate was developed by PR and was provided to SRs in May,2015. They were requsted to start filling out the database from June 1, 2015. All of them have pre and post tests developed and used on regular basis. PR has provided the trianing evaluation form as well that trainees have to fill out for each training.  The SRs were providing the monthly reports using the format provided by the PR. the last 6 moonth summary database was provided by the SRs during January, 2016 which included the total budgeted and total actual costs per training. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV Issue #1:                                                                                                                                                                               Results for indicator \"Number and percentage of IDUs reached with HIV prevention programmes - defined package of services” - SR GHRN clients who are not in direct contact with project staff (secondary reach), but receive service package are considered reached.                                                   Required Actions: While the secondary distribution of commodities ( secondary coverage) might be beneficial for those PWIDs, SSRs should not register beneficiaries with unique identification codes in the database and the SR GHRN should not include these cases within the reported results for this indicator, unless those beneficiaries were already registered in the database and services were provided at least once.\nGiven that there is no mechanism to verify if the clients really received certain number of syringes/needles from their peers, only those who have direct contact with project staff should be counted, and reported.                                                                                                                                                                 Timeline: Immediately\n",null,null,null,null,"Met"," \nWe discussed the issue with the GHRN to understand the real reasons for the reported overachievement. One of the main reasons indicated was the reporting of so called secondary distribution of syringes (giving the syringes to the PWIDs for their friends and reporting this secondary clients also). Since April of 2015  we agreed with the SR to not include these secondary clients in the database, as there is no evidence that the 7 digit codes provided by the direct clients for their friend PWIDs is accurate.  The coverage data doesn't include also PDI clients and people who used only hepatitis C testing service. The final results for the last 6 months of the program implementation showed that the coverage percent went down to the resopnable figure. Although, PR is planning to continue the observation and the monitoring of the reporting the coverage of IDUs during the next implementation period and propose the relevant changes to the GF Secretariat if necessary. PR makes projection that procurement of mobile ambulatories will farther increase the PWID coverage countrywide and improve the geograpfic access to the NSP. \n\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"C.  Comments on Annual Grant Reporting Requirements"]
[]
[null,"! Please indicate a date for the report due for submission.  If a report is overdue, indicate the original due date and explain the reason for delay.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Required Documentation",null,null,null,"Due date \n(dd-mmm-yy)","Status","Comments",null,null,null,null,null,"Due date\n(dd-mmm-yy)",null,"Status",null,null,null,"Comments",null,null,null,"Due date\n(dd-mmm-yy)","Validate Status",null,null,null,"Country Team Comments"]
[null,"PR Audit Report",null,null,null,null,"Preparation on track","The report will be sibmitted by the end of March, 2016"]
[null,"Annual Financial Report (AFR) / Enhanced Financial Report (EFR)",null,null,null,null,"Submitted to GF"]

{"sheet":"PR-LFA Evaluation_5","index":16,"n_rows":55,"n_cols":8,"rows_kept":55,"cut":false,"hidden":false,"merged":[[62,0,62,10],[46,0,51,14],[45,0,45,14],[55,0,60,14],[33,15,33,29],[38,0,43,14],[33,0,33,14],[34,0,34,10],[24,0,24,14],[11,0,15,14],[0,0,0,15],[18,0,22,14],[25,0,29,14],[10,0,10,10],[2,0,2,1],[2,2,2,5],[5,2,5,5],[17,0,17,14]]}
["Ongoing Progress Update and Disbursement Request"]
["PROGRESS UPDATE PERIOD"]
["Grant Name:",null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: PR and LFA Evaluation of Overall Performance"]
[]
["A.  PR's Overall Self-Evaluation of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The self-evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of Sub-Recipients).  See Guidelines for more detailed guidance."]
["For most of the indicators the PR’s and SRs’ performance within the GEO-H-NCDC program was satisfactory during the P4. In some areas the performance was even exceeding the expectations. For instance, the OST program’s achievement regarding the number of OST patients who utilized the service for 6 month period (3.4% instead of 2.6%). Very sound achievement is regarding HCV treatment indicator – 147% of the initial target. Due to improved monitoring of ART, the 12 month retention on treatment was increased up to 88% also (target was 85%).  For other indicators we are very close to the target. \nThere is unexpected decrease in PWID coverage indicator with preventive package services – Achievement is 34% instead of targeted 41%. As discussed with SR – GHRN, the following reason is the major contributor to this reduction. Before GHRN was counted the so called secondary clients of PWIDs who were receiving the services from the primary clients and where registered in the program database. As we agreed not register the secondary clients, the number of PWIDs served has dropped. \nWe believe that with starting the Mobile Ambulatory services that will cover about 65 cities of the country, the indicator results will be considerably increased. At the moment 4 mobile ambulatories operate within the program and by the end of March 2016 the number will be increased up to 6.  \nCoverage of FSWs and MSM with HIV prevention services has been improved but still are slightly behind the targets. During P4 the PR and SR Tanadgoma has tested new strategies to improve the coverage data. PDI strategy worked well with MSMs and FSWs in the regions to attract new clients to the Tanadgoma sites. Despite the efforts made, the low STI treatment coverage remained at Telavi and Zugdidi healthy cabinet . PR and SR agreed to use the Tanadgoma’s office car and provide transportation to FSWs referred for the treatment from other districts and villages, thus ensuring they are getting the required services at the healthy cabinet. The Initiation of LGBT supporting activities by the SR Tanadgoma contributed to promotion of the HIV prevention service utilization by MSM population. PR and SR anticipate further improvement within the LGBT component in the future as well.  \nHigh 58% achievement was detected for screening on TB of key affected populations also (the target was 60%) and facilitated the strengthening of the linkages between the HIV and TB programs. \nThe PR has successfully placed the orders for first line ARVs within the State HIV Program and the SL ARVs within the GF grant with the PFSCM. The total for the GF funding needs for the SL drugs is 852,300 USD. \nTo ensure that adequate funding is included in the 2016 State Budget, the PR has successful communication with the Ministry of Health which resulted in inclusion of 2,630,000 GEL in the State Budget for procurement of the first line ARVs in 2016 also. \nImplementation of BSS study among MSM has been completed. The alarming HIV prevalence was detected among MSM in Tbilisi – 25% which is 12% increase from the 2012 BSS. The study was validated by the UNAIDS in early 2016. \nDespite the fact that SRs are still using the excel based databases, the PR has achieved improved data reporting from SRs based on the continuous oversight and on-site instructions/validations regarding the ways of counting the indicators and the data-base improvement. In parallel, the PR is working on procurement of the service for unified HIV prevention database elaboration. OST module was included in the e-health system of the MoLHSA and is in the pilot phase which will be completed by the end of 2015. PR is regularly validates the paper forms’ data with the e-health OST module data. The PR has announced the tender for HIV prevention database in May, but had to cancel it as the specification of the product wasn’t well prepared couldn’t ensure the effective linkage with the MOHSA’s e-health system. PR has decided to procure the TA for the sound technical documentation for the HIV prevention database and ensure that the documentation is ready for NFM’s first year (2016). \nAll service contracts were completed successfully within the Objective 1. Implementation of media campaign component and the survey of HCWs on HIV related stigma was started in April, 2015 and was finished early December, 2015. \nThe SRs were provided by the training database template and were requested to provide the training information in this format. All SRs are entering the training data using this template. Trainees are required to complete the pre- and post-tests and the training evaluation forms for each training.  \nPSM of the program has been improved also, PR and SRs were monitoring of supply consumption data to make reasonable quantifications for the remaining period of the grant + buffer stock. The PSM team had ensured that there was no stock out for any MPP or HP during the reporting period. Just we had to borrow some stock of methadone from the state program before the GF program procured medicine would be delivered in the country. The LMIS of NCDC is still under development, PR has two times provided the NCDC consultants with the stock file of GF programs to be entered in the LMIS module, which didn't happen due to the technical issues, PR has decided to include this in the ERP technical documentation and run independent LMIS for the GF grant programs. \nFinancial management: the two critical components of this work are a) external to Georgia – reporting to the donor (TGF), and b) internal  – communication and reporting with the Ministries of Health and Finance, with NCDC, state statistics department, tax authorities, state revenue service, suppliers, service providers, etc. Both operations were conducted in a smooth and efficient manner with the stable and robust operations. In 2015 PR has timely submitted the regular PU report. Also, met all of the donor’s additional ad-hock requests on the provision of financial and/or operational data. This includes PR/SR end-of month balances/receivables/parables, grant fund receipts and payments to third parties, etc. SRs have improved their accounting and financial reporting compared to the year 2014. The PR has successfully procured audit service for the year 2015 through tender and relevant contract was signed with BDO. The Audit of Consolidated financial statements is ongoing and the report will be submitted by the end of March as agreed with TGF. To improve financial management system PR has procured the TA for development of the ERP technical documentation and it plans to procure the actual ERP development service within the current TB program.\nDuring the current reporting period the PR received EUR 2,319K worth of two transfer from TGF during.  In addition, direct payments to vendors, with total worth of Eur 827,7K was completed by TGF.\nTotal payments made to the vendors/providers during the current reporting period is Eur 3,349K. \nPR managed the VAT operations smoothly. The first refund, followed by several refunds was completed in the second half of the year 2015. The total refunded amount comprised of  EUR 74,679. The surplus of refundable VAT on the State Revenue Service system amounts of EUR 49,900 as of 31/12/2015 and additional EUR 12,360 is submitted as surplus in the year 2016.\nPR effectively manages State budget funds also and in November 2015 the contract with PFSCM was signed for the FL ARVs under the State HIV Program budget. Advance payment was made in 2015 and the delivery of medicines is planed during 2016. \n\n\nIn general, we are on the track of the program implementation without any major internal or external constrains. \n"]
[]
[]
[]
[]
[]
["B.  Planned Changes in the Program, if any"]
["a) procurement of 2 additional Mobile Ambulatories for GHRN will improve both general and the geographic coverage of PWIDs with HIV preventive interventions;                                                                                                         b) Country is adopting Treat All strategy of WHO which means that PLHIV will be offered ART despite the DC4 cell count, thus more HIV positive people will have access to ART. "]
[]
[]
[]
[]
[]
["C.  External factors beyond the control of the Principal Recipient that have impacted or may impact the Program"]
["a) Implementation of hepatitis C Elimination Program that started in 2015 in the country had positive impact on HIV program implementation. Especially beneficial the new program was for HIV/HCV co-infected patients who got access to highly effective Direct Antiviral (DAAs) Medicines. In addition, HCV servicies are getting integrated with the HIV services (harm reduction basically) and the HIV and HCV tandem testing was offered to interested people countrywide.                                                                                                                                                                                                                                                                                                                                     b) ARV price reduction on the glonal market and regimen simplifications has resulted in savings during placing the ARV orders with the PFSCM. The Gov has already procured FL ARVs with state funds for 2016. "]
[]
[]
[]
[]
[]
["For LFA Use Only"]
[]
["A. LFA  Overall Evaluation and Rating of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of sub-recipients).  See Guidelines for more detailed guidance on the completion of this section."]
[]
["Indicator rating","Select",null,"Any major management issues resulting in downgrade?","Select",null,"Overall Grant Rating","Select"]
[]
[]
[]
[]
[]
[]
[]
[]
["B.  LFA comments on PR planned changes in the program, if any"]
[]
[]
[]
[]
[]
[]
[]
[]
["C.  LFA Comments on External Factors Beyond Control of the Principal Recipients that have impacted or may impact program"]

{"sheet":"LFA_Findings&Recommendations_6","index":17,"n_rows":39,"n_cols":10,"rows_kept":39,"cut":false,"hidden":false,"merged":[[21,0,21,1],[22,0,22,1],[18,2,18,4],[19,5,19,8],[20,5,20,8],[21,5,21,8],[22,5,22,8],[19,2,19,4],[20,2,20,4],[21,2,21,4],[22,2,22,4],[18,0,18,1],[19,0,19,1],[20,0,20,1],[26,2,26,4],[26,5,26,8],[25,2,25,4],[25,5,25,8],[23,5,23,8],[24,5,24,8],[23,2,23,4],[24,2,24,4],[17,5,17,8],[12,0,12,1],[13,5,13,8],[14,2,14,4],[14,5,14,8],[13,0,13,1],[16,2,16,4],[12,2,12,4],[16,0,16,1],[17,0,17,1],[14,0,14,1],[15,0,15,1],[0,0,0,9],[2,0,2,1],[2,2,2,5],[5,2,5,5],[26,0,26,1],[24,0,24,1],[13,2,13,4],[25,0,25,1],[17,2,17,4],[23,0,23,1],[15,2,15,4],[15,5,15,8],[18,5,18,8],[16,5,16,8],[10,0,10,9],[12,5,12,8]]}
[" Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST"]
["Grant Name:",null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
[]
["For LFA Use Only"]
["Section 6: LFA Findings & Recommendations  "]
[]
["! Based on the information provided in the previous sections and your understanding of the grant, please summarise any important management issues, proposing a recommendation for each.\nNB: an issue is considered as 'important' if it impacts or is likely to impact program implementation and results.                                                                                                                                                                                                          ! Instead of repeating detailed descriptions of issues covered in other sections, it is acceptable to state the issue and reference the section containing the details."]
[]
["Functional Areas",null,"Description of Identified Issues \n(in order of importance)",null,null,"LFA Recommendations \n(in order of importance)",null,null,null,"Country Team Comments"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
[]
[]
["Select"]
["Yes"]
["No"]
[]
["Select"]
["Program management (including SR management)"]
["Financial management and systems"]
["Monitoring and evaluation"]
["Pharmaceutical & health product management"]
["Other management issues, including: PR capacity to develop quality programmatic and financial reports"]

{"sheet":"PR EFR_7A","index":18,"n_rows":86,"n_cols":12,"rows_kept":86,"cut":false,"hidden":false,"merged":[[84,4,84,10],[73,4,73,11],[74,4,74,10],[75,4,75,10],[80,4,80,10],[81,4,81,10],[82,4,82,10],[76,4,76,10],[77,4,77,10],[78,4,78,10],[79,4,79,10],[83,4,83,10],[67,0,71,11],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[40,0,40,3],[41,0,43,4],[45,4,45,7],[45,8,45,11],[58,0,60,4],[65,0,65,11],[66,0,66,11],[28,1,28,3],[17,1,17,3],[18,1,18,3],[19,1,19,3],[20,1,20,3],[21,1,21,3],[22,1,22,3],[23,1,23,3],[24,1,24,3],[25,1,25,3],[26,1,26,3],[27,1,27,3],[8,4,9,4],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[16,1,16,2],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,0,8,1],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[2,0,2,5],[1,0,1,5]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7A: PR - Enhanced Financial Reporting"]
[]
["Country",null,null,null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No."]
["PR",null,null,null,null,"TO BE COMPLETED ONLY ONCE A YEAR EXCEPT AT MONTH 18 FOR PURPOSES OF PHASE 2 REVIEW"]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
[null,null,null,null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:","2015-01-01",null,"Cumulative Reporting Period","Start Date:","2014-04-01"]
[null,null,null,null,null,"End Date:","2015-12-31",null,null,"End Date:","2015-12-31"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFR"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDA"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Human Resources",null,null,3037446.6302622398,2543483.9458392016,{"$f":"E18-F18","v":493962.68442303827},"PR - saving EUR 48,226 (some positions remained vacant during the reporting period); Also Fx rate change had an effect.                                                                                                                              \nSRs – Saving EUR 255,109 - Objective 1 related HR cost saved due to postponed implementation; Delay in procurement of mobile ambulatories, in opening of a new OST and AIDS Treatment Centers and hiring relevant personnel, in addition the actual cost of case management and reimbursements for medical consultations, monetary incentives for PDI clients was less than budgeted; Saving was made in prisons activities of TG as they worked in 13 prisons as one of the prisons where they planed to work was under renovation. \nCommitment EUR 190,628 – December service cost reimbursed in January 2016\n",5154744.5533048585,4288500.2930329461,{"$f":"I18-J18","v":866244.26027191244},"PR - saving EUR 58,519 (some positions remained vacant during the reporting period), also Fx rate change had an effect                                                               \nSRs - Saving EUR 617,097 - Objective 1 related HR cost saved due to postponed and shortened  implementation; remaining saving is due to delay in procurement of mobile ambulatories, in opening of a new OST and AIDS Treatment Centers and hiring relevant personnel, in addition the cost of case management and reimbursements for medical consultations, monetary incentives for PDI clients was less than budgeted; Saving was made in prisons activities of TG as they worked in 13 prisons as one of the prisons where they planned to work was under renovation. \nCommitment EUR 190,628 – December service cost reimbursed in January 2016\n"]
[2,"Technical Assistance",null,null,219513.41867335315,137777.11085375029,{"$f":"E19-F19","v":81736.307819602865},"PR –Saving EUR 34,549 -Actual TA cost was less than budgeted \nCommitment- EUR 420 – ERP consultant fee for December Reimbursed in January\nSRs –Saving EUR 37,930 - the management of National AIDS Center couldn't find laboratory expert with required qualification; HAPS Fund hired Study consultant by one month late; \nCommitment EUR 12,862 - December service cost reimbursed in January 2016\nOverspending EUR 4,025 – TA cost of CIF was greater than budgeted in the current period\n",367107.72509880585,223581.61928847333,{"$f":"I19-J19","v":143526.10581033252},"PR –Saving EUR 56,258 -Actual TA cost was less than budgeted; Development of HIV prevention database was moved to NFM;                                                                                       \nCommitment- EUR 420 – ERP consultant fee for December Reimbursed in January\nSRs –Saving EUR 76,668 includes: the management of National AIDS Center couldn't find laboratory expert with required qualification; HAPS Fund hired Study consultant by one month late; international consultant hired by GHRN didn’t provide the final report and the relevant fee wasn’t paid. \nCommitment EUR 12,862 - December service cost reimbursed in January 2016\nOverspending EUR 2,682 – HAPS and CIF had spent more than budgeted amounts on survey technical consultants , but in the limits of service contracts signed with Srs\n"]
[3,"Training",null,null,222599.08005117549,145069.48369942023,77529.596351755259,"PR - Overspending EUR 6,662 actual PR training cost was greater than budgeted in the current period\nSRs – Saving EUR 78,523 - GenPud activists’ meetings of GHRN were not organized as planned, instead round table discussion meeting was organized and less than the budgeted amount was spent; In addition, less amount was utilized for training of service centers' personnel. AIDS Center and GHRN personnel had less than budgted international travels as less number of international trainings/conference participations were approved by TGF than it was budgeted. TG had a saving related to PDI and PLP compensations. HAPS had utilized less than budgeted amounts on the training also.  \nCommitment- EUR 5,996 December service cost reimbursed in January 2016\nOverspending – EUR 327 – by CIF on study results dissemination workshop \n",390722.78593186371,216228.98161860835,174493.80431325536,"PR – Saving EUR 15,310 Actual training costs were less than budgeted\nSRs – Saving EUR 153,514 - Due to changes made in budget lines for staff meetings at the offices of GHRN member organizations, for training of peers, development of IEC materials and organization of round tables for community members; Training on motivational interviewing was not provided by GHRN, less than budgeted amount was spent on international conference participation;  GenPud activists meetings were not organized as planned, instead round table discussion meeting was organized and less than the budgeted amount was spent; In addition, less amount was utilized for training of service centers' personnel. The amounts budgeted for monthly peer educators' training were not utilized fully; December round table meeting amounts per service centers were saved as one large round table meeting was organized, this change was agreed with PR. AIDS Center and GHRN spent less amount on international conference participation. TG had savings in PDI and PLP compensations. MHAPC, RPRV and HAPS also saved money on trainings. AIDS victims' memorial day activity was canceled due to lack of institutional money at HAPS; \nCommitment- EUR 5,996 December service cost reimbursed in January 2016\nOverspending – EUR 327– by CIF on study results dissemination workshop , activity was included in the service contract signed through tender\n"]
[4,"Health Products and Health Equipment",null,null,1831839.4592787647,1511543.1218506759,320296.33742808877,"The expenditure relates to the Health product/equipment procured locally and with IDA. \nSaving: EUR 486,644 - HPHE procurement (lab supplies, disinfectants, tests systems, Flowcytometer; syringes, condoms) is derived from low unit prices as a result of tenders; procurement through pooled procurement, revision of the q-ties based on the consumption data and some cancelled activities. Instead of one flowcytometer with high technical characteristics, in agreement with GF and AIDS Center, four field equipment – BD Presto were procured for CD4 count measurement, which has resulted in substantial saving. \nPostponed Activities: EUR 24,940 –IDA remaining amount for Syringes' Order has been moved to NFM budget\nNegative Variance EUR 163,284  relates to activities  procured in current reporting period and budgeted in the previous year ( mobile ambulatories, lab supplies,); part of budgeted activities had greater unit price and/or quantities were revised according to the consumption rates. Procurement of HP for extension period that was conducted end of 2015 (syringes, tests);                                                                                                                                                        \nSR :  Overspending EUR 28,003 procurement of HPHE budgeted under PR for IBBS surveys and transferred to SR in agreement with GF.\n",3565110.958505,2184838.8445189036,1380272.1139860963,"The category relates to the Health product/equipment procured locally and with IDA (syringes and condoms). \nThe Budget relates to the Health product/equipment procured locally and directly by the Global fund. \nThe variance consists of Positive Variance EUR 1,510,306 and Negative variance EUR 130,034 \nThe amounts spent on the procurement (lab supplies, desinfectants, tests systems, Flowcytometer; syringes, condoms) is a result of the low unit prices offered during the tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nSaving EUR 1,356,181:  EUR 316,349 - Procurement of syringes through IDA and local tenders for syringes, needles and vain sets resulted in low unit costs. Also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 88,619 – Procurement through IDA and local tenders resulted in lower than budgeted cost for condoms, also quantities were recalculated based on consumption data and stocks at SR level.\nEUR 183,858 – Actual costs for procurement of disinfectant and lab supplies/equipment through tenders were less than budgeted also.  \nEUR 24,920 – Based on stocks of Naloxon available at SR level, the less q-ties were procured and  cost was lower also. \nEUR 90,203 – Actual cost of Procurement of tests (rapid tests, tests for STI, including cost of tests budgeted in PR and transferred to CIF) was lower than budgeted\nEUR 652,232 – Actual cost for tests and lab supplies for AIDS Center were less than budgeted through local tenders\nPostponed EUR 24,941 - Order placed for syringes with IDA in 2014 and remaining payment moved to NFM budget.\nCommitments EUR 129,184   - EUR 126,403- Cost of additional 4 Mobile Ambulatories, which were delivered in March, 2016; EUR 2,781 December service cost for CIF reimbursed in January 2016;\nOverspending EUR 130,034 -  EUR 5,411 – Additional request from TG on procurement of micropipetes approved by GF; EUR 2,857 – Actual cost of disinfectants and minor lab supplies was slightly greater than budgeted ; EUR 121,766 – Cost of procurement of additional 4 mobile ambulatories approved by GF.\n"]
[5,"Medicines and Pharmaceutical Products",null,null,3989872.8615848836,1234320.6140011786,2755552.247583705,"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance consists of Positive Variance EUR 2,761,102 and Negative variance EUR 5,550\nDriver of saving is available stock at SR: Cheaper unit prices were gained both from the local procurement and through PPM (ARVs). Saving was made due to simplification of ART regimens based on WHO recommendations. \nSaving EUR 2,052,606 - EUR 141,663 - Volume of Methadone was reduced according to the quota approved for the country and more precise need estimation conducted jointly by Narcology Center and MoH. The actual cost of methadone was less also (4 EUR vs. 9 EUR). \nEUR 7,878 – Actual unit price for vaccines was lower than budgeted.\nEUR 1,531,888 –Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens  \nEUR 371,071 - considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pegylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nEUR 106 – Actual cost of essential drugs procured by Aids Center was less than budgeted\nCommitment EUR 522 – Cost of December service of Aids center (essential drugs) – reimbursed in January 2016\nPostponed EUR 707,974 - ARVs order placed in 2015 and payment moved to NFM budget \nOverspending EUR 5,550 – procurement of STI essential drugs - actual cost is greater than budgeted due to updated quantification of the needs by the SR\n",5140297.1056705983,1403620.9577015636,3736676.1479690345,"The Budget relates to the Medicines and Pharmaceuticals procured locally and through international PSM Agencies to be paid directly by The Global Fund. \nThe variance consists of Positive Variance EUR 3,741,985 and  Negative variance EUR 5,309.\nDriver of saving is available stock at SR: Cheaper unit prices were gained both from the local procurement and through PPM (ARVs). Saving was made due to simplification of ART regimens based on WHO recommendations. \nSaving  EUR 3,033,489 - EUR 210,650 - Volume of Methadone was reduced according to the quota approved for the country and more precise need estimation conducted jointly by Narcology Center and MoH. The actual cost of methadone was less also (4 EUR vs. 9 EUR). \nEUR 15,529 – Actual unit price for vaccines was lower than budgeted.\nEuro 2,431,143–Saving in ARVs resulted from actual PQ signed with PPM and simplification of regimens  \nEuro 4,170 – saving in procurement of essential drugs made by AIDS  Center and lower unit price procurement of STI drugs.\nEuro 371,996 -  considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pagylated interferon and ribavirin budgeted at 342,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nCommitment EUR 522 – Cost of December service of Aids center (essential drugs) – reimbursed in January 2016\nPostponed EUR 707,974 -  ARVs order placed in 2015 and payment moved to NFM budget \nOverspending EUR 5,309 – procurement of STI essential drugs - actual cost is greater than budgeted due to updated quantification of the needs by the SR"]
[6,"Procurement and Supply Management Costs",null,null,773848.45,80839.158389427088,693009.29161057284,"PR – Saving EUR 606,406 – related to savings of ARVs and quality control\nPostpone: EUR 89,863 - ARVs order placed in 2015 and payment moved to NFM budget\nSRs - SRs - Commitment EUR 944 – December service cost of GHRN reimbursed in January 2016\nOverspending EUR 4204 - related to PSM as spending for Harm Reduction Program depends on the volume of supplies to be delivered\n",1005976.6506061351,84591.31808553719,921385.33252059796,"PR – Saving EUR 836,999 – related to savings of ARVs and quality control\nPostpone: EUR 89,863 - ARVs order placed in 2015 and payment moved to NFM budget\nSRs - Commitment EUR 944 – December service cost of GHRN reimbursed in January 2016\nOverspending EUR 6,421 -  related to PSM as spending for Harm Reduction Program depends on the volume of supplies to be delivered and  also change of category by SR (MHDAC) from OVE to PSM\n"]
[7,"Infrastructure and Other Equipment",null,null,153978.48427930826,60891.583832441553,93086.900446866712,"PR – Saving EUR 83,685 – procurement of vehicles cancelled in agreement with GF; actual costs of procurement infrastructure and office equipment satisfy SRs and PR needs was less than budgeted.\nOverspending EUR 12,434 – procurement of office equipment/furniture from both years’ budgets 2104-2015.\nSRs - Saving EUR 20,287  - car maintenance actual costs were less than budgeted for the most of SRs and SSRs) \nCommitment EUR 2,848 – December service cost of GHRN reimbursed in January 2016\nOverspending: EUR 1,300 – GHRN and TG have spent more than budgeted amount on car maintenance, but in the limit of service contract through tender \n",312463.61911834206,92273.926690838562,220189.6924275035,"PR – Saving 177,707 - procurement of vehicles cancelled in agreement with GF; actual costs of procurement infrastructure and office equipment satisfy SRs and PR needs was less than budgeted.\nOverspending EUR 1,396 – Actual cost of procurement office equipment (UPS, Projector) was slightly greater than budgeted\nSRs - Saving EUR 41,031 car maintenance actual costs were less than budgeted.\nSRs - Commitment EUR 2,848 – December service cost of GHRN reimbursed in January 2016\n"]
[8,"Communication Materials",null,null,69146.767570298151,39503.997594098197,29642.769976199954,"PR – Saving EUR 28,831 printing of IEC materials procured through tender and media campaign saving\nOverspending EUR 815 – Actual quantity of printing info materials for TG was greater than budgeted according to SR needs.\nSRs – Saving EUR 1,808 -  Actual cost was less than budgeted\nOverspending EUR 182 – More than budgeted amount was spent on international travel that was budgeted under this category. \n",113889.45684870309,47100.678933771247,66788.777914931852,"PR – Saving EUR 63,121 printing of IEC materials procured through tender, delay in implementation of media campaign \nOverspending EUR 696 – Actual quantity of printing info materials for TG was greater than budgeted according to SR needs. \nSRs – Saving EUR 4,364- Actual Cost of trainings was less than budgeted\n"]
[9,"Monitoring & Evaluation",null,null,181252.1881084124,135082.33248403904,46169.855624373362,"PR – Saving EUR 4,988 Actual cost of PR monitoring costs were less than budgeted\nOverspending –EUR 1,786 Fuel cost for CIF budgeted in the previous year. \nSRs - Saving EUR 35,509-  SRs and SSRs have saved money on M&E visits and on business travels. \nCommitment EUR 8,718 – December service cost reimbursed in January 2016\nOverspending EUR 1,260 – TG has spent more than budgeted amount on M&E visit during the reporting period. \n",316614.61813398567,198387.48308823613,118227.13504574954,"PR – Saving EUR 19,765 fuel procurement through tender and less than budgeted amount was spent on M&E visits; \nSRs - Saving EUR 90,750-  All SRs made savings during M&E visits. AIDS Center's data entry personnel wasn't hired according to the initial time line, saving was made on transportation cost to Abkhazia) :\nCommitment EUR 8,718 – December service cost reimbursed in January 2016\nOverspending EUR 1,006 – MHDAC has moved TA categoty cost to M&E, TG spent more than budgeted amount on M&E visits, but in the limit of service contract signed through tender \n"]
[10,"Living Support to Clients/Target Populations",null,null,107315.22725142298,64841.258119278718,42473.969132144266,"PR- N/A                                                                              \nSR- Saving EUR 41,231  PDI incentives as actual demand from IDUs and MSM were less than anticipated and budgeted; AIDS Center saved money on Fibroscan tests and on infant formula procurement.\nCommitment EUR 3,702 – December service cost reimbursed in January 2016\nOverspending EUR 2,460 – TG has overspent on incentives for LGBT community members due to category change in the tender (T was changed to LS) and HAPS’s spent more than budgeted amount on events for children of PLHIV\n",198639.72607301292,114686.49483763591,83953.23123537701,"PR- N/A                                                                              \nSR- Saving EUR 82,654   PDI incentives as actual demand from IDUs and MSM were less than anticipated and budgeted; AIDS Center saved money on Fibroscan tests and on infant formula procurement; \nCommitment EUR 3,702 – December service cost reimbursed in January 2016\nOverspending EUR 2,403 – TG has overspent on incentives for LGBT community members due to category change in the tender (T was changed to LS) and HAPS’s spent more than budgeted amount on events for children of PLHIV\n"]
[11,"Planning and Administration",null,null,74749.583991785708,41117.485544911484,33632.098446874224,"PR – Saving EUR 29,218 actual costs for program administration was less than budgeted including audit fee, tender announcement costs, and postal fee.\nSRs- Saving EUR 4,669   Most of the SRs and SSRs spent less money for procurement of office supplies\nCommitment EUR 1,743– December service cost reimbursed in January 2016\nOverspending EUR 1,998- GHRN spent more than budgeted amount as the cost depends on the actual office needs of 14 service centers. \n",102543.78114972748,55036.313867039826,47507.467282687656,"PR – Saving EUR 36,206 actual costs for program administration was less than budgeted including audit fee, tender announcement costs and postal fee.\nSRs- Saving EUR 10,232 – The most of SRs and SSRs spent less money for procurement of office supplies\nCommitment EUR 1,743– December service cost reimbursed in January 2016\nOverspending EUR 674 – GHRN’s service centers have overspent money on office related costs. \n"]
[12,"Overheads",null,null,554816.50426046201,357922.38536566362,196894.11889479839,"PR - Saving EUR 66,448 procurement of fuel through consolidated tender resulted considerable savings; also actual project management costs were less than budgeted; \nCommitment EUR 5,634 - Fuel cost for December reimbursed in January 2016 \nSRs - Saving EUR 97,318 – SRs made savings on insurance, utilities, communication and office maintenance costs. The less amount was spent on the supplies for the Mobile Ambulatories by GHRN, TG had savings in the category as  the cost is split between the GF and other programs and about 50% of the cost is covered from other programs.\nCommitment EUR 27,494– December service cost reimbursed in January 2016\n",913403.52562451921,561759.36766142794,351644.15796309127,"PR - Saving EUR 124,417 procurement of fuel through consolidated tender resulted considerable savings; also actual project management costs were less than budgeted; \nCommitment EUR 5,634 - Fuel cost for December reimbursed in January 2016 \nSRs - Saving EUR 194,099 SRs made savings on insurance, utilities, communication and office maintenance costs. The less amount was spent on the supplies for the Mobile Ambulatories by GHRN, TG had savings in the category as  the cost is split between the GF and other programs and about 50% of the cost is covered from other programs. Saving as made during preparation of plastic clients' cards of PWIDs, in procurement of medical and art supplies, not spending whole money budgeted new OST Centers; National AIDS Center saved some amount as opening of Telavi ART Center was canceled postponed and money for transportation of medical supplies to Abkhazia was saved;\nCommitment EUR 27,494– December service cost reimbursed in January 2016\n"]
[13,"Other",null,null,0,6190.507639019972,-6190.507639019972,"VAT amount paid for the service provided by TG under objective 1. The amount is refundable to PR by The State",0,6190.507639019972,-6190.507639019972,"VAT amount paid for the service provided by TG under objective 1. The amount is refundable to PR by The State"]
[null,null,null,"TOTAL",{"$f":"E18+E19+E20+E21+E22+E23+E24+E25+E27+E26+E28+E29+E30","v":11216378.655312106},{"$f":"F18+F19+F21+F20+F22+F23+F24+F25+F26+F27+F28+F29+F30","v":6358582.9852131074},{"$f":"SUM(G18:G30)","v":4857795.6700989986},null,{"$f":"SUM(I18:I30)","v":17581514.506065555},{"$f":"SUM(J18:J30)","v":9476796.786964003},{"$f":"SUM(K18:K30)","v":8104717.7191015501}]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Supportive Environment","To establish supportive environment for HIV/AIDS prevention, treatment, care and support","Supportive environment: Stigma reduction in all settings",199165.81,127224.1495522795,{"$f":"E36-F36","v":71941.660447720496},"PR: Saving EUR 178 – Actual fuel cost provided to TG was less than budgeted\nCommitment EUR 55 fuel cost for December \nSR: Procurement of the service for the Objective 1 was conducted through the state procurement mechanism and the contracts for implementation of Objective 1 were signed during March and April of 2015 and SRs are working on the implementation of the following components:\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV Community - SR: NGO Real People, Real Vision (RPRV).\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\nSaving EUR 73,237 - – The tender procurement of the services has resulted in lower costs per activity. Savings were made in T and OVE categories also as there was no need to spend to spend more on the trainings organized by RPRV and Tanadgoma made saving on the office running costs in LGBT component. \nCommitment EUR 7,104 – TG LGBT December service cost\nOverspending EUR 8,633  is related to VAT cost accounted as OTH cost category(refundable amount) and (RPRV advocacy component and LGBT),  and in LS category which was not budgeted and trough the tender the SR has included some amount in this category. \n",253777.91,127224.1495522795,{"$f":"I36-J36","v":126553.7604477205},"PR - Saving EUR 178 – Actual fuel cost provided to TG was less than budgeted\nCommitment EUR 55 fuel cost for December \nSR : The procurement of the service for the Objective 1 was conducted through the state procurement mechanism and the contracts for implementation of Objective 1 were signed during March and Appril of 2015 and SRs are working on the implementation of the following components:\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV COmmunity - SR: NGO Real People, Real Vision,\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\nSaving EUR 128,933 - The tender procurement of the services has resulted in lower costs per activity. Savings were made in T and OVE categories also as there was no need to spend to spend more on the trainings organized by RPRV and Tanadgoma made saving on the office running costs in LGBT component. \nCommitment EUR 7,104 – TG LGBT December service cost\nOverspending EUR 9,716 is related to VAT cost accounted as OTH cost category(refundable amount) and (RPRV advocacy component and LGBT),  and in LS category which was not budgeted and trough the tender the SR has included some amount in this category. \n"]
[2,"Prevention","To increase coverage and quality of preventive interventions targeted at MARPs","Prevention: Behavioral Change Communication - community outreach",3470619.81,2741884.2905578171,{"$f":"E37-F37","v":728735.51944218297},"PR: EUR 455,081 – mainly due to savings in HPHE (lab supplies, desinfectants, tests systems, Flowcytometer; syringes; condoms) derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nCommitment: EUR 3,624 – Fuel costs for December \nPostpone EUR 24,941 -IDA remainig amount for Syringes Order moved to NFM. \nOverspending: EUR 184,110 – related to activities budgeted in the previous reporting period, mainly HPHE.\nSR: Saving EUR 257,826 - The main contribution to the variance is the delay in procurement of mobile ambulatories and hiring of the relevant personnel that caused savings in HR, ME and OVE categories in GHRN. In order to address the need to meet the increased coverage targets of IDUs with outreach services, PR allowed SR to hire staff for Mobile Ambulatory in advance prior delivery of the Mobile Ambulatory cars who started outreach work with ordinary cars, this way negative impact to the program was mitigated;   Saving was also in cost of case management, reimbursements for medical consultations,  less amount was disbursed as PDI incentives; savings were made in technical services of cars and office equipment, stationary procurement, in preparation of plastic service cards, in expenses related to utilities; in procurement of art supplies; The harm reducation conference was canceled; Training of personnel on overdose was postponed; Savings were made in budget lines for staff meetings at the offices of GHRN member organizations, for training of peers, participation in international conferences, development of IEC materials and organization of round tables for community members as the less amount was spent per event than was budgeted.\nSaving with OST program is mainly results of delays in opening of new OST center, especially in HR, T, IE and OVE categories; personnel was hired, trained with a delay and related administrative and overhead costs were saved; Drug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category during the tender, while it was initially budgeted in the OVE in approved GF budget; \nSaving in implementation of FSW, MSM and prisoners components are in the cost of rent and utilities as the SR was covering this cost from other programs also; the saving is related to PDI interventions were paid based on the actual number of clients served; less number of VCT consultants were working in prisons; less amount was spent per training, less amount was spent for technical services of cars and office equipment, design of IEC materials, per M&E visits, actual disbursed amount for popular leader program activists and PDI cash incentives was less than budgeted; saving was in procurement of office supplies (stationary), in expenses related to rent and utilities; also, preparation of key chain plastic cards for MSM was canceled due to technical reasons. \nDespite this saving the activities budgeted under the Objective 2 were mostly implemented as planned with good achievements regarding the target indicators.  \nCommitment  EUR 177,459  for reimbursement of the December service provided within the objective;\nOverspending EUR 6,086-  is related to PSM as spending for Harm Reduction Program depends on the volume of supplies to be delivered and to PA (spending depends on the office needs for stationary and office running costs), to CM category with OST program, less than budgeted amount was spent on international travel that was included in this Budget category and the actual cost through tender for ME and IE categories for FSW and MSM component was slightly greater than budgeted.\n",6483074.8099999996,4496288.2166154161,{"$f":"I37-J37","v":1986786.5933845835},"PR: Saving: EUR 1,148,035 – mainly due to savings in HPHE (lab supplies, desinfectants, tests systems, Flowcytometer; syringes; condoms) derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities.\nCommitment: EUR 129,888 – Fuel costs for December and additional 4 mobile ambulatories\nPostpone EUR 24,941 -IDA remainig amount for Syringes Order moved to NFM. \nOverspending: EUR 137,435 – Overspending: EUR 137,435 – Actual cost of several procurements and quantities, based on consumption was greater than budgeted and new activities (additional 4 Mobile labs) in agreement with GF.\nSR: Saving EUR 651,999 -The main contribution to the variance in harm reduction component is the delay in procurement of mobile ambulatories and hiring relevant personnel, that caused savings in HR, ME and OVE categories, in order to address the need to increase coverage indicators of IDUs with outreach services, PR allowed SR to hire staff for Mobile Ambulatory in advance who started outreach work with ordinary cars, this way negative impact to the program was mitigated;   Saving was also in cost of case management, reimbursements for medical consultations,  less amount was disbursed as PDI incentives; savings were in technical services of cars and office equipment, stationary procurement, in preparation of plastic service cards, in expenses related to utilities; in procurement of art supplies;\nSaving is also the amount budgeted for harm reeducation conference that wasn't spent due to technical problems in planning; Training of personnel on overdose was postponed; Savings were made in budget lines for staff meetings at the offices of GHRN member organizations, for training of peers, participation in international conferences, development of IEC materials and organization of round tables for community members as the less amount was spent per event than was budgeted.\nSaving in OST component is mainly results of delays in opening of new OST center, especially in HR, T, IE, OVE categories; personnel wasn't hired, wasn't trained according to the initial timeline and related administrative and overhead costs were saved; Less than budgeted amounts were spent on repair of observation cameras, technical services of cars and office equipment, on round tables, in procurement of art supplies, in monetary incentives for PWIDs, for office supplies, in utilities' and security costs.  \nDrug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category, while it was initially budgeted in the OVE in approved GF budget; \nSaving in implementation of FSW, MSM and prisoners components are in the cost of rent and utilities as the SR was covering this cost from other programs also; the saving is related to PDI interventions were paid based on the actual number of clients served; less number of VCT consultants were working in prisons; less amount was spent per training, less amount was spent for technical services of cars and office equipment, design of IEC materials, per M&E visits, actual disbursed amount for popular leader program activists and PDI cash incentives was less than budgeted; saving was in procurement of office supplies (stationary), in expenses related to rent and utilities; also, preparation of key chain plastic cards for MSM was canceled due to technical reasons. \nDespite this saving the activities budgeted under the Objective 2 were mostly implemented as planned with good achievements regarding reaching the target indicators.  \n\nCommitment  EUR 177,459  for reimbursement of the December service provided within the objective;\nOverspending EUR 8,100    is related to PSM as spending for Harm Reduction Program and Narc depends on the volume of supplies/Methadone to be delivered and to PA (spending depends on the office needs for stationary and office running costs), to CM category with OST program, less than budgeted amount was spent on international travel that was included in this Budget category and the actual cost through tender for ME category for FSW and MSM component was slightly greater than budgeted.\n"]
[3,"Treatment","To sustain treatment, care and support for PLHIV including Abkhazia frozen conflict area","Treatment, Care and Support",6779322.75,2913956.4090395118,3865366.3409604882,"PR: Saving EUR 2,985,270 – mainly due to ARVs resulted from actual PQ signed with PPM and simplification of regimens. Also Actual unit price for vaccines, tests and lab supplies provided to Aids Center, was lower than budgeted. Considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pagylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nCommitment EUR 1,751 – December fuel cost provided to SR reimbursed in January 2016.\nPostpone: EUR 797,837- remaining amount for PFSCM order placed in 2014 and new order placed in 2015 pushed to NFM budget.\nOverspending: EUR 152,843 – Procurement of tests and lab supplies for Aids Center budgeted in the previous period. \nSR: Saving EUR 173,417- The main reason for saving was a delay in hiring of planned additional personnel for AIDS treatment centers (they couldn't find relevant professionals with required qualification), hiring of laboratory expert with relevant background and experience and postponing and later canceling of opening of new ART regional center in Telavi as it wasn't possible to find suitable health care institution that would host such specialized treatment facility. Less than budgeted amounts were spent for technical service of cars and medical and laboratory equipment; for international training/conference (one visit was canceled) SR paid less for international laboratory quality control service, saving was also in procurement of office supplies, in utilities and administrative costs and in transportation of supplies to Abkhazia. \nThe savings in the operations of self-support centers of PLHIV has resulted from the following:  less amount was spent on HR, T, OVE, the SR spend less money for international visit; AIDS victims' memorial day activity was canceled due to lack of institutional money before getting cash advance in May; Saving was in technical service of office equipment and procurement ofoffice supplies, in cost of utilities and office rent.  \nThere was no any noticeable impact on implementation of the objective related activities. The AIDS Center has sound achievements related to ART. \nCommittment: EUR 60,092  December service cost\nOverspending EUR 158 – Actual cost of ME and LS was slightly greater than budgeted during operation of PLHIV self-support centers \n",9580900.9299999997,4007198.0223626764,5573702.9076373233,"Saving EUR 4,376,275 – mainly due to ARVs resulted from actual PQ signed with PPM and simplification of regimens. Also Actual unit price for vaccines, tests and lab supplies provided to Aids Center, was lower than budgeted. Considerably lower price procurement of interferon through the local tender. Also Procurement of the last portion of the pagylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.\nCommitment EUR 1,751 – December fuel cost provided to SR reimbursed in January 2016.\nPostpone: EUR 797,837- remaining amount for PFSCM order placed in 2014 and new order placed in 2015 pushed to NFM budget.\nSR: Saving: EUR 341,453 Main reason for saving in ART program was a delay in hiring of planned additional personnel for treatment centers (they couldn't find relevant professionals with required qualification), hiring of laboratory expert with relevant background and experience and postponing and later canceling of opening of new ART regional center in Telavi as it wasn't possible to find suitable health care institution that would host such specialized treatment facility. Less than budgeted amounts were spent for technical service of cars and medical and laboratory equipment; for international training/conference (one visit was canceled) SR paid less for international laboratory quality control service, saving was also in procurement of office supplies, in utilities and administrative costs and in transportation of supplies to Abkhazia. Saving was made in implementation of drug resistance testing component also. \nThe savings in operation of PLHIV self-support centers are related to the following: less amount was spent on HR,T, OVE due to late signing of the contracts with staff, expert for survey was hired by one month late; SR spend less money for international visit; AIDS victims' memorial day activity was canceled due to lack of institutional money before getting cash advance in May; Saving was in technical service of office equipment and procurement office supplies, in cost of utilities and office rent.  \nThere was no any noticeable impact due to not fully utilizing the budgeted amount on the Objactive related activities implementation ; \nCommittment EUR 60,092 - December service cost\nOverspending – EUR 3,706 includes: –Actual cost through tender for ME and TA slightly greater than budgeted in PLHIV self-support centers component.\n\n"]
[4,"Health System Strengthening (HSS)","To generate evidences and document HIV program effectiveness","HSS: Information system & Operational research",318704.25,277186.98199105909,41517.268008940911,"Commitment EUR 220 – December fuel cost provided to SR reimbursed in January 2016\nOverspending – EUR 2451 actual fuel cost budgeted in previous period for the entire year.\nSR: Saving EUR 57,083 Mainly this is the savings under the IBBS study component in HR and ME categories due to spending the less amounts on interviewers fees (unit cost was reduced) and on monitoring visits; Less than the budgeted amount was spent on laboratory testing of survey samples.  Stigma survey was procured as TA with tender in agreement with GF and all costs were budgeted in different categories which caused savings in relevant categories.\nCommittment: EUR 14,668 December service cost.\nOverspending EUR 28,003 – procurement of HPHE budgeted under PR for IBBS surveys and transferred to SR in agreement with GF\n",585224.05000000005,412995.3697558163,172228.68024418375,"PR: Saving EUR 39,928 – actual fuel cost and quantities lower than budgeted and procurement for tests and lab supplies for CIF budgeted under PR costs and moved to SR contract in agreement with GF\nCommitment EUR 220 – December fuel cost provided to SR reimbursed in January 2016\nSR Saving EUR 151,652 Mainly this is the savings under the IBBS study component in HR and ME categories due to the late initiation of IDU survey, due to the spending the less amounts on interviewers fees (unit cost was reduced) and on monitoring visits; Less than the budgeted amount was spent on laboratory testing of survey samples.  Stigma survey was procured as TA with a tender in agreement with GF and all costs were budgeted in different categories which caused savings in relevant categories.\nCommittment: EUR – 14,668 December service cost\nOverspending EUR 34,240 – mainly procurement of HPHE products for the IBBS surveys under PR and transferred to SR in agreement with GF.\n"]
[5,"Supportive Environment","PR Management and Administration ","Supportive environment: Program management and administration",448566.04,298331.15299703198,150234.887002968,"PR: Saving EUR 156,354 – Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist, finance specialist, logistics specialist); saving related to renovation of office; procuring furniture (It was handed over from previous PR); fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee.The FX rate had also impact on savings.\nEUR 543 - Project Management costs (fuel cost, ERP consultant fee ) for December that was actually paid in January 2016\nOverspending 6,662 – Actual cost for training was greater than budgeted in the current period.\n",678536.81,433091.02760240645,245445.7823975936,"PR: Saving EUR 244,903 - Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist, finance specialist, logistics specialist); saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee.The FX rate had also impact on savings.\nEUR 543 Project Management costs (fuel cost, ERP consultant fee ) for December that was actually paid in January 2016\n"]
["TOTAL",null,null,null,{"$f":"SUM(E36:E40)","v":11216378.66},{"$f":"SUM(F36:F40)","v":6358582.9841376999},4857795.6758623002,null,{"$f":"SUM(I36:I40)","v":17581514.509999998},{"$f":"SUM(J36:J40)","v":9476796.7858885936},8104717.7241114043]
["To add additional rows, right click the row number (Row 39 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the variance column to become invalid and will mean the overall information will be inaccurate."]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"SR","SRS","NGO/CBO/Academic",198244.8199458223,126536.25749858785,{"$f":"E48-F48","v":71708.56244723445},"The procurement of the service for the Objective 1 was conducted through the state procurement mechanism and the contracts for implementation of Objective 1 were signed during March and April of 2015 and SRs are working on the implementation of the following components:\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV Community - SR: NGO Real People, Real Vision (RPRV).\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\nSaving EUR 73,237 – The tender procurement of the services has resulted in lower costs per activity. Savings were made in T and OVE categories also as there was no need to spend to spend more on the trainings organized by RPRV and Tanadgoma made saving on the office running costs in LGBT component. \nCommitment EUR 7,104 – TG LGBT December service cost\nOverspending EUR 8,633  is related to VAT cost accounted as OTH cost category(refundable amount) and (RPRV advocacy component and LGBT),  and in LS category which was not budgeted and trough the tender the SR has reallocated some amount in this category. \n",252856.9246551515,126536.25749858785,{"$f":"I48-J48","v":126320.66715656365},"The procurement of the service for the Objective 1 was conducted through the state procurement mechanism and the contracts for implementation of Objective 1 were signed during March and April of 2015 and SRs are working on the implementation of the following components:\n- Strengthening LGBT Community - SR Tanadgoma, SSRs - NGO Identoba and NGO LGBT Georgia\n- Strengthening HIV Community - SR: NGO Real People, Real Vision,\n- Advocacy component - SR: NGO Real People, Real Vision\n- Training of Health Care Workers for HIV related Stigma Reduction in clinical settings - SR: HIV/AIDS Patients Support Foundation\nSaving EUR 128,933 - The tender procurement of the services has resulted in lower costs per activity. Savings were made in T and OVE categories also as there was no need to spend to spend more on the trainings organized by RPRV and Tanadgoma made saving on the office running costs in LGBT component. \nCommitment EUR 7,104 – TG LGBT December service cost\nOverspending EUR 9,716 is related to VAT cost accounted as OTH cost category (refundable amount) and (RPRV advocacy component and LGBT), and in LS category which was not budgeted and through the tender the SR has reallocated some amount in this category. \n\n"]
[2,"SR","Georgian Harm Reducation Network","NGO/CBO/Academic",1329290.5870434465,1112375.6818478047,{"$f":"E49-F49","v":216914.9051956418},"Saving EUR 130,769 - The main contribution to the variance is the delay in procurement of mobile ambulatories and hiring of the relevant personnel that caused savings in HR, ME and OVE categories. In order to address the need to meet the increased coverage targets of IDUs with outreach services, PR allowed SR to hire staff for Mobile Ambulatory in advance prior delivery of the Mobile Ambulatory cars who started outreach work with ordinary cars, this way negative impact to the program was mitigated;   Saving was also in cost of case management, reimbursements for medical consultations,  less amount was disbursed as PDI incentives; savings were made in technical services of cars and office equipment, stationary procurement, in preparation of plastic service cards, in expenses related to utilities; in procurement of art supplies;\nSaving is also the amount budgeted for harm reducation conference that wasn't spent due to technical problems in planning; Training of personnel on overdose was postponed; Savings were made in budget lines for staff meetings at the offices of GHRN member organizations, for training of peers, participation in international conferences, development of IEC materials and organization of round tables for community members as the less amount was spent per event than was budgeted.\nCommitment  EUR 90,558 for reimbursement of the December service;\nOverspending EUR 4,412 is related to PSM as spending depends on the volume of supplies to be delivered and to PA (spending depends on the office needs for stationary and office running costs)\n",2358896.3175999722,1899895.125359247,{"$f":"I49-J49","v":459001.19224072527},"Saving EUR 373,581 -  The main contribution to the variance is the delay in procurement of mobile ambulatories and hiring relevant personnel, that caused savings in HR, ME and OVE categories, in order to address the need to increase coverage indicators of IDUs with outreach services, PR allowed SR to hire staff for Mobile Ambulatory in advance who started outreach work with ordinary cars, this way negative impact to the program was mitigated;   Saving was also in cost of case management, reimbursements for medical consultations,  less amount was disbursed as PDI incentives; savings were in technical services of cars and office equipment, stationary procurement, in preparation of plastic service cards, in expenses related to utilities; in procurement of art supplies;\nSaving is also the amount budgeted for harm reeducation conference that wasn't spent due to technical problems in planning; Training of personnel on overdose was postponed; Savings were made in budget lines for staff meetings at the offices of GHRN member organizations, for training of peers, participation in international conferences, development of IEC materials and organization of round tables for community members as the less amount was spent per event than was budgeted.\nCommitment  EUR 90,558 for December service;\nOverspending EUR 5,138  is related to PSM as spending depends on the volume of supplies to be delivered and PA (spending depends on the office needs for stationary and office running costs)\n"]
[3,"SR","Center of Mental Health and Prevention of Drug Addiction","Other Government",682192.75406895904,573032.64264502458,109160.11142393446,"Saving EUR 58,219 is mainly results of delays in opening of new OST center, especially in HR, T, IE and OVE categories; personnel was hired, trained with a delay and related administrative and overhead costs were saved; Less than budgeted amounts were spent on repair of observation cameras, technical services of cars and office equipment, on round tables, in procurement of art supplies, in monetary incentives for PWIDs, for office supplies, in utilities' and security costs.  \nDrug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category during the tender, while it was initially budgeted in the OVE in approved GF budget; \nDespite delay in opening of new OST center there was no negative impact on the program implementation as Government abolished setting limits per OST center for number of patients served and GF OST Centers also could serve more patients, the target OST patients' indicator was overachieved.\nCommitment EUR 51,123  for December service \nOverspending EUR 182  is related to CM, less than budgeted amount was spent on international travel that was included in this Budget category. \n",1155943.4956102581,956832.34683478356,199111.14877547452,"Saving EUR 150,584 is mainly results of delays in opening of new OST center, especially in HR, T, IE, OVE categories; personnel wasn't hired, wasn't trained and related administrative and overhead costs were saved; Less than budgeted amounts were spent on repair of observation cameras, technical services of cars and office equipment, on round tables, in procurement of art supplies, in monetary incentives for PWIDs, for office supplies, in utilities' and security costs.  \nDrug Addiction Prevention Day Conference was canceled due to technical reasons, participation in international conferences were included into ME category, while it was initially budgeted in the OVE in approved GF budget; \nDespite delay in opening of new OST center there was no negative impact on the program implementation as Government abolished setting limits per OST center for number of patients served and GF OST Centers also could serve more patients, the target OST patients' indicator was overachieved\nCommitment EUR 51,123  for December service \nOverspending EUR 2,596 - Changes in category by SR in tender proposal – EUR 1,957 from OVE to PSM and EUR 639 from T to ME category\n"]
[4,"SR","Tanadgoma","NGO/CBO/Academic",527298.02909379045,424173.06543743948,103124.96365635097,"Saving EUR 68,838 - In cost of rent and utilities as SR was covering this cost from other programs also; the saving is related to PDI interventions were paid based on the actual number of clients served; less number of VCT consultants were working in prisons; less amount was spent per training, less amount was spent for technical services of cars and office equipment, design of IEC materials, per M&E visits, actual disbursed amount for popular leader program activists and PDI cash incentives was less than budgeted; saving was in procurement of office supplies (stationary), in expenses related to rent and utilities; also, preparation of key chain plastic cards for MSM was canceled due to technical reasons. Despite this saving the SR has mostly implemented all planned activities and has improved its coverage indicators for both key population groups (FSWs and MSM). The indicators targets are met at around 80%.  During implementation period SR has addressed the PR regarding the changes in the program implementation asking to test PDI interventions among MSM as it wasn’t much successful among FSWs. PR has agreed on this change with support of FPM and the activity showed better results for MSM population and allowed the SR to increase their coverage with prevention package. PDI activities are expended to regions also (Batumi, Kutaisi). \nThe STI treatment indicators in the regions are still small, the PR has continues communication with the SR and SSR – Association of Dermato-venerologists regarding the development of more effective strategy to increase the utilization of the STI treatment services by clients. \nCommitment: EUR 35,778 December service cost;\nOverspending EUR 1,491 – Actual cost through tender for ME and IE was slightly greater than budgeted\n",922860.73667159572,759615.29000222182,163245.44666937389,"Saving EUR 127,834 -  In cost of rent and utilities as SR was covering this cost from other programs also; the cost is related to PDI interventions were paid based on the actual number of clients served; less number of VCT consultants were working in prisons; less amount was spent per training, less amount was spent for technical services of cars and office equipment, design of IEC materials, per M&E visits, actual disbursed amount for popular leader program activists and PDI cash incentives was less than budgeted; saving was in procurement of office supplies (stationary), in expenses related to rent and utilities; also, preparation of key chain plastic cards for MSM was canceled. The SR has mostly implemented all planned activities and has improved its coverage data for both key population groups (FSWs and MSM). During implementation period SR has addressed the PR regarding changes in the program implementation asking to test PDI interventions among MSM as it wasn’t much successful among FSWs. PR has agreed on this change with support of FPM and the activity showed better results for MSM population and allowed the SR to increase their coverage with prevention package. PDI activities are expended to regions also (Batumi, Kutaisi). \nThe STI treatment indicators in the regions are still small, the PR has continues communication with the SR and SSR – Association of Dermato-venerologists regarding the development of more effective strategy to increase the utilization of the STI treatment services by clients. \nCommitment: EUR 35,778 December service cost;\nOverspending EUR 366 – Actual cost through tender for ME was slightly greater than budgeted\n"]
[5,"SR","Infectious Diseases, AIDS and Clinical Immunology Research Center","Other Government",836229.00162151642,592449.06082255754,243779.94079895888,"Saving EUR 188,348 - Main reason for saving was a delay in hiring of planned additional personnel for treatment centers (they couldn't find relevant professionals with required qualification), hiring of laboratory expert with relevant background and experience and postponing and later canceling of opening of new ART regional center in Telavi as it wasn't possible to find suitable health care institution that would host such specialized treatment facility. Less than budgeted amounts were spent for technical service of cars and medical and laboratory equipment; for international training/conference (one visit was canceled) SR paid less for international laboratory quality control service, saving was also in procurement of office supplies, in utilities and administrative costs and in transportation of supplies to Abkhazia. Despite canceling of opening of new ART Center in Telavi (Kakheti), the SR still had good achievements related to ART indicators as PLHIV living in Kakheti region were receiving the service at National AIDS Center in Tbilisi from more skillful professionals than they would receive in regions. Although, many of patients would prefer receiving treatment in Tbilisi due to confidentiality concerns. \nCommittment EUR 55,432 - December service cost\n",1409355.0439977241,1003669.8701238008,405685.17387392325,"Saving: EUR 350,253 -Main reason for saving was a delay in hiring of planned additional personnel for treatment centers (they couldn't find relevant professionals with required qualification), hiring of laboratory expert with relevant background and experience and postponing and later canceling of opening of new ART regional center in Telavi as it wasn't possible to find suitable health care institution that would host such specialized treatment facility. Less than budgeted amounts were spent for technical service of cars and medical and laboratory equipment; for international training/conference (one visit was canceled) SR paid less for international laboratory quality control service, saving was also in procurement of office supplies, in utilities and administrative costs and in transportation of supplies to Abkhazia. Despite canceling of opening of new ART Center in Telavi (Kakheti), the SR still had good achievements related to ART indicators as PLHIV living in Kakheti region were receiving the service at National AIDS Center in Tbilisi from more skillful professionals than they would receive in regions. Although, many of patients would prefer receiving treatment in Tbilisi due to confidentiality concerns. \nCommittment EUR 55,432 - December service cost\n"]
[6,"SR","HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",158428.32612105788,126815.78186081012,31612.544260247756,"Saving: EUR 24,175 - The budget of this organization contains HAPS activities under 3 and 4 objective and stigma survey (through tender another winner was identified). The reasons for Saving: less amount was spent on HR,T, OVE due SR spend less money for international visit; AIDS victims' memorial day activity was canceled due to lack of institutional money before getting cash advance in May; Saving was in technical service of office equipment and procurement ofoffice supplies, in cost of utilities and office rent.  There was no any noticeable impact due to not fully utilizing the budgeted amount on the program implementation ; Stigma survey was procured as TA in agreement with GF and all costs budgeted in different categories caused savings in relevant categories.\nCommittment: EUR 7,596  December service cost\nOverspending EUR 158 – Actual cost of ME and LS was slightly greater than budgeted.\n",266338.66661352583,219085.31159089311,47253.355022632721,"Saving: EUR 43,364 – – The comment is made related to the budget containing HAPS activities under 3 and 4 objectives and stigma survey (through tender another winner was identified). Saving is a result of the following: less amount was spent on HR,T, OVE due to late signing of the contracts with staff, expert for survey was hired by one month late; SR spend less money for international visit; AIDS victims' memorial day activity was canceled due to lack of institutional money before getting cash advance in May; Saving was in technical service of office equipment and procurement office supplies, in cost of utilities and office rent.  There was no any noticeable impact due to not fully utilizing the budgeted amount on the program implementation ; Stigma survey was procured as TA in agreement with GF and all costs budgeted in different categories caused savings in relevant categories.\nCommittment: EUR 7,596  December service cost\nOverspending – EUR 3,706 includes: –Actual cost through tender for ME and TA slightly greater than budgeted.\n"]
[7,"SR","Curatio International Foundation","Private Sector",224297.45580035466,222591.15429428554,1706.3015060691105,"Saving EUR 17,979 – Mainly this is the savings under the HR and ME categories due the spending the less amounts on interviewers fees (unit cost was reduced) and on monitoring visits; Less than the budgeted amount was spent on laboratory testing of survey samples.  \nCommittment: EUR 11,731- December service cost.\nOverspending EUR 28,003 – procurement of HPHE budgeted under PR and transferred to SR in agreement with GF\n",401411.26443483966,324430.55965252512,76980.70478231454,"Saving EUR 99,489 - Mainly HR and ME Saving due to not using budgeted amount for Q2 for BSS among IDUs (contract was signed with SR end of September), less amount was paid to interviewers (unit cost was reduced); on monitoring visits; Less than the budgeted amount was spent on laboratory testing of survey samples.  \nCommittment: EUR 11,731- December service cost\nOverspending EUR 34,240 – mainly procurement of HPHE products budgeted under PR and transferred to SR in agreement with GF.\n"]
[8,"PR","National Center for Disease Control and Public Health","Other Government",7260397.6816171603,3180609.3397311894,4079788.3418859709,"Net variance of EUR 4,079,788 consists of Positive variance of Euro 4,279,772 and negative variance of EUR 199,984\nTotal Saving  EUR 3,450,940 includes: EUR 2,659,169  – Savings from  MPP &PSM (ARVs, interferon, methadone, STI medicines, quality control of ARVs) is derived from cancelled activities, actual consumption rates of SRs, lower unit prices, including lower unit prices of ARVs offered by PPM and also ART regimens simplification. Considerably lower price procurement of interferon through the local tender. Also Procurement of pagylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.  Procurement of methadone was conducted at much lower price than budgeted also (4 EUR vs. 9 EUR). \nEUR  495,382 - HPHE procurement (lab supplies, disinfectants, tests systems, Flowcytometer;syringes,condoms) is derived from low unit prices as a result of tenders; procurement through pooled procurement, revision of the q-ties based on the consumption data and some cancelled activities. Instead of one flow cytometer with high technical characteristics, in agreement with GF and AIDS Center, four field equipment – BD Presto were procured for CD4 count measurement, which has resulted in substantial saving. \nEUR 140,036  - Procurement of office equipment/furniture and printing of materials through tenders resulted in saving also. Database development cost budgeted in GHRN is moved to NFM period, the amount is included in the savings, Actual fuel cost and quantities were less than budgeted; Procurement of Vehicles for SRs was cancelled in agreement with GF.\nEUR 156,354- Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist vacancies for various periods) ; saving related to renovation of the PR's office; procurement of furniture (It was handed over from previous PR) ; consolidated procurement of fuel; tender announcement costs, Technical assistance; late start of media campaign, lower than budgeted Audit fee.The FX rate had also impact on the savings;\nPostponed Activities: EUR 822,778 – remaining amount for PFSCM order placed in 2014 and new order placed in 2015 transfered to NFM budget. Also IDA remaining amount for Syringes' Order has been moved to NFM budget. \nCommitment EUR 6,054 : EUR 5,511 –Fuel cost provided to SRs in December, paid in January 2016; EUR 543 - Project Management costs (fuel cost of the PR, ERP consultant fee ) for December and paid in January 2016\nNegative Variance EUR 199,984 relates to activity procured in current reporting period and budgeted in the previous year ( mobile ambulatories, lab supplies, office equipment for Srs); part of budgeted activities had greater unit price and/or quantities were revised according to the consumption rates. Procurement of HP for extension period that was conducted end of 2015 (syringes, tests); also PR training cost budgeted in the previous year and moved to 2015.\n",10813852.056482488,4186732.024826536,6627120.0316559523,"Net variance of EUR 6,627,120 consists of Positive variance of Euro 6,764,555 and negative variance of EUR 137,435\nTotal Saving  EUR 5,809,320 include: \nEUR 98,290 – Actual cost and quantities for Srs fuel was less than budgeted\nEUR 3,868,657  –Savings from  MPP &PSM (ARVs, interferon, methadone, STI medicines, quality control of ARVs) is derived from cancelled activities, actual consumtion rates, lower unit prices, including lower unit prices of ARVs offerd by PPM and also regimens were simplified. considerably lower price procurement of interferon through the local tender. Also Procurement of pagylated interferon and ribavirin budgeted at 320,000 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program.  Procurement of methadone was conducted at much lower price than budgeted also (4 EUR vs. 9 EUR). \nEUR  1,389,360 - HPHE procurement (lab supplies, desinfectants, tests systems, Flowcytometer;syringes,condoms) is derived from low unit prices as a result of tenders; revision of the q-ties based on the consumption data and some cancelled activities. Instead of one flow cytometer with high technical characteristic, in agreement with GF and AIDS Center, four field equipment – BD Presto, were procured for CD4 count measurement, which has resuted in substeintial seving. \nEUR 130,132 - Procurement of office equipment/furniture and printing of materials through tenders resulted in saving . Database development cost budgeted in GHRN is moved to NFM period, the amount is included in the savings.\nEUR 77,978  - Procurement of Vehicles for SRs was cancelled in agreement with GF.\nEUR 244,903 - Saving in Project management costs including International PSM consultant's fee, in HR (HIV M&E specialist , finance specialist, logistics specialist ) ; saving related to renovation of office; procuring furniture (It was handed over from previous PR) ; fuel; tender announcement costs, Technical assistance; late start of media campaign, Audit fee.The FX rate had also impact on savings.\nPostponed Activities: EUR 822,778 – remaining amount for PFSCM order placed in 2014 and new order placed in 2015 pushed to NFM budget. Also IDA remainig amount for Syringes Order moved to NFM. \nCommitment EUR 132,457 include: \nEUR 5,511 –Fuel cost provided to SRs in December, paid in January 2016.  \nEUR 126,403- Cost of additional 4 Mobile Ambulatories, which were delivered in March, 2016.\nEUR 543 - Project Management costs (fuel cost, ERP consultant fee ) for December and paid in January 2016\nNegative Variance EUR 137,435 include:\nEUR 121,766 – Cost of addittional 4 mobile ambulatories approved by GF.\nEUR 5,411 – Additional request from TG on procurement of micropipetes approved by GF\nEUR 1,396 – Actual cost of office equipment/furniture was slightly greater than budgeted.\nEUR 2,857 – Actual cost of desinfectants and minor lab supplies was slightly greater than budgeted \nEUR 5,309 – Actual need of STI medicines was greater based on the cuurent consumption \nEUR 696– actual Cost of Printing info materials for TG was greater than budgeted.\n"]
[null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,"TOTAL",{"$f":"SUM(E48:E57)","v":11216378.655312106},{"$f":"SUM(F48:F57)","v":6358582.984137699},{"$f":"SUM(G48:G57)","v":4857795.6711744089},null,{"$f":"SUM(I48:I57)","v":17581514.506065555},{"$f":"SUM(J48:J57)","v":9476796.7858885936},{"$f":"SUM(K48:K57)","v":8104717.7201769603}]
["To add additional rows, right click the row number (Row 51 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the variance column to become invalid and will mean the overall information will be inaccurate."]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
["Diff-ce between Actual Cash outflow and EFR expenditure in the current reporting period in the amount of EUR 9159 is the cash Balance of SRs from the year 2014 (TG and HAPS) which was recognized as current EFR expenditure"]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[1,"Real People, Real Vision","NGO/CBO/Academic",31130.44,"Activities under Objective 1 had 3 implementers (Srs) -Real people real vision (2 contracts); Tanadgoma( 1 contract) ; HAPS (1 contract)"]
[2,"Tanadgoma","NGO/CBO/Academic",76601.91]
[3,"HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",18803.830000000002]
[4,"Georgian Harm Reducation Network","NGO/CBO/Academic",1899895.1253592472]
[5,"Center of Mental Health and Prevention of Drug Addiction","Other Government",956832.34683478368]
[6,"Tanadgoma","NGO/CBO/Academic",759615.29000222182]
[7,"Infectious Diseases, AIDS and Clinical Immunology Research Center","Other Government",1003669.8701238008]
[8,"HIV/AIDS Patients Support Foundation","NGO/CBO/Academic",{"$f":"219085.311590893-8096","v":210989.31159089299}]
[9,"BCG Research","Private Sector",8096,"Stigma Survey among healthcare workers was budgeted under SR HAPS, but through tender another organization was identified as winner"]
[10,"Curatio International Foundation","Private Sector",324430.55965252512]
[null,null,"TOTAL",{"$f":"SUM(D76:D85)","v":5290064.6835634718}]

{"sheet":"LFA EFR_7B","index":19,"n_rows":76,"n_cols":26,"rows_kept":76,"cut":false,"hidden":false,"merged":[[72,4,72,10],[73,4,73,10],[74,4,74,10],[61,0,61,11],[62,0,66,11],[68,4,68,11],[69,4,69,10],[70,4,70,10],[71,4,71,10],[60,0,60,11],[27,1,27,3],[28,1,28,3],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[40,0,40,3],[41,0,43,4],[45,4,45,7],[45,8,45,11],[53,0,55,4],[26,1,26,3],[21,1,21,3],[21,15,21,16],[21,20,21,21],[22,1,22,3],[22,15,22,16],[22,20,22,21],[23,1,23,3],[23,15,23,16],[23,20,23,21],[24,1,24,3],[25,1,25,3],[18,1,18,3],[18,15,18,16],[18,20,18,21],[19,1,19,3],[20,1,20,3],[20,15,20,16],[20,20,20,21],[16,1,16,2],[16,15,16,16],[16,20,16,21],[17,1,17,3],[17,15,17,16],[17,20,17,21],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[15,20,15,21],[15,15,15,16],[8,0,8,1],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,4,9,4]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7B: LFA - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"'[3]PR_Programmatic Progress_1A'!C5:F5","v":{"$error":"#REF!"}},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"'[3]PR_Programmatic Progress_1A'!C7:F7","v":{"$error":"#REF!"}}]
["PR",null,{"$f":"'[3]PR_Programmatic Progress_1A'!C8:F8","v":{"$error":"#REF!"}},null,null,"TO BE COMPLETED ONLY ONCE A YEAR EXCEPT AT MONTH 18 FOR PURPOSES OF PHASE 2 REVIEW"]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
[null,null,null,null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:",null,null,"Cumulative Reporting Period","Start Date:"]
[null,null,null,null,null,"End Date:",null,null,null,"End Date:"]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFR"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDA"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period",null,null,null,null,null,null,{"$f":"IF('[3]PR_Programmatic Progress_1A'!R15=\"Select\",\"Please select currency on Page\n 'PR_Programmatic Achievement (1)'\", \"All amounts are in: \"&'[3]PR_Programmatic Progress_1A'!R15)","v":{"$error":"#REF!"}},null,"Budget for Reporting Period","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance",null,null,null,"1. Total PR cash outflow vs. budget",null,{"$f":"R18+R19","v":{"$error":"#REF!"}},{"$f":"S18+S19","v":{"$error":"#REF!"}},{"$f":"IF(R17=\"\",IF(S17=\"\",\"\",R17-S17),R17-S17)","v":{"$error":"#REF!"}},null,null,{"$f":"W18+W19","v":{"$error":"#REF!"}},{"$f":"X18+X19","v":{"$error":"#REF!"}},{"$f":"IF(W17=\"\",IF(X17=\"\",\"\",W17-X17),W17-X17)","v":{"$error":"#REF!"}}]
[1,"Human Resources",null,null,0,0,0,null,0,0,0,null,null,null,null,"    1a. PR's total expenditures",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C13","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D13","v":{"$error":"#REF!"}},{"$f":"IF(R18=\"\",IF(S18=\"\",0,R18-S18),R18-S18)","v":{"$error":"#REF!"}},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H13","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I13","v":{"$error":"#REF!"}},{"$f":"IF(W18=\"\",IF(X18=\"\",0,W18-X18),W18-X18)","v":{"$error":"#REF!"}}]
[2,"Technical Assistance",null,null,0,0,0,null,0,0,0,null,null,null,null,"    1b. Disbursements to sub-recipients",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C14","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D14","v":{"$error":"#REF!"}},{"$f":"IF(R19=\"\",IF(S19=\"\",0,R19-S19),R19-S19)","v":{"$error":"#REF!"}},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H14","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I14","v":{"$error":"#REF!"}},{"$f":"IF(W19=\"\",IF(X19=\"\",0,W19-X19),W19-X19)","v":{"$error":"#REF!"}}]
[3,"Training",null,null,0,0,0,null,0,0,0]
[4,"Health Products and Health Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,null,null,"Budget for Reporting Period*","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
[5,"Medicines and Pharmaceutical Products",null,null,0,0,0,null,0,0,0,null,null,null,null,"2. Total pharmaceutical & health product expenditures vs. budget",null,{"$f":"R23+R24","v":{"$error":"#REF!"}},{"$f":"S23+S24","v":{"$error":"#REF!"}},{"$f":"IF(R22=\"\",IF(S22=\"\",\"\",R22-S22),R22-S22)","v":{"$error":"#REF!"}},null,null,{"$f":"W23+W24","v":{"$error":"#REF!"}},{"$f":"X23+X24","v":{"$error":"#REF!"}},{"$f":"IF(W22=\"\",IF(X22=\"\",\"\",W22-X22),W22-X22)","v":{"$error":"#REF!"}}]
[6,"Procurement and Supply Management Costs",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2a.  Medicines and pharmaceutical products",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C18","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D18","v":{"$error":"#REF!"}},{"$f":"IF(R23=\"\",IF(S23=\"\",0,R23-S23),R23-S23)","v":{"$error":"#REF!"}},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H18","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I18","v":{"$error":"#REF!"}},{"$f":"IF(W23=\"\",IF(X23=\"\",0,W23-X23),W23-X23)","v":{"$error":"#REF!"}}]
[7,"Infrastructure and Other Equipment",null,null,0,0,0,null,0,0,0,null,null,null,null,"    2b.  Health products and health equipment",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C19","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D19","v":{"$error":"#REF!"}},{"$f":"IF(R24=\"\",IF(S24=\"\",0,R24-S24),R24-S24)","v":{"$error":"#REF!"}},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H19","v":{"$error":"#REF!"}},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I19","v":{"$error":"#REF!"}},{"$f":"IF(W24=\"\",IF(X24=\"\",0,W24-X24),W24-X24)","v":{"$error":"#REF!"}}]
[8,"Communication Materials",null,null,0,0,0,null,0,0,0]
[9,"Monitoring & Evaluation",null,null,0,0,0,null,0,0,0]
[10,"Living Support to Clients/Target Populations",null,null,0,0,0,null,0,0,0]
[11,"Planning and Administration",null,null,0,0,0,null,0,0,0]
[12,"Overheads",null,null,0,0,0,null,0,0,0]
[13,"Other",null,null,0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E18:E30)","v":0},{"$f":"SUM(F18:F30)","v":0},{"$f":"SUM(G18:G30)","v":0},null,{"$f":"SUM(I18:I30)","v":0},{"$f":"SUM(J18:J30)","v":0},0]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E40)","v":0},{"$f":"SUM(F36:F40)","v":0},0,null,{"$f":"SUM(I36:I40)","v":0},{"$f":"SUM(J36:J40)","v":0},{"$f":"SUM(K36:K40)","v":0}]
["To add additional rows, right click the row number (Row 39 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the variance column to become invalid and will mean the overall information will be inaccurate."]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E48:E52)","v":0},{"$f":"SUM(F48:F52)","v":0},0,null,{"$f":"SUM(I48:I52)","v":0},{"$f":"SUM(J48:J52)","v":0},0]
["To add additional rows, right click the row number (Row 51 in a blank template) to the left of the row above the row for TOTAL and select copy, then over the same number, right click again and select Insert Copied Cells. WARNING: Inserting Rows without copying a row as described above will cause the formula in the variance column to become invalid and will mean the overall information will be inaccurate."]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D71:D75)","v":0}]

{"sheet":"Annual Cash Forecast_8A","index":20,"n_rows":36,"n_cols":16,"rows_kept":36,"cut":false,"hidden":false,"merged":[[9,1,9,2],[10,1,10,2],[0,0,0,7],[3,1,3,2],[4,1,4,2],[5,1,5,2],[6,1,6,2],[7,1,7,2],[8,1,8,2]]}
["Ongoing Progress Update and Disbursement Request"]
[]
["Section 8A: The Global Fund Annual Forecast Template"]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[{"$f":"#REF!","v":{"$error":"#REF!"}},{"$f":"+#REF!","v":{"$error":"#REF!"}}]
[]
["Reporting Cycle","From","To"]
["Current reporting period","2015-01-01","2015-12-31"]
["Cumulative Reporting period","2015-01-01","2015-12-31"]
[]
[]
[]
[]
["Summary Breakdown by Cost Grouping"]
[]
["Costing Dimension (Cost Grouping)","Budget for Forecast Period","Unspent from previous periods","Budget for the Buffer Period","Total Budget available (including the buffer)","Adjustment for the  Forecast Period (based on implementable activities)","Adjustment for the Buffer Period","Total Principal Recipient Forecast (including Buffer)","Comments",null,"Local Fund Agent Adjustment on PR Budget","Local Fund Agent Adjustment on Budget for the Buffer Period","Local Fund Agent Adjustment on the Forecast","Local Fund Agent Adjustment on the Buffer Forecast","Local Fund Agent - Adjusted Forecast (including the buffer)","Comments"]
["Human Resources (HR)",0,{"$f":"'PR EFR_7A'!K18","v":866244.26027191244},0,{"$f":"B23+C23+D23","v":866244.26027191244},476282.66599034774,0,{"$f":"E23+F23+G23","v":1342526.9262622602},"Ovesrspendings due to Extension period for 6 months",null,null,null,null,null,{"$f":"K23+L23+H23+M23+N23","v":1342526.9262622602}]
["Technical Assistance",0,{"$f":"'PR EFR_7A'!K19","v":143526.10581033252},0,{"$f":"B24+C24+D24","v":143526.10581033252},-89497.753736657294,0,{"$f":"E24+F24+G24","v":54028.352073675225},null,null,null,null,null,null,{"$f":"K24+L24+H24+M24+N24","v":54028.352073675225}]
["Training",0,{"$f":"'PR EFR_7A'!K20","v":174493.80431325536},0,174493.80431325536,-148170.61159951336,0,26323.192713741999,null,null,null,null,null,null,26323.192713741999]
["Health Products and Health Equipment",0,{"$f":"'PR EFR_7A'!K21","v":1380272.1139860963},0,1380272.1139860963,-763507.65325635846,0,616764.46072973788,null,null,null,null,null,null,616764.46072973788]
["Medicines and Pharmaceutical Products",0,{"$f":"'PR EFR_7A'!K22","v":3736676.1479690345},0,3736676.1479690345,-2959217.0342888827,0,777459.11368015176,"Savings were redistributed to the NFM Budget and Extension Period",null,null,null,null,null,777459.11368015176]
["Procurement and Supply Management Costs",0,{"$f":"'PR EFR_7A'!K23","v":921385.33252059796},0,921385.33252059796,-848281.39473680046,0,73103.937783797504,null,null,null,null,null,null,73103.937783797504]
["Infrastructure and Other Equipment",0,{"$f":"'PR EFR_7A'!K24","v":220189.6924275035},0,220189.6924275035,-205179.84392610137,0,15009.848501402128,null,null,null,null,null,null,15009.848501402128]
["Communication Materials",0,{"$f":"'PR EFR_7A'!K25","v":66788.777914931852},0,66788.777914931852,-64093.36012517444,0,2695.4177897574118,null,null,null,null,null,null,2695.4177897574118]
["Monitoring & Evaluation",0,{"$f":"'PR EFR_7A'!K26","v":118227.13504574954},0,118227.13504574954,-81194.866458813805,0,37032.268586935737,null,null,null,null,null,null,37032.268586935737]
["Living Support to Clients/Target Populations",0,{"$f":"'PR EFR_7A'!K27","v":83953.23123537701},0,83953.23123537701,-47289.658080268528,0,36663.573155108483,null,null,null,null,null,null,36663.573155108483]
["Planning and Administration",0,{"$f":"'PR EFR_7A'!K28","v":47507.467282687656},0,47507.467282687656,-34572.057873102647,0,12935.409409585009,null,null,null,null,null,null,12935.409409585009]
["Overheads",0,{"$f":"'PR EFR_7A'!K29","v":351644.15796309127},0,351644.15796309127,-109325.83055787307,0,242318.32740521821,null,null,null,null,null,null,242318.32740521821]
["Other",0,{"$f":"'PR EFR_7A'!K30","v":-6190.507639019972},0,-6190.507639019972,-54014.280363853977,0,-60204.788002873946,null,null,null,null,null,null,-60204.788002873946]
["Grand Total",{"$f":"SUM(B23:B35)","v":0},{"$f":"SUM(C23:C35)","v":8104717.7191015501},{"$f":"SUM(D23:D35)","v":0},{"$f":"SUM(E23:E35)","v":8104717.7191015501},{"$f":"SUM(F23:F35)","v":-4928061.679013053},0,3176656.0400884976,null,null,{"$f":"SUM(K23:K35)","v":0},{"$f":"SUM(L23:L35)","v":0},0,0,3176656.0400884976]

{"sheet":" Request and Recommendation_8B","index":21,"n_rows":56,"n_cols":18,"rows_kept":56,"cut":false,"hidden":false,"merged":[[58,9,62,14],[36,1,37,8],[32,7,33,17],[55,9,55,14],[32,0,33,6],[36,0,39,0],[39,1,39,8],[48,9,48,12],[50,9,50,12],[52,9,52,12],[41,0,41,8],[52,1,52,4],[39,13,39,17],[41,13,41,17],[41,11,41,12],[39,11,39,12],[40,11,40,12],[40,13,40,17],[42,0,42,8],[9,0,9,17],[38,1,38,8],[30,0,31,6],[27,0,27,16],[28,0,28,16],[20,1,20,3],[30,7,31,17],[36,11,36,12],[36,13,36,17],[37,13,37,17],[38,11,38,12],[37,11,37,12],[38,13,38,17],[6,0,6,4],[6,5,6,9],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 8B.  Disbursement Request and Recommendation"]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered by the Progress Update:"]
[" "]
["1.  Period beginning date:",null,null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":"2016-01-01"},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":"2016-06-30"},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!B36","v":0},null,"Forecasted amount  (PR)",{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!C36+'Annual Cash Forecast_8A'!F36","v":3176656.0400884971}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!B36+'Annual Cash Forecast_8A'!K36","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P13+'Annual Cash Forecast_8A'!M36","v":3176656.0400884971}]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,null,{"$f":"IF(I13=\"\",\"\",I13+1)","v":"2016-07-01"},null,"end date:",{"$f":"IF(F17=\"\",\"\",DATE(YEAR(F17),MONTH(F17)+3,DAY(F17)-1))","v":"2016-09-30"},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!D36","v":0},null,"Forecasted amount  (PR):",{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!G36","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!D36+'Annual Cash Forecast_8A'!L36","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P17+'Annual Cash Forecast_8A'!N36","v":0},null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P13+P17+P24","v":3176656.0400884971}]
[null,"Cash \"buffer\" agreed with FPM (2)",null,null,null,"Select ",null,null,null,null,null,null,null,null,null,null,null,"LFA Total Forecast"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P15+P19+P26","v":3176656.0400884971}]
[]
["(cash \"buffer\") beginning date",null,null,null,null,{"$f":"IF(I17=\"\",\"\",I17+1)","v":"2016-10-01"},null,"end date:",{"$f":"IF(F21=\"\",\"\",IF(F21=\"1M\",DATE(YEAR(I17),MONTH(I17)+1,DAY(I17)-1),IF(F21=\"2M\",DATE(YEAR(I17),MONTH(I17)+2,DAY(I17)-1),IF(F21=\"3M\",DATE(YEAR(I17),MONTH(I17)+3,DAY(I17)-1),\"\"))))","v":""},null,"Approved budget amount:",null,0,null,"Forecasted amount:",0]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,null,null,"LFA-adjusted forecasted amount:"]
[]
["(1) Upon agreement with the FPM, additional Cash buffer can be requested if the PU/DR report contains a completed AFR or EFR report or if there is a request from the Secretariat for the PR to complete the report on SR Cash Reconciliation contained in the “SR Cash Reconciliation 2D”, or if there are any additional Global Fund-specific requirements that cannot be delivered within 60 days.  However such requests may or may not be satisfied based on the review of the current PU/DR."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted.  Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period",null,null,null,null,null,null,"Despite the fact that the budget absorption was less than planned (53,9 % due to reasons justified below), the entire programme activities were performed according the initial workplan.\nThe major reasons for developing the variance are as follows:\nLocal procurement with competitive bidding, with preceding market searches in 2014-2015 period resulted in cheaper unit costs compared to the budget unit costs. The latter resulted in the saving of 1,030,000 GEL.\nPR conducted re-calculation of needed q-ties of some PH based on the available stocks of medicines, condoms, syringes and lab. supplies at SR level, Also simplification of ARV regimens resulted in considerable savings. In order to keep the procurement needs-based, PR supported SR in re-calculating average consumption rates for medicines and lab supplies and this information was applied prior initiating the tenders.  \nProcurement of pagylated interferon and ribavirin budgeted at 340,200 EUR was canceled as within the State Hep C Elimination program the MoH has procured these medications for Hep C patients and patients with HIV/HCV co-infection were given the priority for inclusion in the State Hep C Treatment Program. \nFrom 2014 to the end of the reporting period a significant devaluation of the Georgian national currency GEL took place (GEL's depreciation is 30 percent). This derived savings in the Grant currency.\nSavings from the current grant were redistributed to the NFM budget and HIV grant extension for 6 months (Jan-Jun, 2016); Any additional saving from the extension period may be subject for inclusion in the  NFM budget.\nFunds for grant  implementation  during extension period was already disbursed by GF to PR in December 2015.\n"]
[]
["LFA comments on PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted."]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (Item 5.1 in PRLFA Cash Reconciliation):",null,null,null,null,null,null,null,"PR-reported amounts","PR Comments","LFA-verified amounts",null,"LFA Comments"]
[null,null,null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D52","v":2351877.6392323477},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H52","v":2351877.6392323477}]
[null,"4. Cash in Transit for the reporting period (Disbursements to PR & third party disbursements):",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D63","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H63","v":0}]
[null,"5.Cash in Transit after the current reporting period (Disbursements to PR & third party disbursements) :",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D64","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H64","v":0}]
[null,null,null,null,null,null,null,null,null,"PR-requested amount","PR Comments","LFA-verified amounts",null,"LFA Comments"]
["6. Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,{"$f":"IF(R20=0,0,IF(R20-J38-J39-J40<0,0,R20-J38-J39-J40))","v":824778.40085614938},"Direct Payment to PFSCM and IDA. Disbursement moved to NFM Budget",{"$f":"IF(R22=0,0,IF(R22-L38-L39-L40<0,0,R22-L38-L39-L40))","v":824778.40085614938},{"$f":"IF(T22=0,0,IF(T22-M38-M39-M40<0,0,T22-M38-M39-M40))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,null,"Yes"]
["8.  Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,null,"Yes"]
[]
[null,null,null,null,null,"Rates used by the PR",null,"LFA-verified rates",null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[]
[null,"- used to convert Opening Cash Balance",null,null,null,2.4992000000000001,null,0,null,"Exchange rate at the closing date of the previous reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Closing Cash Balance",null,null,null,2.6168999999999998,null,0,null,"Exchange rate at the closing date of the current reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Total PR Cash Outflow for the Progress Update Period",null,null,null,"-",null,0,null,"Exchange rate at the date of transaction  (source: www.nbg.gov.ge)"]
[]
[]
[null,null,null,null,null,null,null,null,null,"LFA comments on the exchange rates used by the PR"]

{"sheet":"PR Authorization_9A","index":22,"n_rows":14,"n_cols":10,"rows_kept":14,"cut":false,"hidden":false,"merged":[[8,0,8,14],[16,0,16,14],[10,0,10,4],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,5,10,9],[11,5,11,9],[12,5,12,9],[13,5,13,9]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Section 9A.  PR Authorization"]
["The undersigned acknowledges that: (i) all the information (programmatic, financial, or otherwise) provided in this Progress Update and Disbursement Request is complete and accurate; (ii) funds disbursed in accordance with this request shall be deposited in the bank account specified in the Facesheet; and (iii) funds disbursed under the Grant Agreement shall be used in accordance with the Grant Agreement."]
[]
["Signed on behalf of the Principal Recipient:\n(signature of Authorized Designated Representative)"]
["Name:",null,null,null,null,"Irma Khonelidze"]
["Title:",null,null,null,null,"Program Director"]
["Date and Place:",null,null,null,null,"22 March 2016      Tbilisi, Georgia"]

{"sheet":"LFA Authorization_9B","index":23,"n_rows":19,"n_cols":10,"rows_kept":19,"cut":false,"hidden":false,"merged":[[13,0,13,14],[21,0,21,14],[0,0,0,14],[2,0,2,4],[2,5,2,9],[5,5,5,9],[6,0,6,4],[6,5,6,9],[10,0,10,14],[12,0,12,14],[11,0,11,14],[15,3,15,5],[16,3,16,5],[17,3,17,5],[18,3,18,5]]}
["Ongoing Progress Review and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant Name:",null,null,null,null,{"$f":"#REF!","v":{"$error":"#REF!"}}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Disbursement Request  - Number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
["For LFA Use Only"]
["Section 9B.  LFA Authorization"]
["Summary of the LFA's approach used for verification of financial, programmatic and procurement data and Quality Assurance undertaken by the LFA"]
["In this section the LFA should indicate, as applicable, what percentage of expenditures was verified at PR level, if any expenditures were verified at SR level, how many site visits were made, what tender documentation was verified, and any other material parts of verification procedures in line with the verification approach agreed upfront between the LFA and the Global Fund's Secretariat based on country/grant risks.  As a good practice, the verification approach needs to be reviewed jointly by the LFA and the Secretariat annually."]
[]
[]
["The LFA should sign a printed version of the verified PU/DR and send it to the Secretariat as a pdf file by email, or include an electronic signature in the Excel file to be submitted to the Global Fund."]
[]
["Signed on behalf of the LFA:"]
["Name:"]
["Title:"]
["Date and Place:"]

{"sheet":"PR_Disbursement Request_7","index":24,"n_rows":45,"n_cols":19,"rows_kept":45,"cut":false,"hidden":true,"merged":[[33,7,33,12],[40,8,40,11],[42,8,42,11],[44,1,44,4],[44,8,44,11],[30,0,32,0],[0,0,0,9],[2,0,2,4],[2,5,2,8],[5,5,5,8],[6,3,6,8],[10,0,10,18],[11,0,11,18],[23,0,23,19],[24,0,24,19],[26,0,27,7],[26,8,27,18]]}
["On-going Progress Update and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,null,null,null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: Cash Reconciliation and Disbursement Request"]
[]
["B: DISBURSEMENT REQUEST"]
[]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered"]
[" by the Progress Update:"]
["1.  Period beginning date:",null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":"2016-01-01"},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":"2016-06-30"},null,"approved budget amount:",null,"forecasted amount:"]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,{"$f":"IF(H16=\"\",\"\",H16+1)","v":"2016-07-01"},null,"end date:",{"$f":"IF(E18=\"\",\"\",DATE(YEAR(E18),MONTH(E18)+3,DAY(E18)-1))","v":"2016-09-30"},null,"approved budget amount:",null,"forecasted amount:"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"N16+N18+N22","v":0}]
["cash \"buffer\" agreed with FPM (2)",null,"Select "]
["(cash \"buffer\") beginning date",null,null,null,{"$f":"IF(H18=\"\",\"\",H18+1)","v":"2016-10-01"},null,"end date:",{"$f":"IF(C21=\"\",\"\",IF(C21=\"1M\",DATE(YEAR(E22),MONTH(E22)+1,DAY(E22)-1),IF(C21=\"2M\",DATE(YEAR(E22),MONTH(E22)+2,DAY(E22)-1),IF(C21=\"3M\",DATE(YEAR(E22),MONTH(E22)+3,DAY(E22)-1),\"\"))))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[]
["(1) Additional Cash buffer can be requested if the next PU/DR report will contain a completed EFR report or a completed Annex on SR financials, requested by the Secretariat, or if there are any additional GF-specific requirements that cannot be delivered within 45 days. An agreement in principal from the FPM should be obtained prior to requesting an additional cash buffer."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (number 10 from PR Cash Reconciliation sheet):",null,null,null,null,null,null,null,null,null,null,null,{"$f":"+'PR Cash Reconciliation_2A,B,C'!#REF!","v":{"$error":"#REF!"}}]
[]
[null,"4.  Cash \"in transit\" disbursed to the PR:"]
[null,"5. Cash \"in transit\" disbursed to third parties by the Global Fund on behalf of the PR",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"+N31+N33+N34","v":{"$error":"#REF!"}}]
[]
["6.  PR's Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"IF(S20=0,0,IF(S20-S34<0,0,S20-S34))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,"Select"]
[]
["8. Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[null,"- used to convert Opening Cash Balance"]
[]
[null,"- used to convert Closing Cash Balance"]
[]
[null,"- used to convert Total Cash Outflow for the Progress Update Period"]

{"sheet":"Modules","index":25,"n_rows":24,"n_cols":6,"rows_kept":24,"cut":false,"hidden":true,"merged":[]}
[]
[null,"HIVAIDS_Module","HIVTB","Tuberculosis","Malaria","Health Systems Strengthening"]
[null,"Prevention programs for general population","Prevention programs for general population","TB care and prevention","Vector control","HSS - Procurement supply chain management (PSCM)"]
[null,"Prevention programs for MSM and TGs","Prevention programs for MSM and TGs","TB/HIV","Case management","HSS - Health information systems and M&E"]
[null,"Prevention programs for sex workers and their clients","Prevention programs for sex workers and their clients","MDR-TB","Specific prevention interventions (SPI)","HSS - Health and community workforce"]
[null,"Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for people who inject drugs (PWID) and their partners","HSS - Procurement supply chain management (PSCM)","HSS - Procurement supply chain management (PSCM)","HSS - Service delivery"]
[null,"Prevention programs for other vulnerable populations (please specify)","Prevention programs for other vulnerable populations (please specify)","HSS - Health information systems and M&E","HSS - Health information systems and M&E","HSS - Financial management"]
[null,"Prevention programs for adolescents and youth, in and out of school","Prevention programs for adolescents and youth, in and out of school","HSS - Health and community workforce","HSS - Health and community workforce","HSS - Policy and governance"]
[null,"PMTCT","PMTCT","HSS - Service delivery","HSS - Service delivery","HSS - Healthcare financing"]
[null,"Treatment, care and support","Treatment, care and support","HSS - Financial management","HSS - Financial management","Removing legal barriers to access"]
[null,"TB/HIV","TB care and prevention","HSS - Policy and governance","HSS - Policy and governance","Program management"]
[null,"HSS - Procurement supply chain management (PSCM)","TB/HIV","HSS - Healthcare financing","HSS - Healthcare financing"]
[null,"HSS - Health information systems and M&E","MDR-TB","Removing legal barriers to access","Removing legal barriers to access"]
[null,"HSS - Health and community workforce","HSS - Procurement supply chain management (PSCM)","Community systems strengthening","Community systems strengthening"]
[null,"HSS - Service delivery","HSS - Health information systems and M&E","Program management","Program management"]
[null,"HSS - Financial management","HSS - Health and community workforce","Results-based Financing","Results based Financing"]
[null,"HSS - Policy and governance","HSS - Service delivery"]
[null,"HSS - Healthcare financing","HSS - Financial management"]
[null,"Removing legal barriers to access","HSS - Policy and governance"]
[null,"Community systems strengthening","HSS - Healthcare financing"]
[null,"Program management","Removing legal barriers to access"]
[null,"Results-based Financing","Community systems strengthening"]
[null,null,"Program management"]
[null,null,"Results-based Financing"]

{"sheet":"EFR Data","index":26,"n_rows":48,"n_cols":12,"rows_kept":48,"cut":false,"hidden":true,"merged":[]}
["EFRHIVAIDS",null,null,null,null,"SDAMalaria",null,"SDATuberculosis",null,"SDAHIVAIDS",null,"SDAHealthSystemsStrengthening"]
["Please Select…",null,null,null,null,"please select…",null,"please select…",null,"Please select…",null,"Please select…"]
["Prevention",null,null,null,null,"Prevention:  Behavioral Change Communication - Mass media",null,"Improving diagnosis",null,"Prevention: Behavioral Change Communication - Mass media",null,"HSS: Service delivery"]
["Treatment",null,null,null,null,"Prevention:  Behavioral Change Communication - community outreach",null,"Standardized treatment, patient support and patient charter",null,"Prevention: Behavioral Change Communication - community outreach",null,"HSS: Human resources"]
["Care and Support",null,null,null,null,"Prevention: Insecticide-treated nets (ITNs)",null,"Procurement and supply management",null,"Prevention: Condom distribution",null,"HSS: Community Systems Strengthening"]
["TB/HIV Collaborative Activities",null,null,null,null,"Prevention: Malaria prevention during pregnancy",null,"M&E",null,"Prevention: Counseling and Testing ",null,"HSS: Information system & Operational research"]
["Supportive Environment",null,null,null,null,"Prevention: Vector control (other than ITNs)",null,"TB/HIV",null,"Prevention: PMTCT",null,"HSS: Infrastructure"]
["Health System Strengthening (HSS)",null,null,null,null,"Prevention: other - specify",null,"MDR-TB",null,"Prevention: Post-exposure prophylaxis (PEP)",null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,"Treatment: Prompt, effective anti-malarial treatment",null,"High-risk groups ",null,"Prevention: STI diagnosis and treatment",null,"HSS: other - specify"]
[null,null,null,null,null,"Treatment: Home based management of malaria",null,"HSS (beyond TB)",null,"Prevention: Blood safety and universal precaution",null,"Supportive environment: Program management and administration"]
["EFRMalaria",null,null,null,null,"Treatment: Diagnosis",null,"PAL (Practical Approach to Lung Health)",null,"Treatment: Antiretroviral treatment (ARV) and monitoring"]
["Please Select…",null,null,null,null,"Treatment: other - specify",null,"PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,"Treatment: Prophylaxis and treatment for opportunistic infections"]
["Prevention",null,null,null,null,"Supportive environment: Monitoring drug resistance",null,"ACSM (Advocacy, communication and social mobilization) ",null,"Care and support: Care and support for the chronically ill"]
["Treatment",null,null,null,null,"Supportive environment: Monitoring insecticide resistance",null,"Community TB care",null,"Care and support: Support for orphans and vulnerable children"]
["Supportive Environment",null,null,null,null,"Supportive environment: Coordination and partnership development (national, community, public-private)",null,"Programme-based operational research",null,"TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients "]
["Health System Strengthening (HSS)",null,null,null,null,"Supportive environment: other - specify",null,"Other:Specify",null,"Supportive environment: Policy development including workplace policy"]
[null,null,null,null,null,"Supportive environment: Program management and administration",null,"Supportive environment: Program management and administration",null,"Supportive environment: Strengthening of civil society and institutional capacity building "]
[null,null,null,null,null,"HSS: Service delivery",null,null,null,"Supportive environment: Stigma reduction in all settings"]
["EFRHealthSystemsStrengthening",null,null,null,null,"HSS: Human resources",null,null,null,"Supportive environment: Program management and administration"]
["Please Select…",null,null,null,null,"HSS: Community Systems Strengthening",null,null,null,"HSS: Service delivery"]
["Health System Strengthening (HSS)",null,null,null,null,"HSS: Information system & Operational research",null,null,null,"HSS: Human resources"]
["Supportive Environment",null,null,null,null,"HSS: Infrastructure",null,null,null,"HSS: Community Systems Strengthening"]
[null,null,null,null,null,"HSS: Procurement and Supply management",null,null,null,"HSS: Information system & Operational research"]
[null,null,null,null,null,"HSS: other - specify",null,null,null,"HSS: Infrastructure"]
[null,null,null,null,null,null,null,null,null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,null,null,null,null,"HSS: Other, specify"]
[]
[]
["EFRTuberculosis"]
["Please Select…"]
["TB Detection"]
["TB Treatment"]
["TB/HIV Collaborative Activities"]
["Supportive Environment"]
["Health System Strengthening"]
[]
[]
[]
[]
["IE"]
["Please Select…"]
["FBO"]
["NGO/CBO/Academic"]
["Private Sector"]
["Ministry Health (MoH)"]
["Other Government"]
["UNDP"]
["Other Multilateral Organization"]

{"sheet":"Checklist","index":27,"n_rows":30,"n_cols":4,"rows_kept":30,"cut":false,"hidden":false,"merged":[[5,0,5,3],[12,0,12,3],[18,0,18,3],[27,0,27,3]]}
["List of supporting documents for PU/DR review"]
[]
["This checklist is included for information and not for completion."]
[]
["List of Latest Approved Documents by functional area","To be made available to the LFA by the PR  ","To be submitted by the LFA to the Secretariat","Comments"]
["M&E"]
["Performance Framework","x"]
["M&E Plan","x"]
["Survey results","x",null,"For Impact/Outcome indicators"]
["M&E Systems Strengthening Assessment","x",null,"If newly available during the reporting period."]
["Other M&E assessments done by partners to assess data quality and M&E system issues.","x",null,"If newly available during the reporting period."]
[]
["Procurement"]
["Consumption reports for pharmaceuticals and health products","x"]
["Supplier invoices","x"]
["Procurement Plan","x"]
["Stock level reports","x"]
[]
["Finance"]
["Approved budgets","x",null,"For the periods covered by Progress Update and Disbursement Request, including the buffer period."]
["Cash books","x"]
["General Ledger ","x"]
["Cash forecasts ","x"]
["Bank statements","x"]
["Bank Reconciliations","x"]
["Annual PR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["Annual SR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["General Management"]
["Grant Agreement (including implementation letters)","x"]
["Workplan","x"]

{"sheet":"Memo HIV","index":28,"n_rows":26,"n_cols":10,"rows_kept":26,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["Please select…","Please select…","Please select…","Please select…","Please select…",null,null,null,null,"Please select…"]
["Prevention: Behavioral Change Communication - Mass media","% of young women and men aged 15-24 who are HIV infected ","impact","% of young people aged 15-24 who had sex with more than one partner in the last year ","National Health Accounts","Please enter a corresponding indicator here…",null,null,null,"Please select disease and Impact/Outcome first"]
["Prevention: Behavioral Change Communication - community outreach","% of adults aged 15-49 who are HIV infected ","outcome","% of young people aged 15-19 who have never had sex ","DHS/DHS+ (Demographic and Health Survey)","Please enter a data source here…"]
["Prevention: Condom distribution","% of adults and children with HIV still alive 12 months after initiation of antiretroviral therapy (extend to 2, 3, 5 years as program matures) ",null,"% of young people aged 15-24 who never had sex in the last year of those who ever had sex","MICS (Multiple Indicator Cluster Survey)","Please enter a SDA here…"]
["Prevention: Counseling and Testing ","% of infants born to HIV infected mothers who are infected ",null,"% of young people aged 15-24 reporting the consistent use of a condom with non-regular sexual partners in the last year ","AIS (AIDS Indicator Survey)"]
["Prevention: PMTCT","% of most-at-risk population(s) (sex workers, clients of sex workers, men who have sex with men, injecting drug users) who are HIV infected ",null,"% of young women and men who had sex before the age of 15 ","SAMS (Service Availibility Mapping Survey)"]
["Prevention: Post-exposure prophylaxis (PEP)","% of HIV seroprevalence among all newly registered TB patients",null,"% of adults and children who are still on treatment after 6 months, 1, 2, 3, 5 years from the initiation of treatment ","BSS (Behavioral and Surveillance Survey)"]
["Prevention: STI diagnosis and treatment",null,null,"% of injecting drug users who have adopted behaviors that reduce transmission of HIV. ","Sentinel surveillance"]
["Prevention: Blood safety and universal precaution",null,null,"% of orphaned children compared to non-orphaned children aged 10-14 who are currently attending school ","Serological surveys"]
["Treatment: Antiretroviral treatment (ARV) and monitoring",null,null,"% of young people aged 15-24 reporting the use of a condom the last time they had sex with a non-regular sexual partner ","Prevalence surveys"]
["Treatment: Prophylaxis and treatment for opportunistic infections",null,null,"% of people expressing accepting attitudes towards PLWHA, of all people surveyed aged 15-49 ","Facility-based survey "]
["Care and support: Care and support for the chronically ill",null,null,"% of female sex workers reporting the use of a condom with every client in the last month ","Key informant survey"]
["Care and support: Support for orphans and vulnerable children",null,null,"% of men who have had sex with a female sex worker in the last year ","Specific surveys (to be defined)"]
["TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients ","TB/HIV collaborative activities: Intensified case-finding among PLWHA",null,"% of men reporting the use of condom the last time they had anal sex with a male partner in the last 6 months ","Civil registration systems (vital/disease specific registration) "]
["Supportive environment: Policy development including workplace policy","TB/HIV collaborative activities: Prevention of TB disease in PLWHA",null,null,"Census"]
["Supportive environment: Strengthening of civil society and institutional capacity building ","TB/HIV collaborative activities: Prevention of HIV in TB patients",null,null,"Health service statistics"]
["Supportive environment: Stigma reduction in all settings","TB/HIV collaborative activities: Prevention of opportunistic infections in PLWHA with TB",null,null,"Patient register"]
["Supportive environment: Program management and administration",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Service delivery","TB/HIV collaborative activities: Provision of antiretroviral treatment for TB patients during TB treatment",null,null,"Community services assessment"]
["HSS: Human resources","HSS: PAL (Practical Approach to Lung Health)",null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: Community Systems Strengthening",null,null,null,"Operational research"]
["HSS: Information system & Operational research"]
["HSS: Infrastructure"]
["HSS: Procurement and Supply management"]
["HSS: Other, specify"]

{"sheet":"Memo TB","index":29,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Improving diagnosis","TB prevalence rate","impact","Case detection","National Health Accounts"]
["Standardized treatment, patient support and patient charter","TB incidence rate","outcome","Treatment success rate","DHS/DHS+ (Demographic and Health Survey)"]
["Procurement and supply management","TB mortality rate",null,"Smear conversion rate","MICS (Multiple Indicator Cluster Survey)"]
["M&E",null,null,null,"AIS (AIDS Indicator Survey)"]
["TB/HIV",null,null,null,"SAMS (Service Availibility Mapping Survey)"]
["MDR-TB",null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["High-risk groups ",null,null,null,"Sentinel surveillance"]
["HSS (beyond TB)",null,null,null,"Serological surveys"]
["PAL (Practical Approach to Lung Health)",null,null,null,"Prevalence surveys"]
["PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,null,null,"Facility-based survey "]
["ACSM (Advocacy, communication and social mobilization) ",null,null,null,"Key informant survey"]
["Community TB care",null,null,null,"Specific surveys (to be defined)"]
["Programme-based operational research"]
["Other:Specify"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
[null,null,null,null,"Census"]
[null,null,null,null,"Health service statistics"]
[null,null,null,null,"Patient register"]
[null,null,null,null,"Clinical cohort follow-up studies "]
[null,null,null,null,"Community services assessment"]
[null,null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
[null,null,null,null,"Operational research"]
[null,null,null,null,"R&R TB system, quarterly report"]
[null,null,null,null,"R&R TB system, yearly management report "]
[null,null,null,null,"Other Surveillance reports, specify"]

{"sheet":"Memo Malaria","index":30,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Prevention:  Behavioral Change Communication - Mass media","Death rates associated with Malaria: all-cause under-5 mortality rate in highly endemic areas ","impact","% of U5 children (and other target groups) with malaria/fever receiving appropriate treatment within 24 hours (community/health facility)","National Health Accounts"]
["Prevention:  Behavioral Change Communication - community outreach","Incidence of clinical malaria cases (estimated and/or reported) ","outcome","% of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities","DHS/DHS+ (Demographic and Health Survey)"]
["Prevention: Insecticide-treated nets (ITNs)","Anaemia prevalence in children under 5 years of age",null,"% of U5 children (and other target groups) admitted with severe malaria and correctly managed at health facilities","MICS (Multiple Indicator Cluster Survey)"]
["Prevention: Malaria prevention during pregnancy","Prevalence of malaria parasite infection ",null,"% of children U5 sleeping under an ITN the previous night","MIS (Malaria Indicator Survey)"]
["Prevention: Vector control (other than ITNs)","Laboratory-confirmed malaria cases seen in heath facilities",null,"% of households with at least one ITN","SAMS (Service Availibility Mapping Survey)"]
["Prevention: other - specify","Laboratory-confirmed malaria deaths seen in health facilities",null,"% of pregnant women (and other target groups) sleeping under an ITN the previous night","BSS (Behavioral and Surveillance Survey)"]
["Treatment: Prompt, effective anti-malarial treatment","Malaria-attributed deaths in sentinel demographic surveillance sites",null,"% of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa)","Sentinel surveillance"]
["Treatment: Home based management of malaria","API (Annual Parasite Index) (specific to Latin America and Asia)",null,"% of households in malaria areas protected by IRS","MOH (routine HIS or HMIS)"]
["Treatment: Diagnosis",null,null,null,"RBM (Roll Back Malaria)"]
["Treatment: other - specify",null,null,null,"Serological surveys"]
["Supportive environment: Monitoring drug resistance",null,null,null,"Prevalence surveys"]
["Supportive environment: Monitoring insecticide resistance",null,null,null,"Facility-based survey "]
["Supportive environment: Coordination and partnership development (national, community, public-private)",null,null,null,"Key informant survey"]
["Supportive environment: other - specify",null,null,null,"Specific surveys (to be defined)"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
["HSS: Service delivery",null,null,null,"Census"]
["HSS: Human resources",null,null,null,"Health service statistics"]
["HSS: Community Systems Strengthening",null,null,null,"Patient register"]
["HSS: Information system & Operational research",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Infrastructure",null,null,null,"Community services assessment"]
["HSS: Procurement and Supply management",null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: other - specify",null,null,null,"Operational research"]
[null,null,null,null,"Questionnaire"]